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Thesis summary 
Lipid-induced dysfunction of the liver is becoming increasingly prevalent and may be an 
essential link between obesity and type 2 diabetes (T2DM). Elevated circulating saturated fatty 
acids (FA) like palmitate have been shown to contribute to hepatic insulin resistance and 
chronic low-grade inflammation leading to T2DM while other plasma unsaturated FA appear 
protective. Strong emerging evidence point to the potentially protective effect of odd chain FA 
(OCSFA) on T2DM disease development; however, no study has looked at the cellular 
mechanisms underpinning its effect. The transcription factor PPAR alpha is involved in 
regulating hepatic lipid accumulation by upregulating genes responsible for FA transport and 
has been shown to alter hepatic insulin sensitivity, as well as an anti-inflammatory effect on 
monocytes. Therefore, the hypothesis that OCSFA predict fasting plasma glucose and their 
role in modulating hepatocyte and monocyte function (by activating PPAR alpha) has been 
examined. Analysis of the FA profile of a healthy and T2DM cohort showed that C15:0 
occurred in higher proportions in healthy controls compared to T2DM (median difference 
0.07%, p = 0.05) and was found to be negatively correlated with fasting blood glucose (p = 
0.002). In a model of terminally differentiated HepG2 cells, the data showed that C15:0 
ameliorated palmitate-induced dysfunction of glucose output (p < 0.001) and glycogen 
production (p < 0.001); and increased PPAR alpha transcriptional activity by 20% (p < 0.01). 
Furthermore, there was a 72% reduction in TNFα production in monocytes pre-exposed to 
C15:0 before LPS stimulation compared to controls (p < 0.01). Taken together, the potentially 
protective effect of C15:0 regarding T2DM development may be due to PPAR alpha-related 
attenuation of chronic inflammation and improvement of hepatocyte metabolism. 
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FTO Fat mass and obesity-associated protein  
G0/G1 Gap 0/Gap 1 
G2/M Gap 2/Mitosis 
G6P Glucose-6-Phosphate  
GADPH Glyceraldehyde phosphate dehydrogenase 
GC Gas chromatography 
GK Glucokinase  
GLUT2 Glucose transporter 2  
GLUT4 Glucose transporter 4 
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GPC Glycerol-3-phosphocholine 
GPR120 G-protein coupled receptor 120 
GPR41 G-protein coupled receptor 41 
GPR43  G-protein coupled receptor 43 
GSK3β Glycogen synthase kinase 3 beta 
HCL Hydrogen chloride 
HDL High density lipoprotein 
HGF Hepatocyte growth factor  
HHEX Hematopoietically-expressed homeobox protein  
HLA human leukocyte antigen 
HNF Hepatocytic nuclear factors 
HNF1α Hepatocytic nuclear factor 1 alpha 
HNF1β Hepatocytic nuclear factor 1 beta 
HNF3β Hepatocytic nuclear factor 3 beta 
HNF4α Hepatocytic nuclear factor 4 alpha 
HNF6 Hepatocytic nuclear factor 6 
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HOMA-IR Homeostatic model assessment-Insulin resistance 
HPLC High-performance liquid chromatography 
HRP Horseradish peroxidase 
ICAM-1 (Intercellular Adhesion Molecule 1 
IgE Immunoglobulin E 
IGF2BP2 Insulin like growth factor 2 binding protein 2 
IƙB nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor 
IKKβ IκB kinase-β  
IKKβ inhibitor of nuclear factor kappa 
IL-1 Interleukin 1 
IL-10 Interleukin 10 
IL-4 Interleukin 4 
IL-6 Interleukin 6  
IL-8 Interleukin 8 
IL-1β  Interleukin 1 beta 
IRS-1 Insulin receptor substrate 1  
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IRS-2 Insulin receptor substrate 2 
JAZF1 Juxtaposed with another zinc finger protein 1 
JNK c-Jun N-terminal kinases 
KCNJ11 Potassium inwardly rectifying channel, subfamily J, member 11 
KPNA2 Karyopherin subunit alpha 2 
KPNB1 Karyopherin subunit beta 1 
LDL Low density lipoprotein 
L-FABP Liver specific fatty acid binding protein 
LPC Lysophosphatidylcholine 
LPS Lipopolysacharide  
MAT Malonyl-ACP by malonyl-CoA transferase  
MCP-1 Monocyte chemotactic protein 1 
MHO Metabolically healthy obese  
MLYCD Malonyl-CoA decarboxylase  
MMP-9 Matrix metallopeptidase 9 
MoD Median of difference 
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mRNA Messenger RNA 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MUFA Monounsaturated fatty acid 
NAD Nicotinamide adenine dinucleotide oxidised 
NADH Nicotinamide adenine dinucleotide reduced 
NADPH Nicotinamide adenine dinucleotide phosphate 
NAFLD Non-alcoholic fatty liver disease 
NASH Non-alcoholic staetohepatitis 
NCOA2 Nuclear receptor coactivator 2  
NF-κB  Nuclear factor kappa-light-chain-enhancer of activated B cells 
NHS National Health Service 
NLRP3  NLR family pyrin domain containing 3 
nm Nanometre 
NO Nitric oxide 
NOTCH2 Neurogenic locus notch homolog protein 2 
NOX3 NADPH oxidase 3  
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OCSFA Odd-chain saturated fatty acid 
OPD o-phenylenediamine 
OSM Oncostatin M 
P38MAPK  P38 mitogen-activated protein kinases 
p53 TP53 or tumor protein 
p65 Nuclear factor NF-kappa-B p65 subunit  
PAS Periodic acid-Schiff  
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PEA Palmitoylethanolamide 
pH Potential of Hydrogen 
PI-3K Phosphatidylinositide 3- kinase 
PKC Protein kinase C  
PKC-Ɵ Protein kinase C theta 
PMA Phorbol 12-myristate 13-acetate  
PPAR Peroxisome proliferator-activated receptor 
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PPARG Peroxisome proliferator-activated receptor gamma gene 
PPAR alpha Peroxisome proliferator-activated receptor alpha 
PPARγ Peroxisome proliferator-activated receptor gamma 
PPARδ  Peroxisome proliferator-activated receptor delta 
PPRE Peroxisome proliferator response element  
PUFAs Polyunsaturated fatty acids  
qPCR  Quantitative polymerase chain reaction 
RA Retinoic acid 
RIPA Radioimmunoprecipitation assay  
RNase  Ribonuclease free 
ROS  Reactive oxygen species 
RPMI 1640 Roswell Park Memorial Institute 1640 medium 
RR Relative risk 
RT-qPCR  Real-time quantitative polymerase chain reaction 
RXR Retinoid X receptor 
RxRa Retinoid x receptor alpha  
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SAT Subcutaenous adipose tissue 
SCD Stearoyl-CoA desaturase  
SCD1 Stearoyl-CoA desaturase 1 
SCD5 Stearoyl-CoA desaturase 5 
SEM Standard error of mean 
SFA Saturated fatty acid 
Sirt1 Sirtuin 1 
SLC30A8 Solute carrier family 30, member 8 
S-Phase Synthesis phase 
SREBP1c Sterol regulatory element binding protein 1c  
STAT3 Signal transducer and activator of transcription 3 
T2DM  Type 2 diabetes mellitus 
TBX3 T-box transcription factor 3 
TCA Tricarboxylic acid  
TCF7L2 Transcription factor 7-like 2 
TLR1 Toll-like receptor 1 
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TLR2 Toll-like receptor 2 
TLR4 Toll-like receptor 4 
TLRs Toll-like receptors  
TNFα Tumour necrosis factor α 
UK United Kingdom 
UN United Nations 
US United States  
USA United States of America 
VAT Visceral adipose tissue 
VCAM-1 Vascular cell adhesion protein 1  
VIF Variance inflation factor 
VLCFA Very long-chain fatty acids  
VLDL Very low density lipoprotein 
WAT White adipose tissue  
WFS1 Wolfram syndrome 1 
WHO World Health Organisation 
28 
 
β-ME 2-Mercaptoethanol 
ω3-PUFA Omega 3 fatty acid 
ω6-PUFA Omega 6 fatty acid 
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1.1 Type 2 diabetes 
There has been an alarming rise in the prevalence of diabetes over the last few 
decades. Statistics from the USA indicates more than 100% increase in diabetes 
incidence across all age groups between 1980 and 2011 [1]. The World Health 
Organisation (WHO) estimates that around 347 million people had diabetes in 2012, 
representing almost 10% of the global adult population. A more recent pooled analysis 
looking at data from more than 146 countries found that the global age-standardised 
prevalence of diabetes doubled in men (an increase from 4.3% to 9%) and increased 
by approximately 60% in women from 1980 to 2014 [2]. The same study also showed 
that the people living with diabetes rose from 108 million in 1980 to 422 million in 2014, 
age and population growth accounting for 40% of this rise. In the UK, the crude 
prevalence of diabetes increased by more than threefold between 1991 and 2014 as 
a result of an ageing population and a mean increase in survival from diabetes [3]. 
There are currently about 3.7 million confirmed diagnoses of diabetes with up to a 
million remaining undiagnosed and an expectation that more than 12 million people 
are at risk of developing the disease [4].   
The disease has become a global epidemic with a 50% rise in incidence in the last ten 
years. In 2012, a global survey estimated that 1.5-5.1 million deaths were caused by 
diabetes and the WHO predicts it will be the seventh leading cause of death by 2030 
[5]. Despite these daunting statistics, it is perhaps the economic burden of diabetes 
that has increased awareness towards it and other non-communicable diseases. It is 
estimated that the annual cost of diabetes (especially the complications) to the 
31 
 
healthcare system in the UK and US alone is in the region of £10 billion [6] and $250 
billion respectively[7, 8].   
The exact mechanism leading to diabetes mellitus is still unknown and widely debated 
[9]. However, it is well recognised that it is a disease of glucose homeostasis with two 
primary forms: Type 1, characterised by an absolute lack of insulin, accounting for 
10% of cases; and Type 2 (T2DM), characterised by a relative lack of insulin or insulin 
resistance, accounting for 90% of cases. Monogenic diabetes and gestational diabetes 
(a derangement in glucose metabolism occurring in pregnancy, with an increased risk 
of T2DM in later life) are other less commonly recognised variants. T2DM is the most 
researched type of diabetes and centres around a dysfunction in insulin. The 
pathogenesis of T2DM is complex, involving factors such as high energy 
environments, elevated free FAs and inflammation. The consequence of this complex 
interaction is an inability of the pancreatic β-cells to produce insulin which is 
complicated by the widespread development of insulin resistance in peripheral tissues. 
The relationship between T2DM, sedentary lifestyle, and the so-called “western diet” 
is well established, highlighting the importance of the environmental and social risk 
factors for diabetes [10]. The genetic factors contributing to the onset and progression 
of T2DM is, however, less characterised. 
Genetic factors have been consistently linked to an increased risk of T2DM. A family 
history of T2DM is a strong clinical predictor of the disease. Several genetic variants 
have been identified as reliable predictors of T2DM, independent of clinical risk factors.  
A review of genome-wide association studies over the last decade has revealed some 
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genes with a single-nucleotide polymorphism that appear to predict T2DM 
consistently. Some of the genes that have been shown to be predictive for T2DM at 
pre-diabetic states include: TCF7L2, PPARG, FTO, KCNJ11, NOTCH2, WFS1, 
CDKAL1, IGF2BP2, SLC30A8, JAZF1, and HHEX [11]. Despite this recent 
advancement in genetic studies, the specific mechanism by which these genetic 
factors interact to cause T2DM is still unknown. An increasing number of gene-specific 
candidate-driven studies for T2DM have identified more than 70 loci, mostly in non-
coding regions of the genome. Consequently, research is now shifting towards 
identifying variants that affect the activity of enhancer elements regulating target gene 
expression [12]. Therefore, the interaction between environmental factors and 
epigenetic modifications are now being investigated to determine not just the 
mechanism of disease but also to determine why patients differ in disease progression 
and response to drug therapy [13].  
T2DM is a highly heterogeneous disorder in onset and disease progression. A recent 
data-driven cluster analysis identified five different subgroups of individuals with T2DM 
with clear disease progression and risk of complications, highlighting the need for a 
more personalised approach to the management of T2DM [14]. Several publications 
from the Food4Me study have shown promise regarding the personalised 
management of T2DM tailored around the nutritional, environmental and genetic 
differences between individuals [15]. In these studies, personalised nutrition had a 
positive impact on behavioural change, which impacted on physical activity and other 
factors leading to the modification of obesity; regarded as one of the most important 
modifiable risks associated with T2DM.  
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1.2 Obesity 
Obesity defines a complex, multifactorial, and preventable state of abnormal or 
disproportionate accumulation of body fat [16]. It increases the risk of chronic 
metabolic diseases and presents a substantial economic burden regarding morbidity 
and mortality.  Regarding quantifying obesity, a body mass index (BMI) of more than 
30kg/m2 is considered obese. BMI is the most commonly used index for categorising 
disorders of weight, but it is not without bias in the context of predicting metabolic 
outcomes. The BMI cut-off for overweight and obesity is affected by several factors, 
especially age, gender, and race. For example, the BMI for Caucasians is significantly 
higher than that of Asians and people of sub-Saharan origin adjusted for body fat, age 
and gender, highlighting the need for population-specific BMI cut-off points for obesity 
[17]. Furthermore, BMI does not correctly account for muscle mass; therefore, a well-
built athlete with a healthy body fat composition can be erroneously classed as obese 
by BMI. Consequently, the waist circumference is recommended in clinical and 
research settings for categorising obesity, as it accounts for abdominal obesity [18]. A 
pooled analysis of over 1600 population-based studies from almost 200 countries 
shows an alarming increase in the global prevalence of obesity over the last four 
decades. The global age-standardised BMI increased by more than 3kg/m2 and 
2kg/m2 in men and women respectively from 1975 to 2014 [19]. This corresponded to 
a global tripling of obesity prevalence (from 3.2% to 10.4%) in men and a doubling 
(6.4% to 14.9%) in women. If this trend continues, at least 60% of the world’s 
population would be obese or overweight by 2030 [20]; which is grave consequence 
in the US where it is expected that 85% of the population would be overweight or 
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obese [21]. A United Nations (UN) report in 2013 shows that at least one in four 
residents of the UK are obese, with the expectation that at least half the population 
will be obese by 2050 [22]. Obesity arises as a result of energy surplus, where energy 
consumption is not matched by calories expended. Although the complex interaction 
between genetic, environmental and socioeconomic factors contribute to obesity, the 
growing obesity epidemic is more likely due to changes in diet and lifestyle. The 
unexpected rise in obesity in developing countries exemplifies this. In addition to the 
adoption of the ‘Western diet’, which is high in carbohydrates and fat and low in fibres, 
urbanisation, associated with rapid industrialisation and mechanised transportation 
has reduced physical activity, consequently leading to obesity. Importantly, the dietary 
and lifestyle risks of obesity are modifiable; however, the prevalence of obesity has 
not been improved by enhanced campaigns to increase awareness of healthy dietary 
and physical activity recommendations [23]. The importance of developing effective 
strategies to modify these risks, reversing the obesity trend, relates to the numerous 
diseases associated with diabetes. Obesity is associated with diabetes, 
cardiovascular disease, cancer and many other disorders [24].  
The link between obesity and T2DM received increased recognition in the early 1990’s 
and now appears to be well established. There are excellent scientific reasons for this. 
Firstly, the prevalence of obesity tightly mirrors that of T2DM in the last three decades 
[25]. Furthermore, the relative risk (RR) of T2DM increases exponentially with 
increasing BMI; from an RR of 1 at 22kg/m2  to 93.2 at a BMI of 35kg/m2 [26]. Moreover, 
interventions aimed at reducing obesity, like bariatric surgery, low-calorie diets and 
increased physical activity have been shown to either cure T2DM or induce remission 
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[27]. Therefore, focus has switched to identifying the complex mechanisms that 
underpin the relationship between T2DM and obesity. Many theories have been 
suggested, including obesity-induced inflammation associated with a high energy 
state which is characterised by hyperglycaemia and hyperlipidaemia. However, not all 
obese people have insulin resistance or metabolic disease, the so-called 
‘metabolically healthy obese (MHO)’ [28]. Despite high energy states, including 
hyperlipidaemia, the MHO show no signs of inflammation or hyperglycaemia. This 
contributes to the obesity-T2DM axis in two ways. Firstly, it confirms the importance 
of inflammation in the development of T2DM; however, it casts doubts on the 
requirement of obesity in the pathogenesis of T2DM. Secondly, it raised interest in the 
distribution of fat rather than its absolute quantity. Consequently, studies have found 
that visceral adipose tissue (VAT) fat predicts insulin resistance better than 
subcutaneous adipose tissue (SAT) fat, and within the SAT, abdominal distribution 
confers a higher risk of T2DM [29-31]. Naukkarinen and colleagues carried out a 
cross-sectional study where they measured several indices of metabolic disease 
including liver fat, markers of inflammation and insulin resistance in sixteen rare 
obesity-discordant monozygotic adult twin pairs to study the relationship between fat 
depots, MHO and metabolic disease [32]. In this robust study, the authors found liver 
fat accumulation, a downregulation of FA oxidation and a dysfunctional mitochondrial 
oxidative phosphorylation pathway as the differentiating factors between obese twins 
with insulin resistance MHO. Therefore, the liver is an essential organ in the 
pathogenesis of metabolic diseases. The factors that determine dysfunctional ectopic 
fat deposition are still poorly understood.  
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1.3 Liver 
The liver is a major organ involved in glucose homeostasis. The gut and liver account 
for a third of glucose handling in humans under postprandial conditions [33-35]. During 
periods of glucose excess, as seen in post-prandial periods, glucose is phosphorylated 
to Glucose-6-Phosphate (G6P) within hepatocytes and channelled towards energy 
production via the tricarboxylic acid cycle (TCA) or mitochondrial oxidative 
phosphorylation. The glycolytic product, pyruvate, is also directed towards FA 
synthesis (de novo lipogenesis) and the production of Nicotinamide Adenine 
Dinucleotide Phosphate (NADPH) through the Pentose Phosphate Pathway. 
Furthermore, excess glucose converted to G6P is stored as glycogen in a process 
driven by glycogen synthase and facilitated by insulin, which simultaneously blocks 
endogenous glucose production (gluconeogenesis) by 50% in healthy humans [36]. 
Conversely, in the fasted state, glucose homeostasis is maintained by liver-driven 
gluconeogenesis; glucose is produced from glycogen on a short-term basis and from 
lactate, pyruvate, glycerol, and amino acids, long-term, in a process that follows a 
downregulation of insulin and the liver is more ‘glucose-effective’ than muscle cells. 
Glucose effectiveness denotes the ability of glucose to stimulate its metabolism 
independent of insulin.  For example, glucose can move across hepatocyte membrane 
but not muscle cells through glucose transporter 2 (GLUT2), facilitated by glucokinase 
(GK), to suppress gluconeogenesis, independently of insulin signalling, in a bi-
directional manner dependent on glucose concentration. Whereas, muscle cells 
require glucose transporter 4 (GLUT4) in an insulin-mediated pathway. However, the 
liver is still very insulin sensitive, requiring insulin for glycogen synthase derive 
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glycogen [37]. The subtle distinction between liver and muscle handling of glucose is 
made because of the effect it has on obesity-induced insulin resistance (or high-fat 
diet-induced dysregulation of glucose homeostasis). In addition to glucose 
metabolism, the liver is capable of de novo lipogenesis (DNL), a mechanism that is 
important in obesity-related insulin resistance. The justification for targeting the liver 
over muscle cells is highlighted in clinical studies where the resolution of 
hyperglycaemia in T2DM subjects after short-term calorie restriction was related to 
improved hepatic glucose metabolism rather than insulin-mediated glucose 
metabolism in muscle cells [38]. Furthermore, Brøns and colleagues showed that 
hepatic gluconeogenesis-induced elevation of plasma glucose precedes muscle 
insulin resistance in a cohort of young healthy lean individuals fed a high-fat diet for 
five days [39]. Their results are also corroborated by other studies [40]. 
1.4 Hepatocyte 
The hepatocyte is the functional unit of the liver and accounts for up to 80% of liver 
cell mass. Hepatocytes are responsible for a wide range of metabolic activity, including 
carbohydrate, lipid and protein metabolism, as well as detoxification and immune 
surveillance. Hepatocytes are arranged around the portal-central axis. The metabolic 
functions of hepatocytes are highly differentiated and dependent upon their position in 
the portal-central axis. For example, periportal hepatocytes are mostly involved with 
gluconeogenesis, ammonia synthesis, cholesterol synthesis and FA degradation. 
Conversely, perivenous hepatocytes chiefly handle DNL, glycolysis and xenobiotic 
detoxification.  
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The diverse functions of hepatocytes necessitate a complex phenotype which is 
acquired progressively during foetal development by expression of a vast array of 
complement genes and maintained by tight regulation throughout adulthood [41]. 
Hepatocytes differentiate from hepatoblast upon stimulation by hepatocyte growth 
factor (HGF) and oncostatin M (OSM) in the early stages. TBX3 (T-box transcription 
factor 3) then stimulates hepatocyte maturation mediated expression of a host of 
transcriptional factors including several hepatocyte nuclear factors (HNF1α, HNF1β, 
HNF4α, HNF3β, AND HNF6) and c/EBPa (CCAAT-enhancer binding protein α). The 
final steps of hepatocyte maturation involve the repression of oncofetal genes (like 
alpha-fetoprotein, hexokinase 2, and pyruvate kinase M2) and the full expression of 
genes like albumin, transferrin, fatty acid synthase. Hepatocytes exist in vivo as mostly 
quiescent cells but are capable of de-differentiation into foetal forms in cases of liver 
injury; however, this process is tightly regulated to assume a differentiated state upon 
regeneration. Hepatocytes are unique in their ability to regenerate in response to injury 
by cell growth and division and by facultative-stem cell-mediated recovery which 
involves the recruitment of atypical ductal cells (ADC) also known as oval cells [42]. 
Abnormal proliferation leads to conditions like hepatocellular cancer. In in vitro 
hepatocyte models, HepG2 cells, an immortalised cell line is often used in place of 
primary hepatocytes because they are relatively inexpensive and are more 
proliferative. However, HepG2 cells show significant differences in gene expression 
and metabolic function compared to primary hepatocytes. For example, metabolic 
network flexibility analysis of HepG2 cells under different glucose conditions shows 
that in comparison to primary hepatocytes, hepatoma cells favour glycolysis over 
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oxidative phosphorylation, due to their highly proliferative nature. Furthermore, gene 
expression levels of markers of differentiation, like albumin, transferrin, and fatty acid 
synthase are usually low, while xenobiotic enzyme gene expression is often absent.  
However, the feedback responses to energy availability, insulin stimulation, and end-
products of glucose metabolism remain mostly the same. Moreover, HepG2 cells have 
been successfully differentiated by various methods to more closely resemble their 
primary counterpart in gene expression and functional phenotype. 
1.5 NAFLD 
Non-alcoholic liver fatty disease (NAFLD) describes a spectrum of disorders 
associated with the accumulation of fat in the liver in the absence of competing liver 
aetiologies [43]. It ranges from simple hepatic steatosis (liver fat accumulation) to 
steatohepatitis (NASH), where fatty deposits are associated with inflammation, and a 
small proportion may culminate in hepatic fibrosis, cirrhosis, or carcinoma. The current 
burden of NAFLD is as staggering as T2DM and obesity, and it is now increasingly 
recognised as the liver component of metabolic syndrome [44-47]. Indeed, up to  90% 
of people with NAFLD fulfil at least one component of metabolic syndrome, while up 
to a third fulfil three aspects of metabolic syndrome [48].  Many studies have reported 
a close association between NAFLD, obesity and T2DM. The prevalence of NAFLD in 
obese is as high as 90%, depending on the level of obesity [49-51]. Similarly, the 
prevalence of T2DM in a population of people with NAFLD was recorded to be as high 
as 85% (prevalence of T2DM and pre-diabetes combined) in one study [52] and 76% 
in another [50]; while another study showed that those with NAFLD are three times 
more likely to have T2DM [53].  The global prevalence of NAFLD is on the rise. In a 
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meta-analysis of 86 studies by Younossi and colleagues, the global prevalence of 
NAFLD was estimated from over eight million individuals in 22 countries, where 
NAFLD was diagnosed using a range of imaging studies [54]. The prevalence of 
NAFLD was estimated to be 25%; the prevalence of obesity and T2DM among people 
with NAFLD were 51% and 22% respectively. The prevalence of NAFLD is likely to be 
underestimated in this analysis considering the sensitivity of imaging is up to 20% less 
than the gold standard liver biopsy [55]. Moreover, NAFLD is ubiquitous among people 
with T2DM. In a meta-analysis by Dai and colleagues, the pooled prevalence of 
NAFLD among people diagnosed with T2DM was  60%, ranging from 29% to 87% in 
twenty-four studies involving more than thirty thousand participants [56].   
Further justification for the importance of NAFLD in T2DM lies with the value of early 
intervention. Peripheral insulin resistance is already established and indeed plateaus 
by the time T2DM is diagnosed [57]. It is hypothesised that the onset of hepatic lipid 
accumulation and insulin resistance precedes T2DM by five to ten years and 
peripheral insulin resistance is entirely reversible at this stage [57]. Therefore, early 
diagnosis of NAFLD could provide a useful opportunity to halt the progression of 
impaired glucose tolerance to T2DM. NAFLD provides a useful link between obesity 
and T2DM and the effect of circulatory FAs could be key. 
In patients with NAFLD, both saturated (SFA) and monounsaturated fatty acids 
(MUFA) are causally implicated in the pathogenesis of steatosis [58, 59]. However, 
SFA are more likely to induce hepatocellular dysfunction and a pro-inflammatory 
profile consistent with nonalcoholic fatty liver pathology [60]. Cellular dysfunction is the 
result of FAs promoting endoplasmic reticulum (ER) stress, uncoupling mitochondrial 
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respiration and increasing production of reactive oxygen species (ROS), culminating 
in hepatic inflammation and cell death [61-63]. In contrast to previous reports of SFA-
mediated steatosis, some MUFA has been shown to reverse the lipotoxic effect of SFA 
on hepatocytes in vitro, despite a paradoxical increase in lipid accumulation. This 
variation in metabolic consequence has been suggested to be due to the ability of 
different classes of FAs to behave differently as signalling molecules.  
1.6 Fatty acids 
FA are the basic building blocks of lipids. They are made of a carbon skeleton attached 
to a carboxylic acid functional group. Natural occurring FA are usually monocarboxylic 
acids and are classified by chain length, saturation, carbon number, and chain nature. 
Classification by saturation is perhaps the most biologically relevant sub-division of 
FAs. On this basis, FA are designated as either saturated or unsaturated based on the 
presence of double bonds. Palmitic acid is a sixteen-chain FA, and is the most 
abundant saturated FA in humans, accounting for up to 30% of total FAs in plasma. 
Unsaturated FAs contain at least one double bond. They are further classified as 
monounsaturated fatty acids (MUFA) because they contain one double bond, or 
polyunsaturated fatty acids (PUFA), which contains at least two double bonds. The 
most abundant MUFA is oleic acid (C18:1n9), which occurs in diet, but can also be 
synthesised de novo by desaturation enzymes introducing double bonds to its 
saturated counterpart octadecanoic acid (C18:0). FAs can be straight chain (like most 
free FA in human plasma), branched chain, cyclic, or substituted (addition of hydroxyl, 
epoxy, dicarboxy groups attached to straight chain FA), by chain nature. Traditionally, 
FA were classified by carbon chain length as either short-chain (C4-C6), medium chain 
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(C8-C12), long-chain (C14-C20), and very long chain (>C22). The clinical importance 
of FA classification by chain length is highlighted in disorders such as Refsum disease 
and Zellweger syndrome, where the presence of very long FA can be both diagnostic 
and prognostic [64]. However, a new classification has been added by carbon number, 
whereby FA are either odd-chain FA or even-chain FA, depending on the number of 
carbon atoms.  
Ancel keys helped to institute the epidemiologic link between lipids and cardiovascular 
disease as early as the 1940s. The link between fat and cardiovascular disease was 
then fully established in 1970 after the publication of results from Ancel Key’s ‘seven 
countries’ study, which then led to a series of nutritional recommendation to reduce 
dietary fat [65, 66]. However, the significance of FA classification in health and disease 
gained momentum afterwards when many publications showed the potential benefits 
of replacing saturated fats with PUFA [67]. However, growing evidence from re-
analysis of previous incomplete randomised control trials has shown that the effect of 
saturated fats on cardiovascular health, and the potential benefits of its replacement 
may have been overestimated [68]. Nevertheless, many in vitro and in vivo models 
have corroborated the lipotoxic effects of FA over the years. The deleterious effect of 
increased circulating FA, especially SFA on whole-body insulin resistance is well 
studied. Dresner et al. (1999) established that infusion of healthy human subjects with 
free fatty acids (FFA) resulted in insulin resistance in muscle cells [69]. Results from 
muscle biopsies from these subjects showed up to 60% reduction in glucose oxidation 
and glycogen synthesis associated with a 90% decrease in intramuscular G6P, 
suggesting a reduction in glucose transport across cells resulting from IRS-1 (insulin 
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receptor substrate 1) associated PI-3K (Phosphatidylinositide 3- kinase) activity. 
Subsequently, many other mechanisms of FA-induced insulin resistance in peripheral 
tissues have been described, including accumulation of lipid metabolites such as 
diacylglycerol (DAG) and ceramides. Similarly, in animal models, short-term high fat 
diet has been used to induce hepatic insulin resistance via many mechanisms 
including protein kinase C (PKC) activation [70] induced by accumulation of 
diacylglycerol (DAG) resulting in hepatic insulin resistance which occurs long before 
systemic insulin resistance or inflammation, suggesting the pivotal role of hepatic 
dysfunction on the development of T2DM [71]. Furthermore, Dan Gao and colleagues 
found a reduction in hepatic glycogen content as a result of a FA-induced increase in 
NADPH oxidase 3 (NOX3)-derived reactive oxygen species (ROS) in db/db mice fed 
high-fat diets and in palmitate-treated HepG2 cells, mediated via JNK and P38MAPK 
pathway [72]. Although evidence abounds on the general effect of FA on insulin 
resistance and consequently glucose metabolism, some studies have shown that 
there may be significant differences in metabolic outcome and signalling when 
unsaturated FA are used in place of the more commonly adopted palmitate treatment. 
There is so far no study done to understand if these differences exist within SFA with 
odd-numbered carbon chain length.  
Emerging evidence from large-scale longitudinal studies over the last decade has 
drawn attention to the role of odd-chain saturated fatty acids (OCSFA) on health and 
disease in humans. Research interest in OCSFA has evolved from investigating 
factors that affect their composition in ruminant milk to measuring their association 
with metabolic diseases in human studies. OCSFA were initially thought to be 
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physiologically unimportant and non-existent in humans. Therefore, they were used 
as internal standards for the chromatographic identification of other FA. Earlier 
research into OCSFA focused on factors that influenced their composition in ruminant 
milk because of their potential to impact the melting point of milk and animal fat in a 
chain length-dependent manner. Furthermore, OCSFA was found to reduce total SFA 
in milk significantly; therefore, research intensified to influence their composition in 
milk given nutritional policies to keep SFA intake below 30%. Incidentally, these 
studies would provide further insight into its de novo synthesis, including the role of 
foliage ratios, propionate, the gut bacteria, and adipocytes in ruminants. Further 
interests in OCSFA developed as some studies showed its antitumor effect in vitro 
and in vivo reproducible for breast and prostate cancer. The antitumor activity was 
reported to be closely linked to the downregulation of de novo lipogenesis; however, 
this was never replicated in human studies. In the early 2000’s, studies began to 
emerge correlating plasma OCSFA to dairy intake, which correlated positively with 
healthy eating habits and general lifestyle. Therefore, plasma OCSFA were used in 
nutritional studies as a marker for dairy intake. Despite this, it took some time to 
recognise their physiological importance for a few reasons. Most of the scepticism 
about the physiological significance of OCSFA have come from a lack of 
understanding regarding their metabolic fate in humans. The hypothesis regarding 
their catabolism have come from animals and bacteria, and these pathways are 
thought to be redundant in humans [73]. Peroxisome α-oxidation has been proposed 
but remains unproven in humans. However, some studies have shown that phytanic 
acid, a β-branched odd-chain fatty acid, can undergo both β-oxidation and α-oxidation, 
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offering fresh insight into the possible mechanisms for catabolising OCSFA [74, 75]. 
Furthermore, a recent in vitro study showed that OCSFA is produced in adipocytes 
during the early stages of differentiation, proposing a de novo lipogenesis pathway for 
OCSFA. Recent publications from the European Prospective Investigation into Cancer 
and Nutrition (EPIC) have shown an inverse correlation between the concentrations 
of OCSFA in plasma and red cell membranes and the incidence cardiovascular 
diseases and T2DM [76]. Other longitudinal and cross-sectional studies have also 
highlighted the potentially protective effect of OCSFA against a range of conditions 
such as T2DM and pre-diabetes, biotin deficiency, anorexia nervosa, atherosclerosis, 
disorders of propionate, and peroxisome disorders [77-84]. Although the benefits of 
OCSFA are clear from the studies above, the mechanisms by which they are 
protective is still unknown. Moreover, a recent study showed that OCSFA is 
heterogeneous in metabolism, biosynthesis, and relationship with glucose tolerance 
[85]. Therefore, further in vitro and in vivo studies are needed to define the benefit of 
specific OCSFAs. 
1.7 Fatty acid metabolism 
The liver plays a central role in the metabolism of FA [86]. Exogenous FA bound to 
albumin, are mostly transported into hepatocytes via FA transport proteins found in 
the membrane [87]. Intracellular trafficking of FA between organelles is further 
regulated by fatty acid binding proteins (FABP) [88]. The metabolic fate of intracellular 
FA is dependent upon several factors, including FA themselves, which act as 
signalling molecules. The most critical catabolic pathway for FA within the liver is 
mitochondrial β-oxidation, which results in the breakdown of FAs by two carbon atoms 
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in each cycle into acetyl CoA and carbon dioxide. This process is facilitated by 
activation of FAs into Acyl-CoA in the cytosol before transport into the mitochondria by 
carnitine palmitoyltransferase located in the mitochondrial membrane [89]. Minor 
pathways of FA oxidation, like α-oxidation and ω-oxidation, also occur in peroxisomes 
for odd-chain FAs and very long-chain FAs (VLCFA) respectively [90, 91]. FA 
produced de novo, or acquired exogenously, can also be directed towards other 
metabolic pathways, like acylation into cellular lipids (including triglycerides, 
phospholipids and lipoproteins), and elongation and desaturation into VLCFA and 
unsaturated FA respectively [92, 93]. These pathways are tightly controlled, with 
dysregulation leading to metabolic dysfunction such as an accumulation of lipids within 
hepatocytes (steatosis), which may lead to the clinical scenario of non-alcoholic fatty 
liver diseases (NAFLD) [94].  
The ability of the liver to synthesise FA underpins its importance in lipid metabolism. 
The de novo lipogenesis (DNL) is a critical pathway in the liver that is tightly linked 
with glucose metabolism [95, 96]. In fact, the primary product of the glycolytic pathway 
acts as substrates for DNL. Therefore, a substantial carbohydrate diet provides a large 
substrate for the DNL pathway resulting in increased lipid production [97-99]. The 
biochemical process of DNL can be summarised as the condensation of acetyl Co-A 
subunits on to a glycerol backbone in a multiplex reaction regulated by enzymes and 
signalling molecules such as insulin [100]. In the first irreversible step, malonyl-CoA is 
produced by carboxylation of acetyl-CoA, catalysed by acetyl-CoA Carboxylase 
(ACC), mediated by its two catalytic activities; biotin carboxylase (BC) and 
carboxyltransferase (CT). ACC is a complex multifunctional enzyme regulated 
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transcriptionally and encoded by two genes: ACC1 (Acetyl-CoA Carboxylase 1 or 
alpha) and ACC2 (Acetyl-CoA Carboxylase 2 or beta), both coding for two distinct 
ACC isoenzymes with different functions. ACC1 is primarily involved with DNL and 
under short-term regulation by citrate and palmitoyl-CoA. Whereas, the malonyl-CoA 
produced via ACC2 interacts with FA oxidation by blocking carnitine 
palmitoyltransferase I, the rate-limiting step for β-oxidation [101], making it an essential 
anti-obesity drug target. In addition to the transcriptional and allosteric regulation of 
ACC, the DNL is regulated by insulin and glucose through sterol regulatory element 
binding protein 1c (SREBP1c) and carbohydrate response element binding protein 
(ChREBP) respectively [102]. The malonyl-CoA produced by ACC is then converted 
to malonyl-ACP by malonyl-CoA transferase (MAT), and a series of NADPH-mediated 
reduction reactions follows culminating in the formation of acyl-CoA, which is 
converted to palmitate in another series of sequential elongation by 2 carbon atoms 
involving fatty acid synthase (FASN) [Figure 1.1]. Palmitate is then desaturated by 
stearoyl-CoA desaturase (SCD) to MUFA. Fructose can indirectly fuel DNL by the 
interaction of its substrates (dihydroxy-acetone-phosphate and glyceraldehyde 3-
phosphate) with glycolysis. Lipid accumulation is central to the development of 
NAFLD, and DNL is critical to this process. Radioisotope studies have shown that DNL 
contributes up to a quarter of liver fat in NAFLD [59, 103]. Adipocytes produce about 
60%, while 15% is from the diet. Although the majority of this fat is from adipocytes, 
the absence of obesity in some individuals with NAFLD, and the role of hepatic insulin 
resistance (and mitochondrial dysfunction) in the pathogenesis of T2DM (as previously 
discussed) in NAFLD suggests a more prominent role for DNL.  
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Figure 1.1: Schematic of the de novo lipogenesis pathway, showing the 
interaction between glucose metabolism and FA synthesis.  [104] 
GKRP, glucokinase regulatory protein; G6Pase, glucose-6-phosphatase, catalytic subunit; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase; PKLR, pyruvate kinase, liver and RBC; PCK1, phosphoenolpyruvate carboxykinase1; LDH, lactate 
dehydrogenase A; DCT, dicarboxylate transporter; PDK2, pyruvate dehydrogenase kinase isozyme2; PDH, pyruvate 
dehydrogenase; SDHAP3, succinate dehydrogenase complex, subunit A; FASN, fatty acid synthase; SCD1, stearoyl-CoA 
desaturase 1; GPD1, glycerol-3-phosphate dehydrogenase 1 (soluble); MOGAT2, monoacylglycerol O-acyltransferase 2; 
DGAT2, diacylglycerol O-acyltransferase homolog 2. 
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1.8 Inflammation and T2DM 
The connection between T2DM, obesity, and inflammation has been a historic topic of 
hot debate. Early recognition of this paradigm started over a century ago when a series 
of case studies showed that the use of high dose aspirin effectively treated glycosuria, 
followed by intervention studies that showed complete independence from insulin after 
high dose aspirin therapy [105-107]. Although well-designed efficacy trials further 
validated the hypoglycemic action of salicylates, it was not until early 21st century that 
mechanistic studies were able to identify IκB kinase-β (IKKβ)/NF-κB axis as the 
molecular target for salicylate-induced modification of insulin resistance [108, 109]. 
Previous studies on the effect of salicylates had measured insulin secretion from 
pancreatic islet cells with poor outcomes [110]. Further evidence to support the theory 
of inflammation in the pathogenesis of T2DM comes from the observation of a higher 
risk of T2DM among individuals with other chronic inflammatory disorders such as 
rheumatoid arthritis [111]. More so, chronic inflammation and mitochondrial oxidative 
stress are hallmarks of adipocyte expansion and remodelling with obesity, which is 
highly correlated with T2DM [112]. This chronic low-grade inflammatory state is then 
able to start an inflammatory cascade which is fuelled by reactive oxygen species.  
Consequently, expanding adipocytes have been shown to overproduce tumour 
necrosis factor α (TNFα), which impacts directly upon insulin resistance. In fact, some 
studies have been able to show that administration of recombinant TNFα to cells or 
animals impairs insulin function, whereas, TNFα knockdown mice are partially 
protected from high-fat diet-induced insulin resistance [113, 114]. Furthermore, 
chronic systemic inflammation increases leptin-resistance STAT3 (signal transducer 
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and activator of transcription 3) activation/phosphorylation in the hypothalamus and 
the gut, affecting appetite and food intake, which then fuels insulin resistance [115, 
116]. More recent epidemiologic studies have now been able to establish a positive 
correlation between pro-inflammatory markers, like C-reactive protein (CRP), 
interleukin 6 (IL-6), interleukin 8 (IL-8), TNFα and the incidence of T2DM [117-121]. 
However, it is the mechanistic studies that have elucidated the specific links between 
inflammation and T2DM, especially the role of inflammatory cytokines. TNFα is able 
to stimulate the inhibitory phosphorylation of serine residues for insulin receptor 
substrate 1 (IRS-1) inhibiting downstream signalling and insulin sensitivity [122-125]. 
Furthermore, pro-inflammatory cytokines are able to induce insulin resistance by 
interacting with JNK (c-Jun N-terminal kinases), NF-ƙB and PKC-Ɵ. JNK is elevated 
in the liver with obesity, and upon activation by pro-inflammatory cytokines, or directly 
by FAs, it associates and phosphorylates IRS-1 on Ser307[126]. JNK knockdown in 
mouse models protects from development of hepatic insulin resistance, while 
overexpression produces the systemic effect of insulin resistance, underpinning its 
importance in T2DM pathogenesis [127, 128]. An accumulation of ceramides and 
other intermediates are known to interact directly with IKK (inhibitor of nuclear factor 
kappa), JNK, NF-ƙB and PKC-Ɵ. Ceramides can directly activate PKC-Ɵ which 
induces insulin resistance similarly to JNK, or by activating IKKβ. In addition to direct 
interaction with IRS-1, IKKβ activates NF-ƙB by phosphorylating its inhibitor (IƙB), 
which stimulates the production of pro-inflammatory cytokines [129].  
There has also been interest regarding monocytes and macrophage contribution to 
the inflammatory theory of T2DM. The chronic inflammation associated with increasing 
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adiposity stimulates MCP-1 (monocyte chemotactic protein 1), which enhances 
monocyte recruitment to adipocytes, creating a snowball inflammatory effect [130]. 
The theory that monocytes and macrophages, as chief players in innate immunity, 
drive differential response to inflammatory stimuli in healthy individuals compared to 
people with T2DM is gaining popularity [131]. Monocytes infiltrate and interact with 
many organs and tissues such as the liver, gut, pancreas and adipose tissue, and are 
involved with local and systemic response to inflammatory stimuli such as infections 
and hyperglycaemia [132, 133]. Monocyte and macrophage phenotypes have been a 
particular interest. A more precise distinction between pro-inflammatory and anti-
inflammatory monocytes and macrophages are now more possible due to improved 
flow cytometry techniques. Monocytes are classified as classical, intermediate, or non-
classical; depending on the expression of CD14 (cluster of differentiation 14) and 
CD16 (cluster of differentiation 16) on the cell surface [134, 135]. The classical 
monocyte subset represents 80% of circulating monocytes and expresses high levels 
of CD14 and deficient levels of CD16 (otherwise denoted CD14++/CD16- population). 
This subpopulation of monocytes express anti-inflammatory phenotype characterised 
by high phagocytic function, but quick resolution post-inflammation, with reduced 
TNFα and increased IL-β secretion. Intermediate monocyte subset is characterised by 
high levels of CD14, and higher levels of CD16 compared to classical monocytes 
(denoted as CD14+/CD16+ monocytes) and have been denoted pro-atherogenic. 
Along with intermediate monocytes, the non-classical monocytes (or CD14-/CD16++ 
sub-population) are associated with increased production of pro-inflammatory 
cytokines and are increased in infectious diseases as well as chronic metabolic 
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disorders [136-139]. Similarly, macrophages express a pro-inflammatory classically 
generated (M1), or anti-inflammatory alternatively generated (M2) macrophage 
phenotype depending on the inflammatory environment [140]. The M2 macrophage 
has also been subdivided into M2a, M2b, M2c, and M2d subsets on the basis of 
induced transcriptional changes [141, 142]. Evidence for the deleterious effect of M1 
macrophage leading up to T2DM abounds in literature. M1 macrophage numbers have 
been positively correlated with insulin resistance in models of high-fat feeding in 
rodents, and there is evidence of M1 macrophage recruitment around necrotic 
adipocytes in WAT (white adipose tissue [143-145]. Moreover, successful ablation of 
M1 macrophages was associated with improved insulin sensitivity [146]. In humans, 
the accumulation of M1 macrophages in adipose tissue is positively correlated with 
insulin resistance [147, 148]. Furthermore, M2 macrophages tend to replace M1 
macrophages after bariatric surgery, associated with more anti-inflammatory cytokine 
production and improved insulin sensitivity, highlighting their importance in the 
inflammatory pathogenesis of T2DM [149-151]. 
1.9 PPAR alpha 
Peroxisome proliferator-activated receptor alpha (PPAR alpha) is a nuclear receptor 
protein encoded for by the PPARA gene. PPAR alpha is part of the subfamily of PPAR 
along with PPARγ (Peroxisome proliferator-activated receptor gamma) and PPARδ 
(Peroxisome proliferator-activated receptor delta) [152]. It was the first PPAR to be 
discovered and was named on the basis of being activated by chemicals that cause 
peroxisome proliferation [153]. Located on chromosome 22q12.2-13.1, PPAR alpha is 
a transcriptional factor and regulator of lipid metabolism [154]. It is abundant in tissues 
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with high FA oxidation activity, like the liver, where it has been proposed to link glucose 
and lipid metabolism with inflammation, making it an attractive target for T2DM 
research [155]. In fact, its agonists, like Fenofibrate, have been used successfully as 
hypolipidaemic agents for decades [156]. PPAR alpha is activated in a ligand-
dependent and independent manner [157, 158]. In the former, ligand-induced 
phosphorylation of receptors in the cytosol is followed by ligand-activated PPAR alpha 
translocation into the nucleus, forming a heterodimer with RXR (retinoid X receptor), 
which then attaches to the consensus sequence of peroxisome proliferator response 
element (PPRE) of target gene, activating transcription of target genes by direct 
genomic binding, in a process facilitated by co-factors and co-repressors [159]. 
Alternatively, a ligand-dependent activated PPAR alpha upon translocation to the 
nucleus binds indirectly to the target gene by forming complexes with other 
transcription factors which is probably regulated by histone acetylase and deacetylase 
activity [160]. Furthermore, a third mechanism (unbound nongenomic response) of 
action for ligand-dependent activation of PPAR alpha is described, where activated 
PPAR alpha’s activate protein kinase cascades resulting in phosphorylation of kinases 
involved in different signalling pathways, that depends on phosphatidylinositol 
signalling [159]. Mapping of PPAR alpha regulatory network in primary hepatocytes 
show that most of the transcription activity is mediated by direct binding to PPRE [159]. 
PPAR alpha regulation is controlled at different levels including ligand availability, 
receptor abundance, and posttranslational modification [161, 162]. Subcellular 
compartmentalisation and intracellular trafficking achieve further regulation of PPAR. 
There is evidence of different subcellular localisation of PPAR in different cell lines 
54 
 
[163]. For example, PPAR alpha is reported to be cytoplasmic in macrophages and 
endothelial cell lines like the EVC-304 [164, 165]. Although it is predominantly nuclear 
in hepatocytes, reports have suggested a cytoplasmic subpopulation in rat 
hepatocytes [165]. Some authors have reported that ligands and certain conditions 
can affect subcellular localisation of PPAR, which shunts across the nuclear 
membrane with the help of importins and calcium-dependent calreticulin [166, 167]. 
The knowledge of PPAR alpha regulation and localisation is essential in correctly 
quantifying and analysing PPAR alpha transcriptional activity. Most mechanistic 
knowledge on PPAR alpha activity has come from mice and rat models. There are 
some subtle differences between human and rodent hepatocytes regarding PPAR 
alpha activity. For example, PPAR is a known carcinogen in rodents, but this has not 
been reported in humans [168]. However, the critical beneficial metabolic functions of 
PPAR alpha remains the same in both species, vis: improvement of glucose and 
energy homeostasis, reduction in inflammation and attenuation of age-related 
dysfunction [169]. PPAR alpha contributes positively to T2DM by suppressing VLDL 
(very low density lipoprotein) and LDL (low density lipoprotein) production, while 
simultaneously raising HDL (high density lipoprotein) levels (a distinct feature in 
humans, not  seen in rodents) [170-172]. Furthermore, PPAR alpha potentiates FA 
oxidation by upregulating genes responsible for both mitochondrial and peroxisome 
oxidation of FAs. Further evidence of its benefits on old and emerging markers of 
insulin resistance reinforces its continuous usefulness [173-175] 
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2.1 Cell culture 
2.1.1 Reagents 
The THP-1 monocytic cell line (THP-1 ATCC® TIB-202™) and HepG2/C3A 
hepatocellular carcinoma cell line (C3A [HepG2/C3A, derivative of Hep G2 (ATCC HB-
8065)] ATCC® CRL-10741™) were obtained from the American Type Culture 
Collection (ATCC). Gibco modified Roswell Park Memorial Institute medium (RPMI 
1640) was obtained from Thermo fisher scientific (UK). The RPMI 1640 is supplied 
already supplemented with L-glutamine (2mM) and glucose (11.1mM). Foetal bovine 
serum, penicillin and streptomycin solutions were purchased from Sigma (UK).  Cells 
utilised for experiments were within passage 6-20. 
2.1.2 Background 
2.1.2.1 THP-1 cells 
THP-1 cells are a human monocytic cell line derived from the peripheral blood of a 1-
year-old male infant with acute monocytic leukaemia. The cell line expresses HLA A2, 
A9, B5, DRw1, and DRw2 antigens, as well as Fc and C3b receptors, but they lack 
surface and cytoplasmic immunoglobulins. They are phagocytic against latex and 
sensitised erythrocytes. THP-1 cells can also be differentiated into macrophages by 
incubation with either phorbol 12-myristate 13-acetate (PMA) or vitamin D3. PMA 
differentiation of THP-1 cells increases cell surface expression of both CD14 and 
CD16. 
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2.1.2.2 HepG2/C3A 
HepG2/C3A cells are a clonal derivative of HepG2 cells, acquired from the liver of a 
15-year-old male Caucasian with hepatocellular carcinoma. The C3A clone is an 
epithelial adherent cell line selected for strong contact inhibition of growth, high 
albumin production, high production of alpha-fetoprotein (AFP) and ability to grow in a 
glucose-deficient medium. Increasing confluence leads to marked reduction in AFP 
production with an increase in albumin secretion. The cell line expresses many genes 
and proteins similar to primary hepatocytes including, but not limited to: AFP, albumin, 
alpha1 antitrypsin, transferrin, cytochrome P450 enzymes. HepG2 cells can be 
differentiated into a quiescent phenotype very similar to primary hepatocytes by 
incubation with either DMSO or retinoic acid. 
2.1.3 Protocol 
2.1.3.1 THP-1 
The THP-1 monocytes were cultured in growth media made up of RPMI 1640 media 
with 2mM glutamine and 11mM glucose supplemented with foetal bovine serum (FBS) 
at a final concentration of 10% v/v, and penicillin (100 µg/ml)/ streptomycin (100 µg/ml) 
solution to a final concentration of 1% v/v. The THP-1 monocytes were cultured in 
75cm2 flasks (Corning® cell culture flasks) with vented caps incubated in a humidified 
environment at 37°C with 5% carbon dioxide. The THP-1 cells were seeded at 3 x 105 
cells/ml in 20ml of growth media and subcultured after 3 days, or when the cells reach 
a density of 8 x 105 cells/ml by centrifuging at 800g for 5 minutes and resuspending in 
fresh warm growth media prior to being counted by trypan blue staining on a Neubauer 
haemocytometer and diluted to the desired cell density. 
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2.1.3.2 HepG2/C3A 
HepG2/C3A cells were cultured in growth media made up of RPMI 1640 media with 
2mM glutamine and 11mM glucose supplemented with foetal bovine serum (FBS) at 
a final concentration of 10% v/v, and penicillin (100 µg/ml)/ streptomycin (100 µg/ml) 
solution to a final concentration of 1% v/v. The cells were cultured in 150cm2 flasks 
(Corning® cell culture flasks) with vented caps incubated in a humidified environment 
at 37°C with 5% carbon dioxide. The cells were seeded at 3 x 105 cells/ml in 30ml of 
growth media and subcultured after 5 days. To passage cells, old medium was 
discarded, and cells were washed three times with warm PBS or serum-free RPMI 
and then detached by adding 5ml of 0.2% Trypsin-EDTA solution incubated at 37°C 
for 5 minutes. 10ml of growth media was added to inactivate trypsin and aspirated 
gently into a 20ml universal. The cell suspension was centrifuged at 800g for 5 minutes 
and the cell pellet was re-suspended in warm growth medium prior to being counted 
by trypan blue staining on a Neubauer haemocytometer and diluted to the desired cell 
density. 
2.2 Differentiation of HepG2/C3A cells 
2.2.1 Background 
HepG2/C3A cells exhibit contact inhibition upon confluence becoming less 
proliferative and more quiescent. However, they still show important differences in 
gene expression and phenotype compared to primary hepatocytes. Primary 
hepatocytes are regarded as the gold standard and have more gene expression of 
albumin, transferrin and xenobiotic enzymes. Exogenous substances like DMSO and 
Retinoic acid have been used to differentiate HepG2 cells into more mature quiescent 
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phenotypes, but these processes may be associated with cellular stress and apoptosis 
[176]. On the other hand, growing cells in reduced cell media has been shown to offer 
a less stressful alternative for differentiation. 
2.2.2 Protocol 
Cells were seeded at a rate of 200 x 106 cells/ml in growth media supplemented with 
10% FCS as indicated above until they achieve 80% confluency. After three washes 
with sterile PBS, cells are re-supplemented with growth media supplemented with 2% 
FCS for 10 days with changing media every two days. 
2.3 THP-1 macrophage differentiation 
2.3.1 Reagents 
Phorbol 12-myristate 13-acetate (PMA) and lipopolysaccharide (LPS) were obtained 
from Sigma (UK). 
2.3.2 Protocol 
THP-1 cells were seeded in 6 well plates at a rate at 1 x 106  cells/ml (total number of 
cells 3 x 106 cells).The cells were treated then primed for 6 hours with FAs (palmitate 
or pentadecanoic acid)  at 50µM, 150µM, and 300µM concentrations, or 5% BSA, 
followed by 320nM of PMA for 66 hours with total treatment time of 72 hours (Figure 
2.1) as previously described [324]. The resultant macrophage phenotype was 
determined by measuring the cytokine secreted. 
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2.4 Cell cycle analysis 
2.4.1 Reagents 
All reagents were obtained from Sigma (UK). Propidium iodide (PI) solution was made 
up at 50μg/ml in 0.1% Triton-X and 0.1% sodium citrate in distilled water. 
2.4.2 Protocol  
Upon cell treatments, cells were washed three times with PBS then centrifuged at 
800g for five minutes to obtain a cell pellet. The cells were then resuspended in 1ml 
of PI solution overnight, washed three times with PBS to remove excess PI and 
analysed under flow conditions (excitation 518nm and emission 617nm) until 20,000 
events was achieved (using Beckman Coulter Quanta or Epics XCL).  
Seed cells 
Treat with BSA or 
FA
Treat with 320nM 
PMA
6 hours 66 hours 
72 hours 
Figure 2.1: THP-1 macrophage differentiation protocol 
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2.5 Flow cytometry measurement of THP-1 cell surface antigen 
2.5.1 Reagents 
Mouse anti-human CD14 RPE-Cy5 conjugated monoclonal antibody (clone 61D3, Abd 
Serotec); Mouse anti-human CD16-RPE Cy5 conjugated antibody (clone 3G8, Abd 
Serotec); Mouse-anti-human CD36-FITC conjugated antibody (clone SMO); Mouse 
IgG1 isotype control FITC and RPE-Cy5 antibodies were all obtained from Abd 
Serotec (UK). 
 
2.5.2 Protocol 
Upon completion of experimental conditions, cells were harvested and suspended in 
ice-cold serum in eppendorfs for 15 minutes to block receptors. Subsequently, cells 
were again harvested by centrifuging at 800g for 5 minutes, at 4°𝐶 and washed thrice 
with ice-cold PBS. Then, the cells were suspended in 500mls of antibodies or isotype 
control (details of antibodies used in section 2.5.1) at saturation concentrations for 30 
minutes on ice in the dark before analysis of 20,000 events by flow cytometry 
(Beckman Coulter Quanta or Epics XCL). Data was analysed using the Flowing 
software (version 2.5). Median fluorescent intensity was used in preference to mean 
intensity as the data was not normally distributed and the median it is less likely to be 
influenced by outliers than mean values.  
2.6 Trypan blue exclusion staining 
2.6.1 Reagents 
Trypan blue reagent, Neubauer haemocytometer, cover slides, and microscope.  
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2.6.2 Protocol 
Cells suspended in growth media were diluted with trypan blue at a ratio of 1:2 and 
allowed to incubate at room temperature for 5 minutes. The suspension was mixed 
thoroughly by pipetting up and down several times. 10µl was added on to each side of 
a Neubauer haemocytometer and cells in 10 random square grids were counted. The 
cell density was determined by the formula: cells/ml = the average number of cells per 
grid x dilution factor x 104 and the viability was expressed in percentage as follows: 
percentage viability = the total number of viable cells (clear cells)/the total number of 
cells counted (included dead cells) x 100. Cell counting was done in technical 
replicates for each representative sample.  
2.7 Measurement of metabolic activity by MTT assay 
2.7.1 Reagents 
The assay reagent was prepared by dissolving (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) in PBS at a concentration of (5mg/ml). 50% DMSO 
was used to lyse the cells. 
2.7.2 Protocol 
100µl of cells at a concentration of 2 x 105 cells/ml were seeded into a 96-well plate 
and treated with FA conjugated to BSA. 10µl of 5mg/ml MTT was added to each well 
4 hours prior to the treatment endpoint and incubated in a cell incubator in the dark for 
a further four hours. DMSO was added to each well to a final concentration of 50% v/v 
to lyse the cells and the plate was placed on a rocker for one hour. The absorbance 
was read at a wavelength of 570nm on a microplate reader.  
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2.8 Determination of protein concentration by BCA 
2.8.1 Reagents 
Bicinchoninic acid solution (made up of bicinchoninic acid, sodium carbonate, sodium 
tartrate and sodium bicarbonate at pH 11.25), copper (II) sulphate pentahydrate (4% 
w/v) solution and 1mg/ml bovine serum albumin (BSA) protein standard solution 
purchased from Sigma-Aldrich. 
2.8.2 Protocol 
Prior to analysis, cell lysates and plasma samples were diluted 1:5 and 1:10 in PBS 
respectively. 10µl of the diluted samples were loaded onto a clear bottom 96-well plate 
in triplicates. A standard curve was created by adding 0µl, 2µl, 4µl, 6µl, 8µl, and 10µl 
of the 1mg/ml BSA protein standard in triplicates onto the 96-well plate. All wells were 
brought to a final volume of 10µl with PBS bringing the final concentration to 0mg/ml, 
0.2, 0.4, 0.6, 0.8, and 1mg/ml of protein respectively. 200µl of BCA solution (made by 
mixing BCA reagent with copper (II) sulphate solution at a ratio of 50:1) was added to 
each standard and sample well. The plate was incubated at 37°C for 30 minutes prior 
to measurement of absorbance at 570nm on an absorbance microplate reader. 
2.9 Conjugation of FA to bovine serum albumin 
2.9.1 Reagents 
FA-free bovine serum albumin (BSA) and sodium hydroxide were purchased from 
Sigma (UK). HPLC-grade ethanol (VWR, UK), palmitate sodium and pentadecanoate 
sodium were purchased from Nu-Check Prep (USA). Serum-free RPMI 1640 media 
was obtained from Gibco (UK). 
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2.9.2 Conjugation of FAs to BSA protocol 
200mM stock solution of the FAs were prepared by dissolving the corresponding FA 
in 2ml 70% ethanol, 0.1M NaOH, 30% distilled water at 60°C on a hot plate (112mg of 
sodium palmitate, 106mg of sodium pentadecanoate). The stock solution was stored 
in -20°C until required.  
A 5mM working solution was prepared by adding 0.5ml of the working solution to 
19.5ml of 5% BSA in serum-free RPMI 1640 media and stirred at 37°C on a hot plate 
for 4 hours, giving an FA/BSA ratio of 6:1. The solution was brought to a pH of 7.4 and 
sterilised through a 0.2µM filter. Sterile FA/BSA solution was stored at 4°C until 
required and warmed to 37°C before use. Working solutions were stored for up to one 
month. 
2.9.3 Cell treatment 
Stock solutions of FA were prepared and stored as previously described. To determine 
the metabolic activity and viability, cells were treated with 50µM, 150µM, 200µM, and 
300µM FA for 4, 6, and 24 hours. For all other experiments, cells were treated with 
300µM palmitate (C16:0), or 50µM pentadecanoate (C15:0) for 6 hours or 24 hours.  
2.10 Analysis of free fatty acid profile in plasma and cell lysates 
2.10.1 Reagents 
Chloroform, methanol, HCl and BHT (2, 6 – Di-tert-butyl-4-methylphenol) were 
purchased from Sigma and stored at room temperature.12% boron trichloride- 
methanol w/w (BCl3-methanol) was supplied by Sigma (UK) and stored at 4°C. Supelco 
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FAME 37 mix was obtained from Sigma (UK) and stored at -20°C. A stock solution of 
1mg/ml of the internal standards, undecanoic acid (C11:0) and heptadecanoic acid 
(C17:0), was made by dissolving 1mg of C11:0 or C17:0 in 1ml of ethanol and stored 
at -20° until required. A working solution of these internal standards were made by 
diluting the stock solution in chloroform/methanol up to a final concentration of 
0.2mg/ml. C11:0 and C17:0 were purchased from Sigma (UK). Choloroform/methanol 
was made up in the ratio of 2:1 with 0.01% BHT (2, 6 – Di-tert-butyl-4-methylphenol), 
wrapped with foil paper and stored in the fridge. A stock solution of 8% w/v HCl solution 
was made from 8.5ml of conc HCl and 41.5ml of methanol and stored in the fridge. 
FAMEs were analysed using the Agilent 7820A gas chromatography (GC) machine 
with an Omegawax 250 Fused silica Bonded polyethylene phase Capillary column 
[30m x 0.25mm x 0.25µm], and a flame ionisation detector (FID). 
2.10.2 Protocol  
2.10.2.1 Folch lipid extraction 
Plasma samples were added into a glass centrifuge tube using glass pipettes and 
mixed with 100µl of 0.2mg/ml internal standard (C11:0 and C17:0 solution). This was 
then made to a final volume of 600µl with 0.9% saline solution. 1.8ml of 
chloroform/methanol (2:1) with 0.01% BHT was added and vortexed for 30 seconds. 
The mixture was then spun down at 750g for 10 minutes forming three distinct layers. 
The chloroform layer (bottom layer) was eluted and placed into a glass vial after which 
it was dried down by liquid nitrogen and used immediately or stored at -80°C for future 
use.   
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2.10.2.2 Methylation of FA by HCl method 
Plasma samples were extracted by the Folch method as described above, then 0.2ml 
of toluene, 1.5ml of methanol and 0.3ml of 8% HCl solution were added to the dried 
lipid sample extract. The glass vial was sealed with a PTFE lid and heated on the 
heating block at 45°C for 1 hour for FFA methylation. Once methylation was complete 
and the mixture was left to cool to room temperature, 1ml of hexane and 1ml of water 
was added. The mixture was then vortexed and spun at 750g for 2 minutes after which 
the floating hexane layer, which contains the lipids, was eluted into a glass vial. This 
was subsequently dried down completely by liquid nitrogen and re-suspended in 20µl 
of hexane for FAME analysis. 
2.10.2.3 Methylation of FA by BCl3 method 
Plasma samples were added into a glass centrifuge tube using glass pipettes and 
mixed with 100µl of 0.2mg/ml internal standard. For cells, 1 x 106 cells were washed 
thrice with PBS and resuspended in 500µL of chloroform/methanol. Both plasma and 
cell lysates were made to a final volume of 600µl with 0.9% saline solution after which 
2ml of 12% BCl3-methanol was in a glass vial and heated on a heating block at 60°C 
for 10 minutes. After cooling to room temperature, 1ml of water and 1ml of hexane 
was added to the mixture and vortexed for 30 seconds. It was then spun at 750g for 2 
minutes and the top hexane layer eluted. This was then dried down and resuspended 
in 20µl of hexane. 1µl of the sample was injected into the GC for analysis. FA peaks 
were identified by comparing retention times and peak areas to that of the FAME 37 
mix.  
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2.11 Protein carbonyl determination 
2.11.1 Reagents 
Anti-DNP antiserum (mouse IgE), peroxidase labelled rat anti-mouse IgE, o-
phenylenediamine (OPD), NUNC-Immuno MaxiSorp 96 well plates, hydrogen 
peroxide, BSA, citrate phosphate buffer (50mM citric acid, 100mM sodium phosphate), 
2N sulphuric acid and Tween-20, sodium borohydride, trichloroacetic acid, ferrous 
sulphate, desferal, DNPH, Sephadex PD10 column, o- Phenylenediamine (OPD) 
tablets, and guanidine HCl were all purchased from Sigma-Aldrich (UK). 
2.11.2  Preparation of protein carbonyl standards 
40mg of sodium borohydride was added gently into 20ml of BSA (10mg/ml in PBS) in 
a sealed universal at room temperature. It was then allowed to fizz for up to 30 
minutes, as oxygen is eliminated. This was then referred to as reduced BSA (BSAred). 
It was subsequently neutralised by adding 1 N HCl using drops on pH paper. 
Afterwards, it was desalted using two separate PD10 columns of Sephadex G-25, 
which were pre-equilibrated with PBS according to manufacturer’s instructions. 
Finally, the protein content of the BSAred column eluate was measured using the BCA 
method and adjusted to 2 mg/ml with PBS. 
Oxidised BSA (BSAox) was then produced by a Fenton-type reaction using ferrous 
sulphate as follows: Freshly prepared iron solution was neutralised with sodium 
dihydrogen carbonate using a pH meter. The volume was then adjusted to 100ml to 
give an iron concentration of 10mM Fe (II) SO4.  
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0.1ml, 0.5ml and 2ml of the iron solution was then added to each of four separate 
tubes containing 5ml of BSA solution (10 mg/ml in PBS) and incubated for 30 min at 
room temperature. These were then termed BSAox solutions. Desferal was then 
added to a final concentration of 5 mM to chelate the iron and prevent any further 
oxidation. Four separate PD10 columns of Sephadex G-25, which were pre-
equilibrated with PBS according to manufacturer’s instructions, were then used to 
desalt the BSAox. The protein content in the BSAox column eluates was then 
measured using the BCA method and further adjusted to 2 mg/ml BSAox with PBS. 
The remaining BSA (10mg/ml in PBS) was then adjusted to 2mg/ml. This meant there 
were now five oxidised protein standards, vis: BSAox, BSA, BSAox0.1, BSAox0.5, and 
BSAox2. The carbonyl content was then measured by the colourimetric technique 
described in section 2.11.2.1. All the standards were then aliquoted and stored at -
20°C. 
2.11.2.1 Colourimetry method for protein carbonyl determination  
Half a millilitre of each of the albumin standards prepared above were aliquoted into 
Eppendorf tubes in duplicates for mixing with either 10mM DNPH in 2M HCl (in 
duplicates), or 2M HCl alone without DNPH (again in duplicates). This was incubated 
at room temperature for 1 hour, vortexing every 15 min. The proteins were then 
precipitated with a final concentration of 20% trichloroacetic acid (w/v) by adding 
0.25ml of 100% TCA to 1ml of each BSA solution above, which was then subsequently 
vortexed and centrifuged at 13,000g for 3 min. After discarding the supernatant, the 
pellets were washed three times with 1ml ethanol-ethyl acetate (1:1 v/v) and re-
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dissolved in 1ml of 6M guanidine HCl in 20mM potassium phosphate. The solution 
was vortexed and incubated for 30 minutes at 37°C to re-dissolve. After removing any 
remaining insoluble material by centrifugation (again at 13,000g for 1 minute), the 
supernatants were retained in a separate tube. The absorbance of the supernatants 
was measured at 360nm with a spectrophotometer, using plain 6M guanidine HCl in 
20mM potassium sulphate as blank. The carbonyl content was calculated using the 
molar absorption coefficient of 22000 M-1 cm-1 for aliphatic hydrazones. The protein 
content of the samples was measured using BCA method again and the carbonyl 
content of samples was recorded as nmol carbonyl/mg protein. 
2.11.2.2 Protein carbonyl ELISA 
Five carbonyl standards previously prepared as described in section 2.11.2.1 and all 
plasma samples were diluted to 20µg/ml with carbonate buffer. 50µl of each diluted 
standard and sample were loaded on a Nunc Maxisorb 96 well plate in triplicates and 
incubated at 37°C for 1 hour. After washing the wells three times with washing buffer, 
50µl of 1mM DNPH in 2M HCl was loaded in each well and incubated at room 
temperature in the dark for 1 hour. The wash step was repeated and the wells were 
blocked with blocking buffer overnight at -4°C. After another washing step, the plates 
were incubated with primary antibody (anti- DNP antiserum, mouse IgE), diluted 
1:2000 with blocking buffer, at 37°C for 2 hours. The plates were washed again and 
incubated with secondary antibody (peroxidase labelled rat anti-mouse IgE), diluted 
1:5000 in blocking buffer, at 37°C for 1 hour. After another washing step, the wells are 
developed with 50µl of OPD substrate (10ml 0.15M citrate phosphate buffer, 20mg 
OPD tablet and 10µl 8.8M hydrogen peroxide). with OPD substrate for approximately 
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15 minutes in the dark and the reaction with stopped with 2M sulphuric acid. The 
absorbance was read immediately on a microplate reader at 490nm wavelength.  The 
carbonyl content was interpolated from a standard curve of the absorbance of the five 
carbonyl standards and expressed as nmol/mg. 
2.12 Cytokine analysis 
2.12.1 Reagents 
Analysis of human TNFα, IL-10, IL-6, and C-reactive protein (CRP) were performed 
with representative ELISA kits purchased from Affymetrix (eBiosciences, UK). All the 
reagents needed for the ELISA were provided within the kits. ELISA kit numbers: CRP 
(88-7502-28), TNFα (88-7346-86), IL-10 (88-7106-86), IL-6 (88-7066-86). 
2.12.2 Protocol 
The protocol for all the ELISAs are the same and are therefore presented as one. The 
96-well plate was coated with capture antibody overnight at 4°C and washed 5 times, 
after which it was blocked with blocking buffer for 1 hour at room temperature. 
Following another wash step, the plates are incubated with standards and samples 
overnight at 4°C and washed again 5 times. Subsequently, the plates are incubated 
with detection antibody at room temperature for 1 hour and then incubated with Avidin-
HRP at room temperature for 30 minutes. Following another wash step, TMB solution 
is then added to the wells and incubated at room temperature for 15 minutes to allow 
for optimal colour development. The reaction was terminated by adding a stop solution 
and the absorbance reading is measured at 450nm using a microplate reader. The 
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concentration of cytokines in the sample was interpolated from an internal standard 
curve. 
2.13 Cell Lysis 
2.13.1 Reagents 
Radioimmunoprecipitation assay (RIPA) buffer (150 mM sodium chloride, 1.0% triton-
X, 0.5% sodium deoxycholate, 0.1% SDS, 50mM Tris, pH 8.0), protease inhibitor 
cocktail (Sigma-Aldrich, UK), 21-gauge needle, 1ml syringes (Appleton woods, UK). 
2.13.2 Protocol 
Treated cells were harvested by centrifugation at 800g for 5 minutes and washed with 
ice-cold PBS and centrifuged (HepG2/C3A cells trypsinized prior to this step). The 
pellet was lysed in 50µl RIPA buffer supplemented with 0.5µl protease inhibitor cocktail 
before lysis and incubated for 30 minutes on ice. The DNA in the lysate was then 
sheared using a 21-gauge needle attached to a syringe and centrifuged at 16,000xg 
for 30 minutes at 4°C to remove cellular debris.  
2.14 PPAR alpha activation assay 
2.14.1 Reagents 
PPAR alpha Transcription Factor Assay Kit (ab133107) and a nuclear extraction kit 
(40410) were purchased from Abcam and Actif Motif respectively. 
2.14.2 Nuclear extraction protocol 
Cells were collected by centrifugation at 800g for 5 minutes (adherent cells were gently 
lifted with a cell scraper then centrifuged). 500µl of hypertonic buffer was added to the 
72 
 
cell pellet, resuspended by pipetting up and down several times, and incubating on ice 
for 15 minutes for cells to swell. The cells were lysed by adding 25µl detergent and 
vortexing for 1 minute. A sample of the cells was examined under the microscope to 
ensure lysis of cell membrane and expulsion of the nucleus (repeat lysis step if cells 
not lysed). The suspension was centrifuged at 16,000g for 15 minutes at 4°C. The 
supernatant was collected as the cytoplasmic fraction. The pellet was resuspended in 
50µl of complete lysis buffer and incubated on ice for a further 30 minutes after which 
5µl of detergent was added and then vortexed for 1 minute. The suspension was 
centrifuged at 16,000g for 30 minutes. The supernatant was collected as the nuclear 
fraction and stored at -80°C until required. Samples were diluted 1:20 before protein 
determination by BCA. 
2.14.3 PPAR alpha activity assay protocol 
The 96-well plate was purchased pre-coated with a dsDNA sequence containing 
PPRE. The samples were prepared and added to the plates along with a positive and 
negative control and then incubated overnight at 4°C. The plates were washed 5 times 
and a PPAR alpha primary antibody was added and incubated at room temperature 
for 1 hour. After another 5 washes, the plates were subsequently incubated with a goat 
anti-rabbit HRP conjugated secondary antibody at room temperature for 1 hour. 
Following another wash step, the developing solution was then added to the wells and 
incubated at room temperature for 45 minutes after which a stop solution is added and 
the absorbance reading is taken at 450nm using a microplate reader.  
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2.15 Quantification of glucose output 
2.15.1 Reagents 
Glucose (hexokinase) quantification assay purchased from Sigma-Aldrich (UK) 
includes glucose standard (10mg/ml) and a lyophilised glucose assay reagent. 
2.15.2 Protocol 
After the indicative treatment endpoint, cells were washed three times with PBS to 
remove glucose and then incubated for 16 hours in glucose production medium 
(glucose- and phenol red-free DMEM containing gluconeogenic substrates, 20 mmol/l 
sodium lactate, and 2 mmol/l sodium pyruvate). The lyophilised glucose assay buffer 
was reconstituted with 20ml of distilled water. Glucose standards (0.05mg/ml – 
5mg/ml) and samples (50µl) were added to a 96 well plate. The reconstituted glucose 
assay buffer (100µl) was added to each well. The plate was incubated for 15 minutes 
at room temperature prior to measuring absorbance at 340nm on a microplate reader. 
2.16 Glycogen content determination 
2.16.1 Reagents 
0.2M sodium hydroxide (NaOH), 30mM HCl, 0.1mg/ml of amyloglucosidase (Sigma-
Aldrich, UK) in 0.1M sodium acetate buffer pH 5.0, RIPA buffer, glucose assay kit 
(Sigma, UK). 
2.16.2 Protocol  
After the indicative endpoint, treated cells were glucose starved overnight to deplete 
glycogen stores and treated with RPMI media containing 11mM glucose for 48hrs with 
100nM insulin in the final 1hr of incubation. Cells were washed in ice-cold PBS and 
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immediately lysed with RIPA buffer as previously described. 5ml of 0.2M NaOH was 
added to the suspension and boiled for 1 hour. The samples were brought down to a 
final volume of 500µl with a concentrator. The samples were divided into aliquots; one 
used for glycogen content determination, the other two for protein determination and 
baseline glucose content determination as previously described. To the aliquot for 
glycogen content determination, 0.1mg/ml of amyloglucosidase was added and 
incubated overnight at room temperature. The glucose content was then determined 
by the hexose kinase method as previously described. The difference in glucose 
concentration between the first two aliquots gives the total glycogen content. In this 
thesis, one mole of glycogen corresponds to one mole of glycosyl units originating 
from glycogen. 
2.17 Oil red O lipid staining 
2.17.1 Reagents 
Oil Red O was obtained from Cayman (UK) and isopropanol from Fisher (UK). Mayer’s 
Haematoxylin solution and paraformaldehyde were obtained from Sigma (UK). 
2.17.2 Protocol 
Cells were grown in a 24-well plate and treated as previously described. After the 
indicative endpoint, cells were fixed with 4% paraformaldehyde in PBS for 10 min and 
then stained with 1.8 mg/mL oil Red O in 60% aqueous isopropanol for 15 min at room 
temperature. This was then rinsed five times with 60% aqueous isopropanol and PBS. 
Fixed cells were subsequently counterstained with Mayer’s haematoxylin solution for 
1 minute and viewed under a light microscope at x40 magnification. For quantitative 
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analysis of cellular lipids, isopropanol was added to each of the stained culture plates. 
The extracted dye was removed immediately by gentle pipetting and its absorbance 
was monitored at 495 nm using a microplate reader. Cellular neutral lipid content was 
normalised with cellular protein concentration. The protein concentration of each cell 
lysate was measured with BCA protein assay reagent as previously described. 
2.18 Periodic Acid Schiff staining for glycogen 
2.18.1 Reagents 
Periodic Acid-Schiff (PAS) staining was done using the kit (catalogue number: 395B) 
by Sigma, UK following manufacturer’s protocol. 
2.18.2 Background 
Histochemical determination of glycogen is based upon the periodic acid-Schiff 
reaction which was originally described by MacManus in 1948 [177]. The PAS reaction 
involves the oxidation of glycols within polysaccharides (like glycogen) to form 
dialdehydes which react with the Schiff reagent to form a purple-magenta colour. 
However, it is not specific to glycogen as it is able to react with mucopolysaccharides 
and basement membranes. 
2.18.3 Protocol 
Cells were grown in a 24-well plate and treated as previously described. After the 
indicative endpoint, cells were fixed for 10 minutes with 4% paraformaldehyde in PBS 
and stained with periodic acid solution for 5 minutes. After five washes, cells were 
stained with Schiff’s reagent for 15 minutes and counterstained with Mayer’s 
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haematoxylin solution for 1 minute and viewed under a light microscope at x40 
magnification. Staining intensity was quantified using ImageJ software. 
2.19 Extraction of total ribonucleic acid (RNA) 
2.19.1 Reagents 
Extraction of total RNA from cells was done using the RNeasy mini extraction kit 
(Qiagen, UK). Other materials used include sterile RNase-free pipet tips, 
microcentrifuge (with rotor for 2 ml tubes), 70% ethanol, a sterile syringe with 20-gauge 
needle (washed prior to use with 0.1M NaOH, 1mM EDTA and rinsed with RNase-free 
water) and β-mercaptoethanol (β-ME). 
2.19.2 Protocol 
2 x 106 cells were harvested as previously described and washed three times with 
PBS. The cells were centrifuged at 300g for 5 minutes and the PBS removed. 350µl 
of RLT (lysis) buffer supplemented with 3µl of β-ME was added and vortexed for 30 
seconds. A syringe attached to a 20-gauge needle was used to homogenise the 
sample. The lysate was then stored at -80°C until required or extracted immediately. 
350µl of 70% ethanol was then added to the homogenised lysate and mixed 
thoroughly by pipetting up and down several times. 700µl of the sample was then 
transferred (including any precipitate that may have formed) to an RNeasy spin column 
placed in a 2 ml collection tube and centrifuged for 15 seconds at ≥8000 x g (≥10,000 
rpm). The flow-through was discarded. 700µl of Buffer RW1 was added to the RNeasy 
spin column and centrifuged for 15 s at ≥8000 x g (≥10,000 rpm) to wash the spin 
column membrane. After discarding the flow-through, 500µl Buffer RPE was added to 
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the RNeasy spin column and centrifuged for 15 s at ≥8000 x g (≥10,000 rpm) again to 
wash the spin column membrane. After discarding the flow-through, the membrane 
was again washed with Buffer RPE and centrifuged for 2 min at ≥8000 x g (≥10,000 
rpm). The long centrifugation dries the spin column membrane, ensuring that no 
ethanol was carried over during elution of RNA, because residual ethanol may 
interfere with downstream reactions. The flow-through was discarded and the column 
placed in a new 2ml collection tube. The column was centrifuged again for 1 min to 
ensure no residual ethanol is left on the column. The collection tube was then replaced 
with a new 1.5 ml collection tube and 50µl of RNase-free water was added directly to 
the spin column membrane. RNA was eluted by centrifuging for 1 min at ≥8000 x g 
(≥10,000 rpm). The concentration and purity of the extracts were determined using a 
Nanodrop  (diluted in 10 mM Tris·Cl,* pH 7.0 and 10 mM Tris·Cl,* pH 7.5 respectively). 
The ratio at absorbance 260nm and 280nm (260/280) of 2 was used as a primary 
measure for RNA purity while a 260/230 absorbance ratio of 2.0-2.2 was used as a 
secondary measure of nucleic acid purity. 
2.20 Reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) 
2.20.1  Reagents  
All primers were purchased from Thermo Fisher Scientific (UK) except the reference 
gene, YWHAZ, which was obtained from Qiagen (UK). The list of primers sequences 
can be found in table 2.1. The primer sequence for YWHAZ was not made available 
by Qiagen. SYBR green PCR master mix (Primer Design, UK), 96 well PCR plates, 
strip caps, nuclease free water, Quantitect reverse transcription kit (Qiagen, UK), PCR 
primers, Stratagene mx3000p qPCR thermocycler.  
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2.20.2 Protocol 
Reverse transcription was performed using a high capacity reverse transcription kit 
purchased from Qiagen, to convert extracted RNA to cDNA. A master mix solution 
was made from the reverse transcription kit components, consisting of per sample; 4µl 
reverse transcriptase buffer, 1µl Quantiscript reverse transcriptase and 1µl RT primer 
mix. The master mix was mixed by vortexing and 10µl added to 200µl PCR tubes. An 
equal volume of extracted RNA sample (containing 500ng RNA) was added to the 
PCR tubes. To control for possible genomic DNA contamination, the samples were 
also incubated with a master mix solution without the addition of the reverse 
transcriptase enzyme. The converted cDNA was diluted 1 in 10 with nuclease-free 
water and stored at -20°C until needed. The expression of specific mRNA was 
measured by RT-qPCR analysis of the diluted cDNA. A qPCR reaction stock solution 
was made by mixing for each sample: 0.5µl of the forward and reverse primers, 4µl 
nuclease free water and 10µl SYBR green master mix. To each well on a qPCR plate 
15µl of the reaction stock solution was added to 2µl of the diluted cDNA. A negative 
control was included in the experiment by using 2 µl of nuclease-free water instead of 
cDNA. The wells were sealed with strip caps and the plate loaded onto a Stratagene 
mx3000p qPCR thermocycler. The following PCR condition were used: 95⁰ C, 2 
minutes hold for 1 cycle; 95⁰ C, 10 sec hold + 60⁰ C, 30 sec hold, for 45 cycles; 1 cycle 
– 60⁰ C, 30 sec + 95⁰ C, 30 sec. The produced data was analysed using the 
comparative delta-delta CT method. In the delta-delta CT method, the CT value of the 
gene of interest is first subtracted from the CT value of the reference gene to obtain 
ΔCT for each experimental sample, then the difference between the ΔCT values of 
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each experimental gene and the control gene is determined (this is now called ΔΔCT). 
Finally, the formula 2^(-ΔΔCT) was used to calculate the fold change in the expression 
of the gene of interest [178]. Therefore, results are normalised as a fold change relative 
to untreated controls and normalising to the CT  value for the reference gene. Where 
multiple plates were used, a reference gene, negative control and untreated control 
was added to each plate for corresponding experimental genes of interest. 
Table 2.1: List of primers sequences1 used for RT-qPCR, including forward (F) 
and reverse (R) sequences.  
Oligo Name Sequence (5' to 3') 
ABCD1 (F) TACCGGGTCAGCAACATGG 
ABCD1 (R) TGGTCAGGTTGGAGTAGAGGT 
ABCD2 (F) GGATGGAAAAATCGTGAAAAGCA 
ABCD2 (R) ATGGCAATCATAAGCCACTTGA 
ABCD3 (F) GCTGGTGTCTCGAACATATTGT 
ABCD3 (R) ATCTTTCCTGCTACGACCAATG 
ACAA2 (F) CTGCTCCGAGGTGTGTTTGTA 
                                                     
1 Primer sequence for reference gene not made available by QIAGEN (UK) 
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Oligo Name Sequence (5' to 3') 
ACAA2 (R)  GGCAGCAAATTCAGACAAGTCA 
ACAD10 (F) GTACGAACCTGGGTTAAGCAG 
ACAD10 (R)  CAGCCATTCGATCAGCCTCT 
ACADL (R)  CGCAACTACAATCACAACATCAC 
ACDL (F) TGCAATAGCAATGACAGAGCC 
ACOX1 (F) AATCGGGACCCATAAGCCTTT 
ACOX1 (R)  GGGAATACGATGGTTGTCCATTT 
ACSL1 (F) CTTATGGGCTTCGGAGCTTTT 
ACSL1 (R)  CAAGTAGTGCGGATCTTCGTG 
CAT (F) TGGGATCTCGTTGGAAATAACAC 
CAT (R) TCAGGACGTAGGCTCCAGAAG 
CD36 (F) CTTTGGCTTAATGAGACTGGGAC 
CD36 (R) GCAACAAACATCACCACACCA 
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Oligo Name Sequence (5' to 3') 
CPT1A (F) ATCAATCGGACTCTGGAAACGG 
CPT1A (R)  TCAGGGAGTAGCGCATGGT 
CPT2 (F) CATACAAGCTACATTTCGGGACC 
CPT2 (R)  AGCCCGGAGTGTCTTCAGAA 
FABP1 (F) GTGTCGGAAATCGTGCAGAAT 
FABP1 (R)  GACTTTCTCCCCTGTCATTGTC 
FASN (F) AAGGACCTGTCTAGGTTTGATGC 
FASN (R)  TGGCTTCATAGGTGACTTCCA 
GSK3 (F) GTGCCCGAGACAGTGTACC 
GSK3 (R) ACACCTTGACATAGAGGATAGGG 
KPNA2 (F) GGCACTGTAAATTGGTCTGTTGA 
KPNA2 (R) CCTGGCAGCTTGAGTAGCTT 
KPNB1 (F) CCACTTTCCTTGTGGAACTGT 
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Oligo Name Sequence (5' to 3') 
KPNB1 (R) CTCTGCTGATATTGTGCCTTGA 
MLYCD (F) ACCTAGAACGGGTTACCTGG 
MLYCD (R)  CAGGGGTCGAACAGTGAGAA 
NCOA1 (F) AATGAATACGAGCGTCTACAGC 
NCOA1 (R) TTTCGTCGTGTTGCCTCTTGA 
PPARA (F) TTCGCAATCCATCGGCGAG 
PPARA (R) CCACAGGATAAGTCACCGAGG 
RXRa (F) GACGGAGCTTGTGTCCAAGAT 
RXRa (R) AGTCAGGGTTAAAGAGGACGAT 
SCD1 (F) CTCCACTGCTGGACATGAGA 
SCD1 (R)  AATGAGTGAAGGGGCACAAC 
SCD5 (F) TGCGACGCCAAGGAAGAAAT 
SCD5 (R) CCTCCAGACGATGTTCTGCC 
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Oligo Name Sequence (5' to 3') 
SLC25A20 (F) GACACGGTCAAGGTCCGAC 
SLC25A20 (R) GCAGCCATTCCCCGATATAGC 
SLC2A2 (F) GCCTGGTTCCTATGTATATCGGT 
SLC2A2 (R) GCCACAGATCATAATTGCCCAAG 
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3.1 INTRODUCTION 
The increasing burden of T2DM has been associated with an increase in sedentary 
lifestyle, an increasingly ageing population and a rise in the prevalence of obesity 
[179]. The ß-islet cells in the pancreas are responsible for the production and secretion 
of insulin, the primary regulatory hormone for glucose metabolism. An increase in 
body-mass index (BMI) and the consequent increase in adiposity contributes to an 
increase in FFAs in circulation and leads to a selective utilisation of these FFAs for 
energy, at the expense of glucose. Excess FFAs also suppress ß-islet cell function, as 
well as activate processes that lead to impaired cellular insulin signalling [180, 181]. 
Therefore, T2DM is thought to be due to pancreatic dysfunction resulting from a 
complex interplay of peripheral insulin resistance and reduced insulin secretion, 
consequently resulting in impaired glucose and FA uptake from the circulation and 
hyperglycaemia with associated hyperlipidemia [182]. The factors that contribute to 
the onset and complications of T2DM are complex and include genetic and 
environmental factors. 
Obesity has long been established as a modifiable risk factor for T2DM because most 
people with T2DM are obese; supported by the fact that the rise in prevalence of 
obesity has also coincided with a concomitant rise in prevalence of T2DM. Also, 
patients that have undergone bariatric surgery for obesity and/or modified their weight 
through diet or increased physical activity have observed an improvement in glycaemic 
control and reduced diabetic risk [183-188]. Epidemiologic and experimental studies 
have established an association between T2DM and obesity including complex 
interactions that involve mitochondrial dysfunction, deranged FA metabolism, pro-
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inflammatory cytokines and adipokines, energy overload, peripheral insulin resistance 
and ectopic fat deposition (especially liver fat and visceral adipose tissue) [189]. 
Although these interactions are not fully understood, recent studies have expanded 
further on the nature of adipocytes in T2DM. For instance, visceral adipose tissue 
(VAT) over subcutaneous adipose (SAT) was considered by some a more significant 
predictor of insulin resistance [190, 191]. Others suggested that abdominal SAT might 
be as important [31]. Perhaps this difference might also be explained by a diversity of 
immune response in these locations. There is evidence to suggest that diets rich in 
monounsaturated FA (instead of saturated FAs), as is the case with Mediterranean 
diets, can reduce the risks of T2DM even without changes in weight or physical activity 
[192-194]. Furthermore, animal studies show expression of anti-inflammatory 
macrophage phenotypes (M2) in the mesenteric adipose tissue after dietary oleic acid 
intake [195]. There is also evidence of the anti-atherogenic activity of MUFA but not 
saturated FA like palmitate, which preferably displays a pro-inflammatory and pro-
atherogenic phenotype that promotes insulin resistance [196-198]. 
It is a well-accepted fact that the concentration of total FFAs in the plasma increases 
with obesity, T2DM and age. However, knowledge of the distribution of specific FAs 
according to length and saturation is limited despite the view that structural diversity 
determines their functions. The cellular FA distribution, mainly found in phospholipids, 
ceramide and sphingomyelin in membranes, is determined by both dietary FA supply 
and metabolic enzyme activity, including elongases (encoded by the ELOVL genes) 
and desaturases [199]. How membrane phospholipids and the total FA lipidome 
change with age, obesity, insulin resistance, and T2DM is poorly understood. 
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Nevertheless, membrane FAs act as organisational platforms for insulin receptor 
signalling and as substrates for synthesis of anti-inflammatory and pro-resolving 
mediators of inflammation. Furthermore, there is substantial epidemiological evidence 
from the EPIC study linking the FA profile of erythrocyte membrane phospholipids and 
activity of desaturase enzymes with the incidence of T2DM [200]. 
Many obese people do not have T2DM, raising a conundrum about the metabolically 
healthy obese. A cross-sectional study designed to characterise metabolically healthy 
obesity in rare pairs of obesity-discordant monozygotic twins revealed the presence of 
liver fat as the most important predictor of insulin resistance [32]. The ectopic 
deposition of fat in the liver could be explained by SAT inflammation resulting in local 
mitochondrial dysfunction and associated failure to metabolise fat in SAT. Further 
mitochondrial dysfunction in T2DM can also be explained by an increase in reactive 
oxygen species (ROS) leakage from complex 1, which is usually due to nutrient excess 
from circulating glucose and FFAs. This results in a vicious negative feedback cycle 
that includes increased protein oxidation and a down-regulation of glyceraldehyde 
phosphate dehydrogenase (GADPH) as well as an increase in several pathways, that 
include but are not limited to increased formation of advanced glycation end-products 
(AGE); increase in the polyol pathway; increase in the hexosamine pathway; and an 
increase in activation of protein kinase C (PKC) [189, 201]. Figure 3.1 attempts to 
simplify the complex interactions that encompass T2DM. 
T2DM complications are heavily associated with inflammatory changes, especially in 
the vasculature. People with T2DM have a higher risk of myocardial infarction, stroke 
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and other cardiovascular disorders than the general population [202]. Because the 
treatment options for these complications are limited and sometimes palliative, it has 
become imperative to identify markers to predict these complications during the early 
stages of the disease and identify drug targets to help prevent them. Therefore, it will 
be useful to have a model to predict the onset of T2DM in the general population to 
aid focused prevention strategies. 
Much work has been done in developing risk prediction models for the onset of T2DM. 
This practice has been encouraged by evidence from different preventive strategies 
on people with impaired glucose tolerance or impaired fasting glycaemia in different 
countries [184, 190, 203]. Despite the different widespread use of weak prediction 
model methods, some risks have appeared consistently as possible predictors of 
diabetic outcomes [204]. Even though some of these prediction scores are never used 
in practice because the tests are not available for routine use, it has identified 
biomarkers and indices for further research. Regarding FA biomarkers, there has been 
a growing interest in the biological relevance of odd-chain saturated FAs (OCSFA) 
over the last decade. These FA were initially assumed to be metabolically irrelevant in 
humans and were therefore used as internal standards in lipid profiling by gas 
chromatography (GC). However, this narrative has been challenged by growing 
evidence showing a negative correlation between dairy intake and metabolic disease 
development, and emerging evidence pointing to an association between OCSFA and 
dairy intake [205]. Despite ongoing debate regarding the human ability to 
biosynthesise or indeed metabolise OCSFA, its relationship with T2DM prevention has 
been buttressed by publications from the European Prospective Investigation (EPIC) 
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study cohort [200, 206, 207]. However, the relationship between OCSFA and markers 
of inflammation are still not well characterised. 
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3.2 AIMS AND HYPOTHESIS 
This chapter aims to determine the role of FFAs as predictive biomarkers of fasting 
blood glucose and inflammation in T2DM with a particular focus on pentadecanoic 
acid (C15:0), one of the more abundant OCSFA in human plasma. The detection of 
OCSFAs in plasma samples is challenging because they are less abundant in blood 
compared to their saturated counterparts. Traditionally, FAs are recovered from 
plasma samples by a time-consuming two-step method of Folch extraction followed 
by methylation. This chapter will look at optimising a robust method for efficient plasma 
lipid extraction and analysis by a direct method. The direct method is less time-
consuming and requires less resources and has the potential to accurately quantify 
the lipid profile of patients with T2DM, with particular emphasis on OCSFAs, with the 
same efficiency as the two-step method.  
3.2.1 Aims 
1. To develop a method for reproducible plasma lipid extraction and identification 
of OCSFAs using gas chromatography 
2. To characterise the lipidome in patients with T2DM and age-matched controls 
3. To use FA profiles to develop a predictive model for fasting blood glucose and 
markers of inflammation 
4. To evaluate the protein carbonyl content as a marker of oxidative stress for the 
progression of T2DM. 
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3.2.1.1 Hypothesis 
1. The recovery efficiency of FAs from plasma will not differ between the direct 
method and two-step method. 
2. The concentration of C15:0 will negatively correlate with fasting blood glucose 
levels 
3. Markers of adiposity (leptin and BMI) will correlate positively with FAs 
4. FAs will positively correlate with marker of inflammation. 
 
 
Figure 3.1 : A simplified schematic of the interactions that lead to T2DM. CHD (Coronary Heart Disease), CRP (C-
reactive protein), T2DM (Type 2 diabetes) (Misra and Shrivastava 2013) 
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3.3 METHODS 
3.3.1 Protein carbonyl ELISA 
Protein carbonyls were detected in plasma by an ELISA based assay as described in 
section 2.11.2 
3.3.2 BCA assay 
A BCA assay was performed on all the samples to determine their protein 
concentrations. All reagents used were obtained from Sigma (UK). Briefly, 400 µl of 
copper (II) sulphate was added into 20 ml of BCA solution. A protein standard was 
aliquoted into a 96-well plate to correspond to 0, 0.2, 0.4, 0.6, 0.8 and 1.0 mg/ml of 
protein to generate a standard curve. 10 µl of representative samples were then 
aliquoted into separate wells in the 96-well plate in triplicates and 200 µl of the BCA 
solution was then added and left to incubate at 37°C for 30 minutes after which it was 
read on a microplate reader at a wavelength of 570nm. Protein concentration of 
samples were then interpolated from the standard curve.  
3.3.3 Folch lipid extraction from plasma 
A modified Folch method was employed for lipid extraction from plasma samples as 
described in section 2.10.2.  
3.3.4 Methylation of FFA  
 FAs in plasma were esterified to FA methyl esters (FAMEs) using either BCl3 or HCl 
method as described section 2.10.3.2. 
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3.3.5 Study population 
Plasma samples used in this thesis were taken from a cohort of T2DM patients and 
controls recruited in Birmingham. Ninety-six samples (47 controls and 49 T2DM, NHS 
ethics study number 11/WM/0288) were sampled randomly from this cohort for 
analysis. Details of the study population used for this study, the protocol, ethics, 
inclusion and exclusion criteria, has already been described [208]. Briefly, a random 
number was generated by excel and paired with each sample. This number was then 
sorted in ascending order, and the first 50 samples for each cohort were selected for 
the study. Five samples (3 control and 1 T2DM) were excluded from the analysis 
because there was no fasting glucose measurement recorded. Standard universal 
precautions were observed in collecting and extracting plasma samples from whole 
blood. Blood samples were collected in EDTA bottles and centrifuged at 300g for 10 
minutes to extract plasma. All study participants were recruited from the same 
community in Birmingham. Ethical approval was granted by the Aston University and 
Staffordshire NHS Research ethical committees.  
3.3.6 Statistical analysis 
Data were analysed using SPSS version 21 (Armonk, New York, USA). Descriptive 
analysis of biochemical data was performed for all variables with percentages and 
mean (standard deviation) as appropriate for normally distributed data, or median 
(range) for non-normally distributed data. A two-tailed, unpaired student’s t-test was 
used to compare means between two groups of normally distributed data, while a 
Mann-Whitney test was used in the same scenario for non-normally distributed data. 
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3.3.6.1 Statistical model 
The following steps were undertaken in model development. Missing values were 
analysed pairwise and data from all participants (controls and T2DM) were included in 
the regression analysis. 
1. Based on the hypothesis, C15:0 was fitted into a multiple linear regression 
model to predict the independent variable of interest. On the basis that FAs 
interact biologically, all FAs in our data were also included in the model as 
interactors and analysed in a backward stepwise method. Variables with a 
variance inflation factor (VIF) > 10 (to account for multicollinearity) and F 
statistic > 0.10 were removed from the next step of the model. Statistically 
significant variables remaining in the final step of the model were considered 
predictive of the independent variable and added to the next step in the model. 
2. Subsequently, a bivariate analysis was performed to determine the variables 
(baseline characteristics) which correlated significantly with the independent 
variable of interest. These variables were then used to adjust for the predictor 
variable of interest.  
3. Statistically significant FAs and variables from step 2 were then fitted into a 
generalised linear regression.
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3.3.7 Gas chromatography 
Table 3.1:  Details of the GC protocol used in the analysis of fatty acid methyl esters (FAME) 
Column  Omegawax 250  
Fused silica 
Bonded; poly(ethylene) phase 
Capillary column 
30m x 0.25mm x 0.25µm 
280
°
C maximum oven temperature  
Injection volume  1µl  
Inlet type  Splitless  
Injection port temperature  280
°
C  
Carrier gas velocity  35cm/sec at 40
°
C  
Splitless hold time  1 minute  
Start oven temperature  40
°
C  
Oven temperature programme  40
°
C hold 2 minutes, then ramp 50
°
C per minute to 260
°
C, hold 6.6 minutes (13 minutes runtime)  
Final oven temperature  260
°
C  
Standard mix used  SUPELCO 37 FAME mix  
Instrument  Agilent 7820A  
Data analysis software  ChemStation  
96 
 
Table 3.2: GC protocol for SUPELCO (recommended) method 
Column  Omegawax 250  
Fused silica 
Bonded; poly(ethylene) phase 
Capillary column 
30m x 0.25mm x 0.25µm 
280
°
C maximum oven temperature  
Injection volume  1µl  
Inlet type  Splitless  
Injection port temperature  250
°
C  
Carrier gas velocity  30cm/sec at 50
°
C  
Splitless hold time  0.75minute  
Start oven temperature  50
°
C  
Oven temperature programme  50
°
C hold 2 minutes, then ramp 4
°
C per minute to 220
°
C, hold 15 minutes (59 minutes runtime)  
Final oven temperature  220
°
C  
Standard mix used  SUPELCO 37 FAME mix  
Instrument  Agilent 7820A  
Data analysis software  ChemStation  
97 
 
3.4 RESULTS 
3.4.1 Gas chromatography optimisation 
The GC optimisation aimed to reduce analysis time, to allow increased sample 
throughput, without negatively affecting elution pattern, peak identification, resolution, 
and quantification. The optimised method used for this study was adapted from the 
protocol recommended by Supelco for use on the Omegawax 250 column for the 37 
FAME mix. Details of the protocol for both methods are found in Table 3.1. The first 
step of the optimisation involved increasing the oven temperature ramp at a rate of 
4°C per run until the maximum ramp rate the machine can handle without lagging was 
achieved. The outcome measured was the number of resolved peaks identified. It was 
expected that any optimum condition would resolve 35 peaks as stated on the Supelco 
FAME mix catalogue. For the Agilent 7820a, 52°C/minute was the highest oven 
temperature ramp rate that did not result in oven temperature lag. 50°C/minute was 
therefore used as the set ramp rate for this method.  
3.4.1.1 Inlet temperature 
To determine the optimum inlet temperature, temperatures within a range of +/-50°C 
of the recommended injection temperature (250°C) was tested. The outcome 
measures were the number of peaks and mean peak areas from each standard 
injection temperature run. A repeated measure one-way ANOVA was used to analyse 
the experiment with the 250°C run set as control (Figure 3.2). All the inlet temperatures 
yielded 35 peaks; hence, attention was then focused on the mean peak area from 
each run. The mean peak area increased with increasing inlet temperature as shown 
in Figure 3.2a (p < 0.001). Also, high molecular weight discrimination reduced with 
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increasing inlet temperature (Figure 3.2b), which is depicted by an increase in the 
mean peak areas of the last eight peaks (each FAME is represented by a single bar 
within each temperature run in Figure 3.2b) as temperature increases. Furthermore, 
the mean peak areas of inlet temperatures of 300°C and 280°C were statistically 
significantly higher than 250°C (p < 0.0001 and 0.04 respectively) as shown in Figure 
3.2c. 
The decision to stick with 280°C as the optimal inlet temperature was made based on 
the fact that there was no thermal degradation of any of the FAMEs. In comparison, 
several lower molecular weight FAMEs were degraded with the 300°C run (Figure 3.2: 
signal overlay of both runs). 
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Figure 3.2 : Effect of Inlet temperatures on FAME elution.  
The Supelco FAME 37 mix was run at the recommended Supelco protocol and the inlet temperature was altered for each run. Five separate 
standard runs were carried out for each set inlet port temperature. The FAMEs were analysed using the resultant peak areas from the GC. (a) The 
difference in total mean peak areas of each temperature runs. Data presented as Mean and 95% CI. **** represents a p < 0.00001, ** represents 
p = 0.001, and * p < 0.05 after a repeated measure one-way ANOVA with Geisser Greenhouse correction and Tukey post-test comparison. (b) 
Shows the mean difference and 95% CI between each inlet temperature run and the control (250°C).  
Inlet temperature 
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3.4.1.2 Splitless Purge Time 
In a splitless injection, excess solvent (and sometimes excess sample) in the inlet is 
purged through the split vent to prevent tailing of the solvent throughout the 
chromatogram that would otherwise prevent identification of analytes. Because 
different analytes have different boiling points and migrate at different speeds in the 
inlet, it is important that the purge time be long enough to capture as much sample as 
possible and short enough to prevent tailing of the solvent on an analyte. To determine 
the optimal splitless purge time for the study protocol, different purge times were 
plotted against mean peak areas of all analytes (Figure 3.3a) and analytes of interest 
(Figure 3.3b). The ‘analytes of interest’ were C4:0, C17:0 and C24:0, representing 
early, middle and late eluting FAMEs. There was a statistically significant linear 
increase in mean peak areas as split purge time increased from 0.5 minutes to 1.25 
minutes. The smallest observed difference in mean peak areas was between 0.75 and 
1.0 minute. However, this difference was also statistically significant (mean difference: 
451.6; 95% CI: 180-722; p = 0.0005). From these data, a splitless purge time of 1.25 
minutes looked to be the optimal choice, however, on further analysis of analytes of 
interest, C4 was observed to co-elute with the solvent when a splitless purge time of 
1.25 minutes was applied (Figure 3.3b). Therefore, 1 minute was set as the optimal 
splitless purge time. 
3.4.1.3 Final oven temperature 
Final oven temperatures of 200°C, 220°C, 240°C and 260°C were compared for the 
number of peak areas that could be identified (maximum oven temperature for column 
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= 280°C). Final oven temperatures of 200°C, 220°C and 240°C only eluted 34 peaks 
compared to the 35 peaks observed in the 260°C run. 
3.4.1.4 Other variables 
All other variables like inlet pressure, carrier gas velocity and flow rate were left at the 
recommendations of SUPELCO for use on the 37 FAME mix (Table 3.2). The FID 
detector temperature was increased from 260°C (SUPELCO recommendation) to 
300°C based on the recommendation of the Agilent 7820a GC manual (to set detector 
temperatures to at least 300°C to prevent soot collection). A splitless injection was 
used instead of a split because it was predicted that the samples to be analysed would 
be in minute quantities.  
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Figure 3.3 : Effect of altering Inlet splitless purge time on FAME elution.  
The Supelco FAME 37 mix was run at the recommended Supelco protocol and the splitless purge time was altered for 
each run. 5 separate standard runs were carried out for each set splitless purge time. The FAMEs were analysed using 
the resultant peak areas from the GC. (a) Shows the mean peak areas of all 37 FAME analytes between different splitless 
purge times. b) Shows peak areas for C4, C17 and C24 plotted against different splitless purge times. 
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3.4.1.5 New protocol vs SUPELCO recommended protocol 
The new protocol had a run time of 13 minutes compared to 59 minutes (SUPELCO), 
saving 46 minutes, which is enough time for just over three runs with the new protocol. 
To validate the new protocol, its variability and reliability were compared with the 
recommended protocol. The coefficient of variation (CV) for retention time was 
calculated for both protocols using data from 20 runs of Supelco FAME 37 mix (5 runs 
each on Day 1, 2, 8 and 9; to account for inter-run, inter-days and inter-week variation). 
The CV of the new and old protocol was 1.35% and 0.46% respectively (usually, a CV 
of 4% or less is an acceptable level of variation/precision for an instrument). To 
determine the reliability of the new protocol, the Cronbach's alpha internal consistency 
reliability estimate was calculated. The new protocol was found to be 99.6% reliable. 
3.4.1.6 Limit of detection 
To determine how sensitive the GC was in identifying small samples, the FAME  37 
mix was diluted serially with a factor of 10 until the GC could no longer identify 35 
peaks. This limit was reached with a 1:100 dilution which represents 2ng of C17:0. 
3.4.1.7 C17:0 standard curve. 
To determine how accurately the GC quantifies different concentrations of FAMEs 
after methylation, a standard curve was generated using C17:0 (internal standard). 
The peak area was used for quantification and found to be highly correlated to C17:0 
amount (R2 = 0.99) 
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Figure 3.4: Standard curve for C17:0 internal standard.  
1mg/ml solution of C17:0 was prepared in chloroform/methanol as previously described. A serial dilution was done to obtain 
0.2mg/ml, 0.4mg/ml, 0.6mg/ml and 0.8mg/ml C17:0 solutions. Three 100µl aliquots of each dilution were extracted by the 
direct method and derivatised using BCl3 and analysed by GC. The R2 for the curve was 0.99 
 
 
3.4.2 Lipid extraction and methylation optimisation  
3.4.2.1 Lipid extraction before methylation 
FA analysis by GC depends upon the volatility of the different FAs and discrete 
chromatographic separation of them in the absence of contaminating molecules. 
Methylation of FA to yield (FAMEs) renders them volatile. The Folch method (modified 
by adding BHT to prevent FA oxidation) is one of the most widely used and reliable 
extraction methods for lipids from biological samples, but it is time-consuming. To test 
the value of pre-extraction before methylation, three independent aliquots from the 
same pool of plasma sample were analysed directly (without prior extraction), or by a 
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measure the FFA recovery from both methods as represented by peak areas of 
FAMEs quantified by the GC. The peak area represents the quantity of FAMEs 
detected on GC. 
To measure the difference between both derivatisation methods, a Wilcoxon matched-
pairs test and a two-way ANOVA were applied to test the difference between the total 
FAME amount detected and the peak areas for individual FAMES respectively (Figure 
3.5). The two-step method had a higher average peak area (mean difference: 16.48; 
95% CI: -117.5 to 150.6) compared to the direct method, but this was not statistically 
significant (two-tailed p value = 0.58), even after excluding C17:0 (internal standard) 
from the analysis (p = 0.79). However, the direct method recovered more internal 
standard (C17:0) on average than the two-step method (OR: 1.6; p= 0.144) and was 
expected, therefore, to differ significantly for the amount of FAMEs detected as 
interpolated by C17:0. However, this was not exactly the case. Although the direct 
method had a higher FAME recovery (mean difference: 57.4ng, 95% CI: -254.6 to 
369.4; median of difference [MoD]: 33.8, 97.85% CI -25 to 86) compared to the two-
step method, this was not statistically significant (two-tailed p value = 0.16). 
Interestingly, the direct method also recovered more C15:0 compared to the two-step 
method (Figure 3.5a), but this was not statistically significant (mean peak area 
difference 144.6; 95% CI: -426 to 719).  
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Figure 3.5 : The effect of extraction and derivatisation approach of fatty acid quantification from plasma.  
Pooled plasma (500µl) were either derivatised and extracted in one step (Direct method) or extracted by modified Folch method prior 
to derivatisation (Two-step method). Three independent samples were derivatised with HCl as detailed in methods and analysed for 
each group. Derivatised lipids were separated by GC and detected as peak areas and compound amount. (a) A comparative recovery 
of FAMEs between the two methods showing log peak area for selected FFA identified. (b) Total FFA recovered determined against 
a standard curve of FAMEs and relative to internal standard.  A Two-Way Anova with repeated measures was used to test the 
difference between derivitisation methods and FAME peak areas for (a), and a Wilcoxon matched-pairs sign rank test was used to 
assess statistical significance for (b).  
Key for box and whisker plot: Vertical line within box represents median, cross within box represents mean, whiskers represent 
highest and lowest observations, box represents interquartile range, dots outside box represents an outlier. 
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3.4.2.2 Methylation methods 
To determine which methylation method to employ, two acid-catalysed 
transmethylation methods were compared. Three 500µl pooled plasma samples were 
aliquoted, extracted and derivatised separately by the direct method. Each sample 
was run thrice on the GC with identified FFA recorded as peak areas. C17:0 was 
added as an internal standard, and FAME amounts were interpolated from the areas 
of identified peaks on the chromatogram. The recovery amount for the two methods 
was analysed using a Wilcoxon matched-pairs sign rank test. 
After excluding C17:0 recovery from the analysis, the BCl3 method showed higher 
amounts of FAMEs compared to the HCl method (Figure 3.6b), with a MoD of 121.1 
(97.85% CI: 66.7 to 3047, two-tailed exact p < 0.001). The most statistically significant 
observed differences between both methods in terms of FA recovered were among 
C18:1n9 and C18:2n6 (two-tailed p value < 0.01 for both observations).  
3.4.3 Plasma sample volume 
Different volumes of plasma were compared to determine the lowest optimal volume 
required to identify and quantify FAMEs with no loss of sensitivity. Decreasing plasma 
volumes (500µl, 100µl and 50µl) were compared and analysed by repeated measure 
one-way ANOVA using the amount of FAMEs recovered as an outcome. To correct 
for identification and quantification bias due to dilution, a dilution correction was 
applied to the final lipid extract volume as follows: final lipid extracts from 500µl, 100µl, 
and 50µl plasma samples were dried down to 250µl, 50µl, and 25µl respectively.  
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As shown in Figure 3.7, the amount of FAMEs recovered reduces with increasing 
volumes of plasma samples used for extraction and methylation. A repeated measures 
one-way ANOVA analysis showed that there is a 92.57% chance that the differences 
in the mean FAME amounts observed between the different plasma volume groups in 
this study is real and not due to chance (p value= 0.015). The most considerable 
observed mean difference (and only statistically significant difference found) in FAME 
amount was between the 50µl and 100µl samples (mean difference: 9.912µg/ml; p = 
0.03). However, when C17:0 was removed from the analysis, there was no statistically 
significant difference in the FAME amounts recovered between all groups. The mean 
differences between 50µl samples compared to 500µl samples was 9.039µg/ml (p = 
0.06), and there was no significant difference in FAME concentrations between 500µl 
and 100µl samples (mean difference: -0.87µg/ml; p = 0.92).  
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Figure 3.6 : The effect of derivatisation methods on free fatty acid quantification from plasma.  
500µl of pooled plasma were either derivatised with HCl or BCl3.Three independent samples were derivatised and 
analysed for each group. Derivatised lipids were separated by GC and detected as either peak area of selected fatty 
acids (a) or total fatty acid recovery amount (b). Amount was calculated using a calibration table that measures 
individual response factors of each FAME based on an external standard run (FAME 37 mix) and the amount of C17:0  
internal standard in the sample. A Two-Way Anova with repeated measures was used to test the difference between 
derivitisation methods and FAME peak areas for (a), and a Wilcoxon matched-pairs sign rank test was used to assess 
statistical significance for (b).  
Key for box and whisker plot: Vertical line within box represents median, cross within box represents mean, whiskers 
represent highest and lowest observations, box represents interquartile range, dots outside box represents an outlier. 
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Figure 3.7 : The effect of plasma volume on FFA quantification by GC.   
BCl3 was used to derivatise three volumes of pooled plasma (50µl, 100µl or 500µl). Three independent samples 
were derivatised and analysed for each group. Derivatised lipids were separated by GC and detected as the 
compound amount. The amount was calculated using a calibration table that measures individual response factors 
of each FAME based on an external standard run (FAME 37 mix) and the amount of C17:0 internal standard in the 
sample. A dilution was applied to avoid identification bias. Dilution calculation resulted in diluting the final 
concentrations of 500µl and 100µl samples by 10 and two times the final volume of 50µl sample. Data presented 
as mean and 95% CI. Statistical analysis assessed by One-way ANOVA, applying a Geisser Greenhouse 
correction, with Tukey’s post-test comparison.  
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3.4.4 Baseline characteristics of study participants 
Participants from this study were sampled from an existing cohort of type 2 diabetics 
(T2DM) and healthy controls as detailed in the method section. 
There was no significant difference in the disposition of males or females between 
control and healthy cohorts. The diabetic cohort was significantly older (mean 
difference: 17.71years, p < 0.0001), with a higher BMI (mean difference: 8.85kg/m2, p 
< 0.0001), compared to the control cohort. A statistically significant higher difference 
was also observed with the visceral fat score in the diabetic cohort compared to the 
control (mean score difference: 6.69, p< 0.0001). Fasting plasma glucose, Leptin, 
soluble E-selectin, soluble thrombomodulin, C-reactive protein and protein carbonyl 
levels were higher in the diabetic cohort compared to healthy controls (Table 3.3). 
To estimate how well protein carbonyl levels and the plasma lipid profile predict T2DM 
or inflammation, a multiple linear regression model was developed comparing them 
(predictor variables) to fasting plasma glucose, leptin, BMI and markers of 
inflammation. The regression models were fit through a backward step method. The 
variance inflation factor (VIF) was used to detect colinearity, while the R squared 
values and chi-squared of each variable were used as factors to eliminate variables 
from the model.  Any variable with a VIF > 10 and chi-square > 0.05 was eliminated 
from the next step of the model. The best fit model was achieved when all the variables 
left in the model had a VIF <10, a statistically significant ANOVA and chi-square value. 
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Table 3.3: Baseline characteristics of study participants 
Statistically significant differences between control and diabetic cohorts were adjusted 
for during regression analysis.  
Healthy 
controls  
n=47  
Type 2 
Diabetes 
group 
n=49  
Total (n=96)  
Frequency/ 
Mean difference 
p value  
     
Gender   
-female 
-male  
15 (51.7%) 
14 (48.3%)  
13 (41.9%) 
18 (58.1%)  
28 (46.7%) 
592 (53.3%)  
0.44  
Age (years)  42.21 (12.63)  59.48 (14.25)  17.71  <0.0001  
Height(cm)  171.38 (1.95)  167.10 (1.76)  4.27  0.10  
Weight (Kg)  72.941 (2.65)  85.32 (8.43)  12.37  0.01  
BMI (Kg/m2)  24.45 (0.95)  30.31 (1.10)  5.85  <0.0001  
Visceral fat score 
(1-59) 
5.93 (0.63)  12.62 (0.86)  6.69  <0.0001  
Leptin ng/ml  8.41 (1.09)  1160 (180)  1151.59  <0.0001  
Soluble E-selectin 
ng/ml 
33.28 (4.59)  48.08 (4.7)  14.80  0.01  
Fasting plasma 
glucose (mmol/L)  
4.3 (0.13)  9.3 (0.8)  5.03  <0.0001  
CRP (µg/ml)  0.85 (0.14)  5.06 (0.75)  0.79  <0.0001  
Protein carbonyl 
(nmol/mg)  
2.75 (.08)  3.89 (0.17)  1.14  <0.0001  
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Table 3.4: Fatty acid concentration in plasma (expressed as a percentage of total 
FA) from fasting healthy controls and patients with T2DM.  
Comparisons between healthy controls and the T2DM group was performed using 
appropriate statistical tests: chi-squared tests for categorical variables, Student's t-test 
for normally distributed continuous variables and Mann–Whitney U-test for non-
normally distributed continuous variables 
FAME (% of total FA) 
Healthy controls  
 
Median(range)/ 
Mean (SD) 
 
n=47  
Type 2 diabetes group  
 
Median (range)/ 
Mean (SD) 
 
 
n=49  
p value  
C14:0a  0.95 
(6.39)  
1.07 
(3.43)  
0.34  
C15:0a 0.07 
(2.05)  
0.00 
(0.36)  
0.05  
C16:0a  20.01 
(44.81)  
21.82 
(100.00)  
0.33  
C16:1  2.13 
(1.14)  
2.56 
(1.36)  
0.14  
C18:0  5.25 
(2.88)  
4.98 
(2.73)  
0.64  
C18:1 27.47 
(6.70)  
29.33 
(10.15)  
0.32  
C18:2n6  33.44 
(12.36)  
26.51 
(12.26)  
0.01  
C18:3n6a  0.06 
(56.02)  
0.25 
(41.22)  
0.43  
C18:3n3a  0.48 
(1.48) 
0.60 
(38.59) 
0.25  
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3.4.5 Predicting fasting plasma glucose 
To find out how lipid profile and protein carbonyl level predict fasting plasma glucose, 
they were fitted into a model comparing them with the most significant predictors of 
fasting plasma glucose in our data, vis: age, gender and BMI (Table 8.1 in appendix). 
Pentadecanoic acid (C15:0), palmitic acid (C16:0), stearic acid (C18:0), linoleic acid 
(C18:2n6) and alpha-linolenic acid (C18:3n3) were found to be the only FA that 
predicted fasting plasma glucose in our model (Table 3.5). The correlation between 
fasting plasma glucose and these FAs in the model was 0.54, representing a moderate 
correlation, and the observations accounted for 22.6% of the variation in fasting 
plasma glucose after adjusting for chance agreement (R2 = 0.292, adjusted R2 = 
0.226). C16:0 had the largest predictive effect on fasting plasma glucose (0.843, 95% 
CI: 0.009 to 0.047), and along with C18:3n3, were the only FAs that predicted a unit 
increase in fasting plasma glucose. After adjusting for the effects of age, gender and 
BMI, only C15:0, C18:0 and C18:3n3 were found to be statistically significant 
predictors of fasting plasma glucose (Table 3.6). 
The lipidome and protein carbonyl levels were also tested in a model with leptin. It is 
not surprising to find that FFA that were negatively correlated with fasting plasma 
glucose is also positively correlated with plasma leptin (Table 3.7) since leptin 
correlates negatively with fasting plasma glucose. There was a moderate correlation 
(R 0.56) between the variables in the model and leptin, and these variables accounted 
for 26.4% of the variation in the data for leptin after chance adjustment. The model 
showed a negative correlation between protein carbonyls and leptin levels even after 
adjusting for age, gender, BMI and fasting plasma glucose (Table 3.8). 
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There was a strong correlation (R = 0.64) between FAs and BMI as shown in Table 
3.8. The FAs in the model accounted for 37.2% of the variability in BMI. The model for 
BMI showed a positive correlation with cis-13,16-docosadienoic acid (C22:2) and oleic 
acid (C18:1n9). Only linoleic acid (C18:2n6) showed a negative correlation (Table 3.9). 
These three FFAs were still statistically significant even after adjusting for age and 
gender (Table 3.10). 
Table 3.5: Predictors of fasting plasma glucose 
Variable  Unstandardised 
coefficients  
Standardised 
coefficients  
p 
value  
95% CI  
Constant  7.355  
 
< 
0.0001  
4.508 to 10.202  
C15:0  -0.879  -0.491  0.003  -1.453 to – 0.304  
C16:0  0.28  0.843  0.005  0.009 to 0.047  
C18:0  -0.077  -0.561  0.022  -0.143 to -0.012  
C18:2n6  -.006  -0.438  0.016  -0.011 to -0.001  
C18:3n3  0.235  0.428  0.010  0.059 to 0.411  
Model summary: R = 0.540; R
2
 = 0.292; Adjusted R
2 
= 0.226; outcome variable = Fasting plasma glucose  
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Table 3.6: Predictors of Fasting blood glucose. Adjusted for age, gender, and 
BMI 
Variable  Standardised 
coefficients  
p 
value  
95% 
CI  
C15:0  0.454  0.002  0.273-
0.754  
C18:0  0.938  0.038  0.882-
0.996  
C18:3n3  1.237  0.013  1.043-
1.463   
Age 1.037 0.126 0.990- 
1.086 
BMI 1.027 0.674 0.906- 
1.165 
Gender (male) 1.654 0.500 0.383- 
7.134 
Table 3.7: Predictors of Leptin 
Variable  Unstandardised 
coefficients  
Standardised 
coefficients  
p value  95% CI  
Constant  10.028  
 
0.003  3.534 to 16.522  
Protein carbonyl  -2.120  -0.373  0.003  -3.499 to -0.742  
C16:0  -0.031  -0.685  0.021  -0.057 to -0.005  
C18:0 0.108  0.577  0.015  0.022 to 0.199  
C18:2n6  0.007  0.341  0.062  0.000 to 0.014  
C18:3n3  0.235  0.428  0.010  0.059 to 0.411  
Model summary: R = 0.560; R
2
 = 0.314; Adjusted R
2 
= 0.264; outcome variable = Leptin  
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Table 3.8: Predictors of Leptin: Adjusted for fasting plasma glucose, BMI, age 
gender 
Variable  Standardised coefficients  p value  95% CI  
Protein carbonyl  0.093  <0.0001  0.25-0.345  
Fasting plasma glucose  0.716  0.011  0.553-0.927  
Gender (M)  0.046  0.006  0.005-0.405 
Age 0.981 0.547 0.920- 1.045 
BMI 0.992 0.934 0.828- 1.190 
C18:2n6 1.001 0.832 0.995- 1.005 
C18:3n3 1.059 0.562 0.572- 1.287 
 
Table 3.9: Predictors of BMI 
Variable  Unstandardised 
coefficients  
Standardised 
coefficients  
p value  95% CI  
Constant  28.392  
 
< 0.0001  25.527 to 31.257  
C15:0 -0.452  -0.182  0.096  -0.986 to 0.082  
C18:1n9  0.019  0.746  <0.0001  0.011 to 0.027  
C18:2n6  -0.016  -0.818  <0.0001  -0.022 to -0.011  
C22:2  0.181  0.225  0.038  0.059 to 0.411  
Model summary: R = 0.644; R
2
 = 0.414; Adjusted R
2 
= 0.372; outcome variable = BMI  
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Table 3.10: Predictors of BMI after adjusting for age, gender, fasting blood 
glucose and Leptin 
Variable  Standardised coefficients  p value  95% CI  
C18:2n6  0.983  <0.0001  0.978-0.989  
C18:1n9  1.021  <0.0001  1.013-1.027  
C22:2  1.215  <0.0001  1.151-1.281  
Age 0.969 0.492 0.886- 1.060 
Gender 1.689 0.647 0.179- 15.921 
Fasting plasma glucose 1.190 0.142 0.943- 1.501 
Leptin 1.025 0.791 0.853- 1.232 
 
3.4.6 Predictors of inflammation 
 To determine which FFAs predict inflammatory events, FFAs and protein carbonyl 
levels were tested against three markers of inflammation, vis: C-reactive protein, 
soluble thrombomodulin and soluble E-selectin. 
In one of the models, palmitoleic acid (C16:1) and an ω3 FA, cis-11,14,17-
eicosatrienoic acid (C20:3n3) were found to be moderately (R = 0.447) negatively 
correlated with soluble thrombomodulin (Table 3.11). On the contrary, C18:0 and 
C18:1n9 were positively correlated even after adjusting for possible confounders 
(Table 3.12). The FAs in the model accounted for only 14.2% of the variation within 
soluble thrombomodulin within the data. 
Soluble E-selectin was predicted by C15:0, C18:2n6 and C18:3n3. C15:0 and C18:2n6 
were negatively correlated with soluble E-selectin (Table 3.13). There was a weak 
correlation between the FAs in the model and soluble E-selectin (R = 0.43), and the 
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predictors could only account for 14.2% of the variation in soluble E-selectin. However, 
when these FFAs were adjusted for other inflammatory markers, the only FFA that 
predicted soluble E-selectin was C18:2n6 (Table 3.14).  
Only protein carbonyl levels and C18:3n3 were found to be correlated significantly with 
C-reactive protein, both showing positive moderate (R = 0.58) correlations (Table 
3.15). However, when adjusted for known predictors of inflammation, leptin also 
becomes negatively correlated with CRP (Table 3.16). 
 
Table 3.11: Predictors of soluble thrombomodulin 
Variable  Unstandardised 
coefficients  
Standardised 
coefficients  
p value  95% CI  
Constant  4.609  
 
< 0.0001  2.667 to 6.551  
C16:1  -0.056  -0.478  0.024  -0.105 to -0.008  
C18:0 0.028  0.320  0.072  -0.003 to 0.059  
C18:1n9  0.006  0.472  0.021  0.001 to 0.010  
C20:3n3  -0.037  -0.524  0.003  -0.062 to -0.013  
Model summary: R = 0.447; R
2
 = 0.220; Adjusted R
2 
= 0.142; outcome variable = soluble thrombomodulin  
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Table 3.12: Predictors of Soluble thrombomodulin. Adjusted for age, fasting 
blood glucose, CRP, soluble E-selectin and BMI 
Variable  Standardised coefficients  p value  95% CI  
C18:2n6  0.996  0.008  0.993-0.999  
C18:1n9  1.003  0.031  1.001-1.015  
C16:1  0.933  0.002  0.892-0.975  
C18:0 1.022  0.040  1.001-1.044  
Fasting blood glucose  1.307  0.008  1.072-1.593  
Age 1.006 0.729 0.972- 1.042 
BMI 0.989 0.827 0.892- 1.095 
Soluble E-selectin 1.017 0.098 0.997- 1.037 
CRP 0.817 0.083 0.651- 1.027 
Protein carbonyl 0.745 0.330 0.412- 1.348 
 
 
Table 3.13: Predictors of soluble E-selectin 
Variable  Unstandardised 
coefficients  
Standardised 
coefficients  
p 
value  
95% CI  
Constant  60.465  
 
< 
0.0001  
47.219 to 73.712  
C15:0  -3.168  -0.302  0.050  -6.338 to 0.001  
C18:2n6  -0.037  -0.434  0.002  0.060 to -0.014  
C183n3  1.081  0.336  0.048  0.010 to 2.150  
Model summary: R = 0.431; R
2
 = 0.186; Adjusted R
2 
= 0.142; outcome variable =  soluble E-selectin  
 
 
 
 
121 
 
 
Table 3.14: Predictors of soluble E-selectin: Adjusted for Age, BMI, Fasting 
plasma glucose, leptin, and CRP 
Variable  Standardised coefficients  p value  95% CI  
C18:2n6  0.960  0.004  0.934-0.987  
Age  0.616  0.004  0.442-0.858  
Fasting blood glucose  6.503  <0.0001  2.777-15.228  
BMI 1.217 0.740 0.381- 3.893 
Leptin 0.595 0.515 0.125- 2.843 
CRP 1.189 0.874 0.141- 10.032 
 
 
Table 3.15: Predictors of C-reactive protein 
Variable  Unstandardised 
coefficients  
Standardised 
coefficients  
p value  95% CI  
Constant  -3.776  
 
0.01  -0.668 to 0.884  
Protein 
carbonyl  
1.718  0.446  <0.0001  0.885 to 2.551  
C18:3n3  0.165  0.328  0.004  0.056 to 0.274  
Model summary: R = 0.588; R
2
 = 0.345; Adjusted R
2 
= 0.322; outcome variable = C-reactive protein  
 
 
Table 3.16: Predictors of CRP. Adjusted for Age, BMI, Fasting plasma glucose, 
and soluble E-selectin 
Variable  Standardised coefficients  p value  95% CI  
Protein carbonyl  3.017  0.032  1.101-8.264  
C18:3n3  1.179  0.003  1.056-1.316  
Leptin  0.851  0.031  0.735-0.985  
Age 1.020 0.483 0.966- 1.077 
Fasting blood glucose 0.973 0.836 0.751- 1.260 
Soluble E-selectin 1.016 0.471 0.973- 1.060 
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3.5 DISCUSSION 
This chapter describes the successful validation and application of reproducible and 
robust methods for determination of plasma FAs and protein carbonyls in populations 
of healthy adults and patients with T2DM.  
Many direct derivatisation techniques have been developed over the years to eliminate 
time spent on lipid extraction and potentially cut cost on reagents. Most of these 
techniques have been modifications of the method by Lepage and Roy (1984). This 
study compared a direct method, which involved methylation of plasma without prior 
extraction, with a two-step method that involved prior extraction by the modified Folch 
method. The direct method recovered more C17:0 standard compared to the two-step 
method. A logical explanation to this could be that C17:0 is possibly lost during the 
modified Folch extraction of lipids from plasma since this involves several extraction 
steps and manipulations (Sattler et al., 1991, Lepage and Roy, 1986). However, 
Amusquivar et al. (2011) showed that the direct method recovered less internal 
standard compared to the standard two-step method, leading to an overestimation of 
quantified FFAs. They explain that the high polarity of most internal standards used 
(C15:0 and C17:0) means that prior extraction with chloroform/methanol is more 
favourable, especially with increasing amounts of internal standards added 
(Amusquivar et al., 2011). Paradoxically, the direct method recovered less FAMEs on 
average than the two-step method, although this was not statistically significant. C13:0 
caused most of the variation between FAME recoveries between both methods. The 
twentyfold difference in recovery of C13:0 (shown in the appendix) between both 
methods suggests it is possibly due to an artefact. Artefacts are expected to be 
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produced with the modified Folch method due to the methylation of BHT (formation of 
methyl-toluene) that is added to extracting solvent and used to minimise oxidation. 
However, the artefact for methyl-toluene is usually expected to elute with C16:0 or 
C16:1 rather than C13:0. It is important to note that there are conflicting reports from 
literature reviewing both direct and two-step-method (Cavonius et al., 2014, 
Amusquivar et al., 2011, Castro-Gómez et al., 2014). Most studies comparing the two 
methods usually use methods partially modified in their labs, making it difficult to 
standardise or compare directly. However, in this study, both methods did not differ 
much, and the most likely cause of the variation could be as a result of artefact 
formation. 
The HCl method of FFA methylation offers the advantage of being safer and producing 
fewer artefacts, compared to the conventional boron trifluoride method (BF3). The HCl 
method is the reference method used in our laboratory. However, reports suggest that 
the BCl3 method is associated with less unwanted side reactions seen with BF3 and is 
as effective (Klopfenstein, 1971). Perhaps the most significant advantage of using 
either BF3 or BCl3 is that less time is required for derivatisation. It takes between 5-10 
minutes for full derivatisation of FFA with the BCl3 method compared to 60 minutes for 
the HCl method. This study found a statistically significant difference in the mean 
recoveries of FAMEs between both methods. The BCl3 method recovered more 
FAMEs on average than the HCl method, the most prominent difference being with 
the long chain FFA- especially those with 18 carbon atoms or more. The significant 
higher recovery of these long-chain FAs is unlikely due to methyl-toluene artefact since 
both methods were evaluated with the direct method. There is insufficient literature 
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covering the derivatisation of FFA with BCl3, although its efficacy has been compared 
to BF3 (Klopfenstein, 1971). The most cited limitation of BF3 is the shelf-life. Left for 
too long, even when refrigerated, it is notorious for producing artefacts with significant 
loss of PUFAs. Here, BCl3 recovery of PUFA was better than that of HCl. 
This study showed that there is no difference in FAME recovery when 50µl, 100µl, or 
500µl of plasma is derivatised. To correct for detection bias and water content, both 
50µl and 100µl samples were diluted to a consistent final volume of 500µl with PBS. 
Small amounts of water in plasma, glassware, reagents and the atmosphere can 
interfere with FAME formation, especially PUFAs (Christie, 2011); therefore it was 
important to account for this in the analysis. Because water is a stronger electron donor 
than most aliphatic alcohols, the presence of water favours the formation of 
intermediates and prevents the completion of the reaction. 
The second phase of optimisation that is described in this report is in use of 
instrumentation. In GC, the three most common consequence of an inappropriate inlet 
temperature is high molecular weight discrimination, sample decomposition and 
splitless purge time (Klee, 2015). These were the measures considered for optimising 
the GC protocol for this study. High molecular weight discrimination often occurs when 
the inlet temperature is too low and high molecular weight analytes fail to vaporise in 
the inlet; therefore, not adequately reaching the column. During the optimisation of this 
protocol, it was observed that peak areas towards the last third of the run increased 
with rising temperature. Another possible cause of high molecular weight 
discrimination, needle discrimination, was accounted for in this study by using the hot 
125 
 
needle injection technique. Optimal inlet temperature choice for this study also 
considered sample decomposition. Some low molecular weight highly volatile analytes 
are thermally labile and decompose at high inlet temperatures, which is usually 
observed on the chromatogram as several split peaks in the first third of the 
chromatogram. In this study, the inlet temperature showing the least discrimination 
was the 300°C run. However, the 280°C run was chosen as the optimal temperature 
because, unlike the former, it did not display any signs of thermal decomposition of 
any analytes (Restek, 2012).  
Finally, inject mode protocol was considered. The splitless purge time is the time 
between sample introduction and the opening of the split vent in splitless liners. When 
the split vent is open, the inlet is purged of any excess solvent to prevent solvent tailing 
throughout the chromatogram. The optimal splitless time is the amount of time 
required for all or most of the analytes to transfer to the head of the column, particularly 
high molecular weight analytes. One minute was determined as the optimal splitless 
purge time for the study protocol because it was just enough time to improve elution 
of high molecular weight analytes while preventing tailing of the solvent on the first 
analyte of interest (C4:0). 
With the conditions established for optimal separation and identification, the protocol 
was validated for sensitivity and reproducibility using conventional clinical chemistry 
approaches. These studies confirmed limits of detection and coefficients of variation 
that were suitable for subsequent sample analysis to test the hypothesis that specific 
FFA are predictors of T2DM.   
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It is accepted and backed by strong evidence, that plasma levels of FFA increases 
with obesity. This potentially results in insulin resistance, which consequently leads to 
increased lipolysis in a vicious cycle that explains the process of T2DM. This simplistic 
view has come under heavy scrutiny in recent times as evidence from several studies 
shows the relationship between FFA, obesity and T2DM is much more complicated.  
There are strong suggestions that the association between increased FFA and T2DM 
might be confounded by other metabolic predictors of T2DM like BMI and gender 
(Il’yasova et al., 2010). Therefore, here, the associations between FFAs and these 
metabolic predictors were examined.  
This study found a statistically significant positive correlation between C22:2 and 
C18:1n9 to BMI, while C18:2n6 returned a negative correlation (even after adjusting 
for age and gender). A systematic review of 43 studies suggests that there is no 
relationship between FFAs and BMI or body fat mass, and differences observed are 
mainly due to within-subject day-to-day variations in fasting FFAs (Karpe et al., 2011). 
An important observation from reviewing literature is that most studies that try to 
quantify the effect of FFAs on the metabolic predictors of T2DM focus on total FFAs 
or FFA categories like saturated vs unsaturated FFAs rather than individual effects of 
FFAs. Perhaps the variation in the effect of total FFAs in these studies can be 
explained by variations in the individual FFA profile.  It is interesting that this study 
found a positive correlation between docosahexaenoic acid and a negative interaction 
between linoleic acid with BMI. Lu et al. (2012) found that meal-related increase in 
docosahexaenoic acid and linoleic acid interacts with a long-chain FA receptor, 
GPR120, on ghrelin cells to inhibit ghrelin secretion. Ghrelin is a gastric peptide 
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hormone that regulates appetite and energy homeostasis. Interactions between 
plasma concentrations of these FAs with ghrelin have not been established; however, 
going by this evidence, a negative correlation between BMI and linoleic acid would not 
be surprising. It will be interesting to find out if the positive correlation of 
docosahexaenoic acid found here is an adaptation of the adipose tissue to increasing 
BMI (or obesity).  
The positive correlation found between alpha-linolenic acid (ALA) and fasting plasma 
glucose in this study has been considered in other studies. Dietary ALA has been 
found to be useful in decreasing insulin resistance in several studies (Lee et al., 2014, 
Hollander et al., 2014), while (Alssema et al., 2014) did not find any significant 
correlation between ALA and fasting blood glucose. ALA has been shown to reduce 
pancreatic islet cell damage in rats (Budin et al., 2007) and could be the possible 
mechanism by which it contributes to reduced fasting plasma glucose in humans. It is 
possible that the observed increase in ALA with increasing blood glucose levels is an 
adaptation to improve insulin secretion in those with high fasting blood glucose.  
The discovery of a negative correlation between pentadecanoic acid (C15:0) and 
fasting plasma glucose here (after adjusting for leptin, BMI, age, and gender) is in line 
with growing evidence from several prospective studies showing negative 
associations between OCSFA and metabolic disease development [78-80, 209, 210]. 
Historically, even-chain saturated FAs (SFA) are associated with increased risk of 
metabolic diseases, and the odd-chain SFA were regarded as physiologically 
unimportant. Consequently, odd-chain SFAs have been used mostly as internal 
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standards for lipid research. Following its use as a biomarker for dairy fat consumption 
[211, 212], evidence began to emerge on the possible beneficial effects of odd chain 
SFA on various disease states, including T2DM and coronary heart disease. The 
possible protective effect of OCSFA on T2DM development has been attributed to its 
dietary sources, like fish and dairy products, which correlate favourably with healthy 
eating habits and lifestyle [213]. However, there is a reversal in the ratio of C15:0 to 
C17:0 in these dietary sources (usually 2:1) in human plasma [214, 215], suggesting 
that there may be other sources of OCSFA, including the possibility of human 
biosynthesis [216]. In addition to plasma, OCSFAs have been detected in other tissues 
such as the brain and liver [217], highlighting the possibility of endogenous production 
and metabolism. In this study, dietary patterns were not analysed and the possible 
effect it would have on C15:0 levels or its association with insulin resistance cannot 
be quantified. Future in vivo and in vitro research will likely address the cellular 
mechanisms underlying the effect of OCSFAs on insulin signalling and glucose 
homeostasis (Benjamin Jenkins, 2015).  
Only age, fasting plasma glucose and protein carbonyl levels predicted leptin in this 
study. The relationship between protein oxidation (measured as protein carbonyls in 
this study) and leptin depends on the pathological state. Under normal physiologic 
conditions, leptin increases thermogenesis by inducing gene expression of PPARƳ 
co-activator 1-α (Pgc1a) and plays a vital role in energy homeostasis by inducing FA 
oxidation and lipolysis (Becerril et al., 2012). Furthermore, it stimulates nitric oxide 
(NO) which induces endothelium-dependent vasorelaxation. However, under 
pathological conditions, like obesity or diabetes, this vasorelaxation property is 
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impaired and could induce peroxy-nitrite oxidative stress (Chatterjee et al., 2013, 
Bełtowski, 2012).  
Conflicting reports exist in the literature on the relationship between linoleic acid 
(C18:2n6) and the pro-inflammatory soluble E-selectin, which is also a marker of 
vascular endothelial dysfunction. This study found a negative correlation after 
adjusting for other markers of inflammation. On the contrary, other in-vitro studies have 
shown that linoleic acid promotes the expression of soluble E-selectin, a cell adhesion 
molecule that is expressed in endothelial cells and induced by IL-1 and TNF-α 
(Matesanz et al., 2012, Chiang et al., 2012). 
After adjusting for other predictors of inflammation, fasting plasma glucose and four 
FFAs were significantly correlated with soluble thrombomodulin. Stearic acid (C18:0) 
and oleic acid (C18:1n9) positively correlated with soluble thrombomodulin, while 
palmitoleic (C16:1) and linoleic (C18:2n6) were negatively correlated with soluble 
thrombomodulin. Soluble thrombomodulin is a protein expressed on the surface of 
endothelial cells where it serves as a co-factor for thrombin-induced activation of 
protein C. It has been shown to reduce vascular inflammation in chronic kidney 
disease by downregulating VCAM-1, ICAM-1 and chemokines in TNF-expressing 
endothelial cells (Rajashekhar et al., 2012). It has also been shown to reduce 
apoptosis, improve NRF2 activity, and reduce diabetic nephropathy via anti-NF-
ҡB/NLRP3 inflammasome-mediated inflammation (Yang et al., 2014). The anti-
inflammatory properties of Oleic acid are well documented (Camell and Smith, 2013), 
while palmitic acid (C16:0) and Linoleic acid (C18:2n6) have been shown to depress 
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thrombomodulin activity in a dose-dependent fashion (Wang et al., 2006). Palmitoleic 
and not palmitic acid was correlated with soluble thrombomodulin in this study. There 
is no report in the literature showing any relationship between palmitoleic acid or 
stearic acid and thrombomodulin. It is possible that palmitoleic acid depresses 
thrombomodulin activity in the same manner as palmitate. Most reports in the literature 
suggest that stearic acid promotes more pro-inflammatory than anti-inflammatory 
phenotypes (Anderson et al., 2012, Lavrador et al., 2014, Stryjecki et al., 2012).  
In summary, this chapter described a throughput and sensitive method for extracting 
and analysing lipids from plasma, associated with improved recovery of OCSFAs. 
Here, we found that the OCSFA, C15:0, predicted plasma glucose level as well as 
known inflammatory markers leptin and soluble E-selectin in the context of obesity and 
T2DM. 
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4 CHAPTER 4: EFFECT OF FATTY ACIDS ON HEPATOCYTE 
FUNCTION 
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4.1 INTRODUCTION 
The liver is the largest visceral organ in humans with critical metabolic functions 
including glucose and lipid homeostasis [218]. It is comprised mostly (80%) of 
parenchymal cells (or hepatocytes), which are the metabolic unit of the liver, and non-
parenchymal cells, like kupffer and hepatic stellate cells. Valuable insight into liver 
activity and pathophysiology have come from both in vivo animal and human models 
as well as invitro hepatocyte models. Primary hepatocytes are regarded as the gold-
standard for gaining mechanistic insights into metabolic and regulatory pathways in 
cellular models [219-221]. However, cost, inter-donor variability, and the non-
proliferative nature of primary hepatocyte raise concerns about its use in vitro [222, 
223]. Consequently, hepatocyte cell lines have been developed to mitigate these 
challenges. Hepatocyte cell lines like HepaRG, HepG2, Hep3b, and Huh 7.0 cells have 
been used numerous times as invitro substitutes for hepatocyte models. HepG2 cells 
are the most commonly used hepatocyte cell lines and have been shown to have 
morphological and physiological differences compared to primary hepatocytes [224-
227]. For example, concerning organelle abundance, the mitochondria make up a 
significantly higher percentage of primary hepatocytes (25%) compared to HepG2 
cells (12%), while the reverse is the case for the nucleus in hepatocytes (12%) and 
HepG2 cells (25%) [228]. Subsequently, mitochondrial proteins are more abundant in 
hepatocytes; therefore, FA β-oxidation and oxidative phosphorylation are the common 
metabolic pathways in hepatocytes compared to glycolysis in HepG2 cells. 
Furthermore, HepG2 cell models are less useful in xenobiotic metabolism research 
because there is a marked difference in the mRNA expression and protein abundance 
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of enzymes responsible for drug metabolism (cytochrome P450 enzymes) between 
hepatocytes and HepG2 cells, with the latter having a deficient expression of these 
enzymes [225, 229]. It is plausible that these metabolic differences are due in part to 
the marked difference in age of the source of HepG2 cells (16-year-old) compared to 
the primary hepatocytes, which are usually sourced from over 65-year-olds. Despite 
these dissimilarities, HepG2 cells are still the most commonly used hepatic cell line for 
lipid research mainly because they have been shown to accumulate triglycerides 
similarly to primary hepatocyte in response to exogenous glucose and FA [230]. 
Moreover, HepG2 cells can be differentiated using different exogenous chemicals to 
further resemble primary hepatocytes phenotypically [231-233]. Furthermore, C3A, a 
clonal derivative of HepG2 cells, has been selected for its ability to become quiescent 
upon confluency, with increased secretion of albumin, assuming a phenotype more 
similar to primary hepatocytes compared to its parent cell [234].  
HepG2 cells have been used to investigate the mechanisms that underpin saturated 
FA-induced hepatotoxicity and insulin resistance [235]. While the mechanistic link 
between FAs, NAFLD, and T2DM is still heavily debated, peroxisome proliferator-
activated receptors (PPARs) have been suggested to play a significant role [236-239]. 
PPAR alpha is highly expressed in the liver and regulates genes involved in enhancing 
FA transport and mitochondrial β-oxidation [240-243]. Moreover, synthetic PPAR 
alpha agonists like fenofibrate have been used with varying degree of success for 
treating hyperlipidaemia [244, 245]. PPAR alpha activation has been shown to prevent 
intrahepatic lipid accumulation and even reverse the effects of steatohepatitis 
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(including insulin resistance) in mouse models and clinical studies [246-250]. 
Physiologically, specific FA, mainly PUFA, act as natural ligands for PPAR alpha [251].  
 
4.2 AIMS AND HYPOTHESIS 
Recent studies have shown an inverse relationship between OCSFA and T2DM 
development. However, the mechanisms underpinning this relationship is still 
unknown. The liver is heavily involved in glucose homeostasis, and insulin resistance 
is thought to occur in the liver before appearing peripherally. Furthermore, obesity is 
causally associated with insulin resistance and the effect of even numbered FAs on 
hepatic insulin resistance has been extensively studied by using a model of HepG2 
cells. Studies have shown that HepG2 cells show genotypic and phenotypic 
differences compared to primary hepatocytes and various differentiation methods 
have been applied in literature to mitigate these differences. Therefore, this chapter 
will aim to examine the differential effects of OCSFA on hepatocyte function and PPAR 
alpha activation using HepG2 as a model system. Glucose output, glycogen storage, 
and gene expression profiles for genes involved in lipid metabolism will be used as 
surrogate markers of hepatocyte function. 
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4.2.1 Hypothesis 
The hypotheses for this study are as follows: 
1. HepG2 cells cultured in low serum media will exhibit increased markers of 
differentiation 
2. C16:0 treated cells at indicative concentrations will accumulate more neutral 
lipids compared to C15:0 treated cells  
3. C15:0 treated cells will show no difference in glucose or glycogen content 
compared to controls 
4. The expression of mitochondrial and peroxisomal β-oxidation genes will be 
upregulated in C15:0 treated hepatocytes 
5. C15:0 will increase PPAR alpha transcriptional activity in hepatocytes 
4.2.2 AIMS 
The purpose of this chapter was to determine the differential effect of OCSFA on 
hepatocyte function and had the following aims: 
1. To determine the effect of OCSFA on glucose homeostasis and inflammation 
in hepatocytes 
2. To determine the effect of OCSFA on FA metabolism in hepatocytes 
3. To determine the differential effect of OCSFA on de novo lipogenesis 
4. To describe the role of PPAR alpha in OCSFA mediated effect on hepatocyte 
function 
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4.3 METHOD 
4.3.1 Differentiation of hepatocytes 
HepG2/C3A cells were differentiated by growing  in low serum as detailed in section 
2.2. 
4.3.2 Determination of metabolic activity 
Following treatment, the metabolic activity of dHepG2 cells was determined by the 
MTT assay as described in section 2.7. 
4.3.3 Determination of Albumin and Urea output 
Following differentiation, albumin and urea output were measured using a plate-based 
assay. 
4.3.4 Quantification of cellular growth and viability 
Cell growth and viability were measured using the trypan blue exclusion method 
method with the counting of cells using a haemocytometer as described in section 2.6. 
4.3.5 Quantification of intracellular neutral lipids 
Following treatment with FAs, the intracellular accumulation of neutral lipids was 
evaluated by Oil Red O staining as described previously [252] and detailed in section 
2.17. 
4.3.6 PAS staining for Glycogen 
Intracellular glycogen content was determined by PAS stain using a kit from Sigma 
(Product 395B) according to manufacturer’s instructions and as detailed in section 
2.18. 
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4.3.7 Glycogen content quantification 
A plate based assay was used to quantify the amount of glycogen stored in 
hepatocytes after an overnight fast and glucose stimulation as described in section 
2.16. 
4.3.8 Quantification of cytokines 
Following treatment, IL-8 and TNFα were quantified from supernatants by ELISA as 
described in 2.12. 
4.3.9 PPAR alpha transcription factor assay 
PPAR alpha activity in the nuclear fraction of cells was measured using a PPAR alpha 
transcription factor ELISA kit (Abcam, ab133107, UK) as described in section 2.14. 
4.3.10 mRNA analysis by RT-qPCR 
Following treatment, total RNA was isolated and converted to cDNA and then analysed 
by RT-qPCR as described in section 2.20. Relative gene expression was calculated 
using the delta delta ct formula 2-ΔΔCT 
4.3.11 Statistical analysis 
Data expressed as mean +/-  SEM for three independent experiments. Statistical 
significance was estimated using a repeated measures one way ANOVA with a 
Geisser-Greenhouse correction to correct for unequal variability of differences, and  
the Two-stage step-up method of Benjamini, Krieger  and Yekutieli [253] for gene 
expression data (displaying the false discovery rate – FDR), or a Dunnett test for 
testing significant difference between treatment and control or 300µM C16:0. Data 
obtained was analysed using GraphPad Prism (v7.0). FDR provides the same degree 
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of assurance as other multiple comparison methods, like Bonferroni, but are more 
powerful in detecting individual false positives primary because it does not provide a 
strong control for familywise error correction [254-256]. In this study, a strict FDR 
criteria of 1% (or p = 0.01) was set to further reduce the chance of false positives. 
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4.4 RESULTS 
4.4.1 Differentiation of HepG2 cells 
HepG2 cells are often used in translational research into the metabolic functions of 
hepatocytes. However, studies have shown that the metabolic behaviour of HepG2 
cells can differ from primary hepatocytes [257]. To improve representativeness in 
comparison to primary cells, various methods have been used to differentiate HepG2 
cells into more quiescent profiles. This includes the use of DMSO, retinoic acid, low 
serum media, among other methods. Here, HepG2 cells were differentiated with low 
serum containing media before experimental conditions as described in methods. In 
order to determine the effect of differentiation, gene expression levels of Albumin and 
Transferrin were measured (Figure 4.1a and 4.1b). The raw CT values for albumin and 
transferrin were lower than 30, showing a high abundance of these genes in the 
sample. CT values represent the number of cycles needed for the fluorescent signal to 
cross the required threshold and is inversely proportional to the amount of target gene 
in the sample. However, CT values are not indicative of expression levels or relative 
abundance; hence the need for ΔCT calculations which normalises for the amount of 
loaded sample by factoring in the CT values of the reference gene. From Table 4.1, it 
is clear that the ΔCT value for albumin and transferrin in the differentiated HepG2 cells 
(dHepG2) are higher compared to control cells (undifferentiated cells), showing that 
these genes become relatively more abundant with differentiation (Table 4.1). dHepG2 
cells showed a fourfold increase in albumin expression compared to control (mean 
difference 3.27; 95% CI 2.11 – 4.37, p < 0.001). Subsequently, albumin production by 
dHepG2 cells were on average 50% higher compared to control (mean difference 
49.9%; 95% CI 37% - 77%, p < 0.001). Gene expression of transferrin in dHepG2 cells 
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was approximately eightfold higher compared to control cells (mean 7.53; 95% CI 6.20 
– 8.90), while the amount of urea  excreted into the supernatant per cell was 2.5 times 
higher in dHepG2 cells compared to control (mean 2.53; 95% CI 2.30 – 3.00, p < 
0.001). Put together, dHepG2 cells showed consistent increases in markers of 
hepatocyte differentiation compared to controls.  
4.4.2 Effect of FAs on cell viability 
Following differentiation of HepG2 cells, it was then essential to understand if there 
was any toxic effect of FA on dHepG2 cells. To determine this, HepG2 cells were 
treated with varying concentrations of the FAs for 6 and 24 hours to represent acute 
and long-term effects of FAs on cells. The toxicity of PPAR alpha antagonist and 
agonist (fenofibrate and GW6471) were also examined at concentrations considered 
therapeutic according to literature (100µM and 10µM respectively) [258, 259]. Cell 
viability and cell count were measured by trypan blue exclusion method, while cellular 
metabolic activity was measured using the MTT assay. Three concentrations of each 
FA were used to represent the usual range of concentration of C16:0 found in healthy 
and diseased subjects (50µM, 150µM, and 300µM). 
The result shows that cells treated with the odd-chain FA (C15:0) showed an increase 
in metabolic activity compared to both control and C16:0 treated cells after 6hrs 
incubation (Figure 4.2a). C15:0 treated cells showed higher formazan reduction 
compared to control  by 24% (p < 0.01), 16.5% (p < 0.001), and 7.5% (p < 0.05) for 
50µM, 150µM, and 300µM concentrations respectively. This slight increase in 
metabolic activity appeared to be short-term as there was no significant difference in 
metabolic activity between C15:0 treated cells and controls after 24hrs of treatment 
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(Figure 4.2b). In fact, while metabolic activity increased by 5% in control cells between 
6hrs and 24hrs, C15:0 treated cells showed  a reduction by 15%, 9%, and 0.5% for  
50µM (p < 0.001), 150µM (p < 0.001), and 300µM (p > 0.05) concentrations 
respectively, between 6hrs and 24hrs. Palmitate (C16:0) at lower concentrations of 
50µM and 150µM did not appear to alter MTT reduction compared to controls after 
6hrs or 24hrs of treatment. Furthermore, there was a 5% (p < 0.001) and 8% (p < 0.05) 
increase in formazan reduction in cells treated with 50µM and 150µM C16:0 
respectively between 6hrs and 24hrs incubation. However, C16:0 at higher 
concentrations, normally found in disease states  like T2DM, significantly reduced 
cellular metabolic activity by 10% (p < 0.05) and 11% (p < 0.001) after 6hrs and 24hrs 
respectively compared to control cells, which is reversed by co-incubation with C15:0 
(Mean difference 0.3%, p > 0.05). There is a 4.4% increase in formazan reduction in 
300µM C16:0 treated cells between 6hrs and 24hrs incubation, but this was not 
statistically significant (p > 0.05). 
To ensure that changes to metabolic activity were not confounded by the possible 
toxicity of treatments to cells, cellular viability and cell growth were measured using 
the trypan blue exclusion method. There were no significant changes to indices of cell 
death after 24hrs incubation; either by trypan blue exclusion method (Figure 4.3a) or 
by flow cytometric estimation of propidium iodide intake (Figure 4.3b). Furthermore, 
FA treatments at different concentrations did not affect cell growth (Figure 4.3c), 
remaining at a total of five million cells for all treatments. The result also shows that 
treating cells at therapeutic doses of fenofibrate and GW6471 did not alter indices of 
cellular viability, metabolic activity or cell growth.  
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Figure 4.1: Culturing HepG2-3CA clone in low serum media increases markers of differentiation   
HepG2-3CA clones were seeded at 200,000 cells/ml and cultured until 80% confluency as outlined in methods, then  cultured in media 
containing 10% serum or  low serum media (2% FBS) for 10 days. The differentiated HepG2 cells (dHepG2) were washed thrice with ice-cold 
PBS and lysed for total RNA extraction (5 million cells) and RT-qPCR estimation (a and c), or further incubated in serum-free media for 24hrs 
for quantification of albumin and urea output in media (b and d). (a) Gene expression levels of albumin. (b) Albumin output in media per 
million cells. (c) Transferrin gene expression levels. (d) Urea output per 104 cells. Results are expressed as mean +/- SEM  (n=3 independent 
experiments performed in triplicate). Statistical comparison was done using a paired t test and *** represents a statistically significant 
difference at a two-tailed P value of <0.001. 
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Table 4.1: Raw CT  values for a reference gene (YWHAZ) and selected genes of 
interest (Albumin and Transferrin) in the determination of hepatocyte 
differentiation. 
total RNA was isolated from differentiated and undifferentiated HepG2 cells and 
converted to cDNA and used to evaluate the levels of Albumin and transferrin genes 
by RT-qPCR using YWHAZ as reference gene. N represents number of independent 
experiments 
Gene YWHAZ Albumin Transferrin 
 
Mean CT SEM N Mean CT SEM N Mean CT SEM N 
Undifferentiated 25.6 0.1 3.0 26.8 0.6 3.0 27.7 0.2 3.0 
Differentiated 25.2 0.1 3.0 24.2 0.1 3.0 24.4 0.3 3.0 
 
Table 4.2: Raw CT  values for a reference gene (YWHAZ) and selected genes of 
interest (Albumin and Transferrin) in the determination of changes to acute 
phase proteins by differentiated hepatocytes. 
total RNA was isolated from differentiated and undifferentiated HepG2 cells and 
converted to cDNA and used to evaluate the levels of Albumin and transferrin genes 
by RT-qPCR using YWHAZ as reference gene. N represents number of independent 
experiments 
Gene YWHAZ Albumin Transferrin 
  Mean CT SEM N Mean CT SEM N Mean CT SEM N 
Control (5% BSA) 25.8 0.1 3 21.8 0.2 3 23.4 0.4 3 
100µM Fenofibrate  25.4 0.1 3 17.8 0.2 3 21.9 0.4 3 
10µM GW6471 25.5 0.1 3 21.7 0.3 3 22.5 0.4 3 
50µM C15:0 25.5 0.2 3 17.6 0.2 3 19.1 0.5 3 
150µM 15:0 25.8 0.1 3 19.3 0.2 3 20.4 0.3 3 
300µM C15:0 25.8 0.1 3 19.7 0.2 3 20.3 0.4 3 
50µM C16:0 25.3 0.2 3 19.0 0.1 3 20.9 0.1 3 
150µM 16:0 25.2 1.2 3 19.0 0.2 3 20.3 0.2 3 
300µM C16:0 25.7 0.3 3 24.8 0.1 3 24.8 0.1 3 
150µM 15:0 + 150µM 16:0 25.1 0.1 3 18.8 0.2 3 20.5 0.2 3 
200ng/ml LPS 25.4 0.4 3 26.4 0.2 3 26.4 0.3 3 
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Figure 4.2: C15:0 is only associated with an increase metabolic activity of dHepG2 cells after 6hrs but not after 24hrs of incubation.  
dHepG2 cells were treated with fatty acids conjugated to BSA and analysed for metabolic activity using MTT reduction after 6 and 24hrs of 
exposure. Cells were exposed to varying concentrations of fatty acids conjugated to BSA, or control (5% BSA), and/or a PPARα 
agonist/antagonist (100µM FB, or 10µM GW6471) as outlined. MTT reagent was added to the media 4 hours prior to the end of the 
experiment. Cells were then lysed with lysis reagent overnight before analysis under absorbance spectrometry at 570nm. (a) Effect of fatty 
acid treatments after 6hrs and (b) 24hrs. Results are expressed as mean +/- SEM  (n=3 independent experiments performed in triplicate).  
Statistical significance was determined by a repeated measures one-way ANOVA with Geisser-Greenhouse correction and a Dunnett’s post-
test comparison.   Ψ represents a statistical significant difference between treatment versus control,  Ξ represents a statistical significant 
difference between treatment versus 300µM C16:0, and  φ represents a statistical significant difference between the treatment versus both 
control and 300µM C16:0. All symbols represent a statistical significance P value of < 0.05. 
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Figure 4.3: Fatty acid treatment at different concentrations do not affect cell viability or growth after 24hrs of exposure. 
dHepG2 cells were treated with fatty acids conjugated to BSA and analysed for viability, apoptosis, and cell number after 24hrs incubation. 
Cells were exposed to varying concentrations of fatty acids conjugated to BSA, or control (5% BSA), and/or a PPARα agonist/antagonist 
(100µM FB, or 10µM GW6471) as outlined. At the end of the experiment, cells were washed thrice with PBS and trypsinised. (a) To assess 
viability, cells were mixed 1:1 with Trypan blue before counting on a haemocytometer as outlined in methods. Data is expressed as percentage 
viable cells. (b) To estimate early apoptotis, cells at a concentration of 500, 000cells/ml were incubated with a hypo-osmotic flourochrome 
solution containing 50µg/ml of propidium iodide (PI) at 4°C  overnight then washed thrice with PBS  and analysed by flow cytometry with FL3. 
The percentage of apoptosis was quantified by measuring the number of hypoploid nuclei detected after 50,000 events on flow cytometry. 
Data is expressed as mean percentage of apoptotic cells. 50µM FCCP was used as a positive control.  (c) Cells were counted after experiments 
with a haemocytometer to determine if FA treatments had any effect of cell growth. Results are expressed as mean +/- SEM (n=3 independent 
experiments performed in triplicate).  
Statistical significance was determined by a repeated measures one-way ANOVA with Geisser-Greenhouse correction and a Dunnett’s post-
test comparison.   Ψ represents a statistical significant difference between treatments versus control (P value < 0.05). 
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4.4.3 C15:0 attenuates the palmitate-induced increase in markers of inflammation 
Accumulation of SFA in the liver is known to promote a pro-inflammatory environment 
with detrimental long-term consequences. The liver reacts to noxious stimuli by 
altering the levels of so-called acute phase proteins. These proteins are either 
produced in increased amounts (like pro-inflammatory cytokines), or become 
diminished (like albumin and, transferrin). So far, the results have shown that palmitate 
in high concentrations can limit cellular metabolic activity without necessarily affecting 
cell growth or apoptosis.To determine the immunological response of hepatocytes to 
FA, dHepG2 cells were incubated with varying concentrations of FAs conjugated to 
BSA for 24hrs, measuring levels of four acute phase reactants.  
As expected, dHepG2 cells treated with 200ng/ml LPS showed a classical acute phase 
reaction characterised by a threefold increase in the production of pro-inflammatory 
cytokines TNF-α and IL-8 (p value <0.001) with a similar reduction in gene expression 
for albumin and transferrin (Figure 4.4 and Table 4.2). Similarly, dHepG2 cells cultured 
with high concentrations of C16:0 showed a twofold increase in TNF-α and IL-8 output 
(p value <0.001) as well as a sixfold and threefold reduction in gene expression of 
albumin and transferrin respectively (p value < 0.01). There was no difference in gene 
expression levels or cytokine production when dHepG2 cells were incubated with 
varying concentrations of C15:0, or with low concentrations of C16:0 (50µM and 
150µM). Interestingly, co-incubating cells with both odd and even chain FAs showed 
no significant difference in the production of acute phase proteins compared to control. 
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4.4.4 C15:0 ameliorates palmitate-induced glucose dysfunction 
The liver plays a pivotal role in glucose homeostasis by prioritising glucose production 
during fasting and glycogen production from excess glucose in the fed state. To 
determine how FAs affect the ability of hepatocytes to maintain optimal glucose levels, 
dHepG2 cells were cultured with varying concentrations of C16:0 and C15:0 at 
different glucose concentrations simulating fasting and fed states as described in 
method. A plate based assay was used to measure glucose output and glycogen 
content as described previously. Cells treated with high concentrations of C16:0 
(300µM) showed a 54% increase in glucose output (Figure 4.5a) compared to control 
cells (% difference 54.5%; 95% CI 39.6% - 69.4%, p < 0.001). Conversely, there was 
no significant difference between cells treated with a similar concentration of C15:0 
(300µM) compared to control. In fact, there was no significant increase in glucose 
output in cells treated with 50µM and 150µM C15:0. In comparison with C15:0 treated 
cells, those incubated with 300µM C16:0 had a statistically significant higher glucose 
output by 64.0%, 53.5%, and 44.0% for 50µM, 150µM and 300µM C15:0 respectively 
(p < 0.001). Furthermore, when cells are co-incubated with both C15:0 and C16:0 up 
to a concentration of 300µM, there was no significant difference in glucose output 
compared to controls.  
dHepG2 cells treated with palmitate showed a reduction in glycogen content by 37.5% 
(Figure 4.5b and Figure 4.6) compared to controls (% difference 37.5%, 95% CI 13.8% 
- 61.2%, p < 0.01) in a fed state. On the other hand, there was a slight average 
increase in glycogen content in cells treated with different concentrations of C15:0 
compared to controls; however, this was not statistically significant. C15:0 treated cells 
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at concentrations of 300µM showed  a statistically significant increase in glycogen 
content by 41.5% compared to cells treated with similar concentrations of C16:0 (% 
difference 41.5%, 95% CI 1.9% - 81.1%, p < 0.05) and co-incubating cells with both 
C16:0 and C15:0 up to a concentration of 300µM had similar glycogen contents 
compared to control.  
RNA expression levels of glucose transporter 2 (GLUT2) and glycogen synthase 
kinase 3β (GSK3β) were measured to test the upstream effect of FAs on glucose 
transport and glycogen production/regulation (Figure 4.5c and 4.5d). The overall gene 
expression of GLUT2 was deficient in dHepG2 cells irrespective of treatment, 
compared to the reference gene (Raw CT values are shown in Table 4.3). However, 
dHepG2 cells had very high expression levels of GSK3β. Both C16:0 and C15:0 
treated cells upregulated the expression of GLUT2 compared to controls irrespective 
of concentration (False discovery rate -FDR- of <1%). GLUT2 transports glucose 
across the cell membrane in a bi-directional manner; therefore, it is difficult to interpret 
the results of this gene expression data in isolation without referencing the results of 
the glucose output assay detailed above. Both C15:0 and C16:0 at low concentrations 
(50µM and 150µM) downregulated GSK3β expression by up to twofold (FDR <1%), 
whereas FA treatment at 300µM concentrations showed an upregulation of GSK3β 
(FDR < 0.01%). Cells treated with 300µM C16:0 showed a 98% increase in gene 
expression of GSK3β compared to controls (FDR <0.01%), while those treated with 
300µM C15:0, although showing a 45% upregulation of GSK3β, did not meet statistical 
significance (FDR 1.6%). Cells treated with 300µM C16:0 had a 52% higher 
expression of GSK3β compared to cells treated with 300µM C15:0 (FDR < 0.001%).
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Figure 4.4 : C15:0 attenuates palmitate-induced increase in markers of acute inflammation.  
 dHepG2 cells were treated with fatty acids conjugated to BSA for 24hrs and analysed for markers of early inflammation. Gene expression levels of albumin 
and transferrin were used to determine negative acute phase proteins, while positive acute phase response was measured by expression of IL-8 and TNFα 
levels. Cells were exposed to varying concentrations of fatty acids conjugated to BSA, or control (5% BSA), and/or a PPARα agonist/antagonist (100µM FB, 
or 10µM GW6471) as outlined. At the end of the experiment, cells were either (a) washed thrice with ice-cold PBS then lysed for total RNA extraction (5 
million cells) and RT-qPCR estimation, or (b) the supernatant is extracted for quantification of IL-8 and TNFα by ELISA as outlined. Results are expressed as 
mean +/- SEM  (n=3 independent experiments performed in duplicate for a and b, or triplicate in c and d).  
Statistical significance was determined by a repeated measures one-way ANOVA with Geisser-Greenhouse correction and a Dunnett’s post-test comparison 
test (figure c and d), or the Two-stage step-up method of Benjamini, Krieger  and Yekutieli (figure a and b). Ψ represents a statistical significant difference 
between treatment and control,  Ξ represents a statistical significant difference between treatment and 300µM C16:0, and  φ represents a statistical 
significant difference between the treatment versus both control and 300µM C16:0. All symbols represent a statistical significance q value (adjusted false 
discovery rate -FDR) of <1% for the two-stage step-up method of Benjamini, Krieger  and Yekutieli, or a statistical significance P value of  < 0.05 for Dunnett’s 
test. 
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Figure 4.5: C15:0 ameliorates palmitate-induced glucose dysfunction  
dHepG2 cells were treated with fatty acids conjugated to BSA for 24hrs and analysed for markers of glucose homeostasis.(a)  After 24 hours of FA 
exposure, cells were washed three times with PBS to remove any residual glucose in the media and then incubated for 16 hours in glucose production 
medium as outlined in methods. Insulin (100nmol/l; Sigma) was added during the last hour of incubation. A quantity of the medium was sampled for 
measurement of glucose concentration using a glucose hexose kinase assay kit (Sigma). Glucose concentration was normalized with cellular protein 
concentration. (n=3 independent experiments in duplicate, results expressed as mean +/- SEM). (b) After FA exposure for 24hrs, cells were glucose-
starved overnight in serum and glucose free RPMI media to deplete intracellular glycogen stores and exposed to RPMI media containing 11mmol/l 
glucose for 48hrs with 100nmol/l insulin in the final hour of incubation. Cells were washed and harvested using ice-cold 30mmol/l HCL for the glycogen 
assay as outlined in method (n=3 independent experiments in duplicate, results expressed as mean +/- SEM).  (c) and (d) Cells were washed thrice with 
ice-cold PBS then lysed for total RNA extraction (5 million cells) and RT-qPCR estimation of the gene expression levels of Glut2 and GSK3 respectively as 
upstream markers of glucose homeostasis (Results are expressed as mean +/- SEM   for n=3 independent experiments performed in duplicate). Statistical 
significance was determined by a repeated measures one-way ANOVA with Geisser-Greenhouse correction and a Tukey’s post-test comparison test 
(figure a and b), or the Two-stage step-up method of Benjamini, Krieger  and Yekutieli (figure c and d). Ψ represents a statistical significant difference 
between treatment and control,  Ξ represents a statistical significant difference between treatment and 300µM C16:0, and  φ represents a statistical 
significant difference between the treatment versus both control and 300µM C16:0. All symbols represent a statistical significance q value (adjusted 
false discovery rate -FDR) of <1% for the two-stage step-up method of Benjamini, Krieger  and Yekutieli, or a statistical significance P value of  < 0.05 
for Dunnett’s test. 
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Figure 4.6: C15:0 increases intracellular glycogen content in C16:0 exposed cells.   
PAS staining of differentiated HepG2 cells exposed to FAs showing intracellular glycogen accumulation (pink). Control and 
C15:0 (a and b respectively) exposed cells show increased glycogen content compared to C16:0 exposed cells (c). Cells exposed 
to both C16:0 and C15:0 (d) Show higher glycogen content compared to cells exposed to C16:0 alone. 
  
a 
c 
b 
d 
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Table 4.3: Raw CT values for a reference gene (YWHAZ) and selected genes of 
interest (GSK3 and GLUT2) for determining the effect of FA on glucose and 
glycogen homeostasis in dHepG2 cells. 
total RNA was isolated from d HepG2 cells and converted to cDNA and used to 
evaluate the levels of GSK3 and GLUT2 genes by RT-qPCR using YWHAZ as 
reference gene. N represents number of independent experiments. Reference values 
for each gene presented independently because experiments were performed on a 
separate plate. 
Gene YWHAZ (GSK3) GSK3 YWHAZ (GLUT2) GLUT2 
  Mean CT SE
M 
N Mean CT SE
M 
N Mean CT SE
M 
N Mean CT SE
M 
N 
Control (5% BSA) 25.3 0.3 3 21.8 0.2 3 25.3 1.1 3 29.7 0.7 3 
100µM Fenofibrate  25.7 0.2 3 17.8 0.2 3 25.4 0.3 3 32.6 1.2 3 
10µM GW6471 25.9 0.0 3 21.7 0.3 3 25.6 0.3 3 32.6 1.0 3 
50µM C15:0 25.5 0.3 3 17.6 0.2 3 25.7 0.1 3 27.7 0.1 3 
150µM 15:0 25.6 0.2 3 19.3 0.2 3 25.5 0.4 3 28.0 0.4 3 
300µM C15:0 25.2 0.2 3 19.7 0.2 3 25.6 0.2 3 28.0 0.1 3 
50µM C16:0 25.6 0.5 3 19.0 0.1 3 25.5 0.1 3 27.5 0.2 3 
150µM 16:0 25.4 0.1 3 19.0 0.2 3 25.3 0.1 3 28.2 0.0 3 
300µM C16:0 25.6 0.0 3 24.8 0.1 3 25.3 0.1 3 28.0 0.1 3 
150µM 15:0 + 150µM 16:0 25.5 0.3 3 18.8 0.2 3 25.2 0.1 3 27.6 0.1 3 
Table 4.4: Raw CT  values for a reference gene (YWHAZ) and selected genes of 
interest (L-FABP and CD36) for determining the effect of FA on lipid transport in 
dHepG2 cells. 
total RNA was isolated from d HepG2 cells and converted to cDNA and used to 
evaluate the levels of L-FABP and CD36 genes by RT-qPCR using YWHAZ as 
reference gene. N represents number of independent experiments. Reference values 
for each gene presented independently because experiments were performed on a 
separate plate 
Gene YWHAZ (L-FABP) L-FABP YWHAZ (CD36) CD36 
  Mean CT SE
M 
N Mean CT SE
M 
N Mean CT SE
M 
N Mean CT SE
M 
N 
Control (5% BSA) 25.8 0.1 3 25.8 0.1 3 25.7 0.2 3 29.0 0.3 3 
100µM Fenofibrate  25.6 0.4 3 23.3 0.2 3 25.8 0.1 3 25.2 0.3 3 
10µM GW6471 25.7 0.1 3 25.8 0.2 3 25.8 0.1 3 29.1 0.2 3 
50µM C15:0 25.6 0.2 3 24.2 0.4 3 25.8 0.2 3 28.6 0.3 3 
150µM 15:0 25.5 0.1 3 24.3 0.5 3 25.1 0.2 3 26.8 0.1 3 
300µM C15:0 25.2 0.2 3 20.7 0.3 3 25.9 0.1 3 27.6 0.2 3 
50µM C16:0 25.6 0.5 3 23.1 1.0 3 25.1 0.0 3 27.3 0.1 3 
150µM 16:0 25.4 0.1 3 23.0 0.1 3 25.3 0.1 3 27.9 0.2 3 
300µM C16:0 25.6 0.0 3 23.3 0.2 3 25.6 0.2 3 25.2 0.2 3 
150µM 15:0 + 150µM 16:0 25.5 0.3 3 23.2 0.7 3 25.3 0.3 3 27.6 0.3 3 
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4.4.5 Palmitate is associated with higher intracellular lipid uptake and accumulation 
compared to C15:0 
The accumulation of neutral lipids is a standard physiological response to excess 
energy. However, extreme and prolonged accumulation has been linked with 
metabolic diseases like T2DM. To determine the degree of lipid accumulation within 
cells, an Oil Red O stain was adapted to a plate-based assay. Furthermore, gene 
expression of CD36 and liver-specific FA binding protein (L-FABP) were measured as 
markers of cellular FA trafficking. 
Both FA increased accumulation of neutral lipids compared to control irrespective of 
concentration (Figure 4.7). C15:0 treated cells saw an increase in oil red o stain 
absorbance by 7% (Pp < 0.05), 17%  (p < 0.01), and 23% (p < 0.001) compared to 
control cells for 50µM, 150µM, and 300µM respectively. Similarly, there was an 
increase by 12%, 23% and 50% for cells treated with 50µM (p < 0.01), 150µM (p < 
0.001), and 300µM (p < 0.001) C16:0 respectively compared to control. For lower 
concentrations of treatment (50µM and 150µM), C16:0 treated cells showed slightly 
higher accumulation of neutral lipids compared to C15:0 treated cells (4.8% and 5.6% 
higher in C16:0 compared to C15:0 for 50µM and 150µM respectively), but this was 
not statistically significant. However, there was a statistically significant increase in 
neutral lipids in cells treated with 300µM C16:0 compared to 300µM C15:0 (26.2%, 
95% CI 18.5% - 34.0%, p < 0.001).  
CD36 (FA translocase) modulates the rate of FA uptake by hepatocytes and 
contributes to the development of fatty liver. Both C16:0 and C15:0 upregulate CD36 
expression (Figure 4.8a). C15:0 increases CD36 gene expression levels in a dose-
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dependent manner compared to controls (62.1%, 183.2%, and 207.8% for 50µM, 
150µM, and 300µM C15:0 respectively, FDR < 0.001%). Furthermore, incubating cells 
with 300µM C16:0 dramatically increased CD36 gene expression up to 8 times more 
compared to control (FDR < 0.001%) and up to 4 times more compared to 300µM 
C15:0 (FDR < 0.001%). L-FABP promotes intracellular trafficking of FAs into cellular 
organelles. Similar to CD36 gene expression profile, all  FA concentrations used 
upregulated L-FABP gene expression (Figure 4.8b), especially cells treated with 
300µM C15:0, which showed a sixteenfold increase compared to controls (FDR < 
0.001%) and a fourfold increase relative to 300µM C16:0 treated cells (FDR < 
0.001%). Both CD36 and L-FABP genes are relatively abundant in dHepG2 cells as 
shown in Table 4.4.  
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Figure 4.7: Formation of neutral lipids is greater in the presence of C16:0 compared to C15:0.  
dHepG2 cells were treated with fatty acids conjugated to BSA for 24hrs and analysed for neutral lipid formation using the Oil Red O stain. Cells were washed 
three times with PBS after 24hrs incubation and then fixed with 1% paraformaldehyde at room temperature for 30 min prior to adding 60% isopropanol for 
5 min. Oil red O stain was then added for 5 minutes prior to washing in isopropanol before analysis under absorbance spectrometry at 490nm. Results are 
expressed as mean +/- SEM (n=3 independent experiments performed in triplicate).  
Statistical significance was determined by a repeated measures one-way ANOVA with Geisser-Greenhouse correction and a Dunnett’s post-test comparison.   
Ψ represents a statistical significant difference between treatment versus control, Ξ represents a statistical significant difference between treatment versus 
300µM C16:0, and  φ represents a statistical significant difference between the treatment versus both control and 300µM C16:0. All symbols represent a 
statistical significance P value of < 0.05. 
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Figure 4.8: Both C15:0 and C15:0 promote intracellular uptake and trafficking of lipids.  
dHepG2 cells were treated with fatty acids conjugated to BSA for 24hrs and analysed for markers of intracellular uptake and traffic of FA by looking at the 
total RNA expression of proteins responsible for intracellular uptake of FA (CD36) and cytoplasmic trafficking of FA into organelles (L-FABP). After 24hrs 
incubation, cells were washed thrice with ice-cold PBS and lysed for total RNA extraction (5 million cells) and RT-qPCR estimation of (a) CD36, or (b) L-FABP. 
Results are expressed as mean +/- SEM (n=3 independent experiments performed in duplicate).  
Statistical significance was determined by a repeated measures one-way ANOVA with Geisser-Greenhouse correction and the two-stage step-up method of 
Benjamini, Krieger and Yekutieli (figure c and d). Ψ represents a statistical significant difference between treatment and control,  Ξ represents a statistical 
significant difference between treatment and 300µM C16:0, and  φ represents a statistical significant difference between the treatment versus both control 
and 300µM C16:0. All symbols represent a statistical significance q value (adjusted false discovery rate -FDR) of <1%. 
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4.4.6 C15:0 potentiates mitochondrial and peroxisomal beta-oxidation of FAs 
Intracellular FA have different metabolic fates. In most cases, FFA are catabolised in 
the liver to release energy mostly driven by mitochondrial beta-oxidation. Alternatively, 
FFA could be diverted towards triglyceride/neutral lipid formation and storage. In order 
to determine if a dysfunction in the catabolic pathway contributes to the increased 
accumulation of neutral lipids as seen previously, the gene expression levels of 
proteins involved in mitochondrial and peroxisomal beta-oxidation pathways were 
measured. 
All the FAs at varying concentrations increased gene expression of long-chain fatty 
acid co-ligase 1 (ACSL1) by as much as fourfold (Figure 4.9a) when treated with higher 
concentrations (300µM) of C15:0 and C16:0 (FDR <0.001%), or more than twofold 
when treated with lower concentrations (50µM or 150µM) of FA (FDR <0.001%). 
ACSL1  encodes the enzyme responsible for converting free long-chain FA to Acyl-
CoA esters, a step required for intra-mitochondrial trafficking of FA. Carnitine 
palmitoyltransferase 1 and 2 (CPT1 and CPT2) provide a shuttle system for the 
transfer of acyl-CoA esters of FA into the mitochondrial matrix. Gene expression levels 
of both CPT1 (Figure 4.9b) and CPT2 (Figure 4.9c) were upregulated by lower 
concentrations (50µM or 150µM) of C15:0 and C16:0 FA compared to controls (FDR 
< 0.001%). Cells treated with 50µM or 150µM C15:0 upregulated both CPT1 and CPT2 
by twofold higher than C16:0 cells treated with similar concentrations (FDR < 0.001%). 
There was no difference in gene expression levels of CPT1 and CPT2 between control 
cells and those treated with 300µM C16:0. Furthermore, cells treated with 300µM 
C15:0 showed a sevenfold and fourfold increase in CPT1 and CPT2 gene expression 
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level respectively compared with cells treated with 300µM C16:0 (FDR < 0.001% for 
both comparisons). CPT1 and CPT2 gene expression levels were restored with co-
incubation of C15:0 and C16:0 (fourfold and twofold increases for CPT1 and CPT2 
respectively, FDR < 0.001%). After establishing the effect of FAs on the gene 
expression levels of mitochondrial transport proteins responsible for trafficking FAs, 
the gene expression levels of enzymes involved in the final steps of mitochondrial 
beta-oxidation were examined: ACADL (long-chain acyl-CoA dehydrogenase), 
ACAD10 (acyl-CoA dehydrogenase family, member 10), and ACAA2 (Acetyl-
Coenzyme A acyltransferase 2). C15:0 treatment is associated with an upregulation 
of ACADL (Figure 4.10a) compared to controls (threefold, eightfold, and sixfold 
increase with 50µM, 150µM, and 300µM respectively; FDR < 0.001% for all 
comparisons). Lower concentrations of C16:0 (50µM and 150µM) were also 
associated with increases in gene expression for ACADL (Figure 4.10a) and ACAD10 
(Figure 4.10b). However, there was no significant difference in gene expression levels 
of ACADL, ACAD10 and ACAA2 (Figure 4.10c) between cells treated with 300µM 
C16:0 and controls. Even though C15:0 treatments upregulated gene expression 
levels of ACAD10 and ACAA2, there appears to be a negative correlation between FA 
concentration and level of gene expression (Figure 4.10b and 4.10c). Co-treating cells 
with C15:0 and C16:0 upregulated ACAD10 and  ACADL gene expression levels. 
Peroxisomal beta-oxidation acts as a secondary pathway for FA catabolism especially 
for very long chain and odd chain FAs and was assessed similarly to mitochondrial 
beta-oxidation above. Firstly, peroxisomal FA transporters were examined (Figure 
4.11a, 4.11b, and 4.11c). ATP Binding Cassette Subfamily D Member 1-3 (ABCD1, 
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ABCD2, ABCD3) gene expression levels were measured to assess the effect of FAs 
on peroxisomal very long chain FA transporters. Only C15:0, irrespective of 
concentration used, upregulated ABCD1 activity compared to controls Figure 4.11a). 
The addition of 300µM C16:0 downregulated ABCD2 and ABCD3 transporters 
compared to controls (eightfold and 45% reduction respectively, FDR < 0.001%). 
Whereas, all C15:0 treatments as well as lower concentrations of C16:0 treatments 
significantly upregulated gene expression of ABCD2 and ABCD3 in comparison to 
control. The first reaction in peroxisomal beta-oxidation is catalysed by Peroxisomal 
acyl-coenzyme oxidase 1, encoded by the gene ACOX1. All FA treatments 
upregulated ACOX1 gene expression (Figure 4.11d) compared to control apart from 
300µM C16:0. There was no correlation between the concentration of C15:0 with gene 
expression levels. During peroxisomal oxidation, catalase (encoded by the gene CAT) 
is usually produced to mop up hydrogen peroxide. All FA treatments resulted in an 
upregulation of CAT (Figure 4.11e), except 300µM C16:0. 
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Figure 4.9: C15:0 reverses palmitate induced reduction in mitochondrial uptake of fatty acids.  
dHepG2 cells were treated with fatty acids conjugated to BSA for 24hrs and analysed for gene expression markers  of FA activation and transport within 
the mitochondria. After 24hrs incubation, cells were washed thrice with ice-cold PBS and lysed for total RNA extraction (5 million cells) and RT-qPCR 
estimation of (a) ACSL1- responsible for activating FA for beta-oxidation by converting FA to fatty acyl-COA esters, or (b) CPT1 and (c) CPT2 both  responsible 
for intra-mitochondrial transport of fatty acyl-COA esters, and (d) SLC25A20- responsible for facilitating intra-mitochondrial fatty acyl transport by 
trafficking both carnitine-FA complexes and carnitine across the inner mitochondrial membrane. Results are expressed as mean +/- SEM  (n=3 independent 
experiments performed in duplicate).  
Statistical significance was determined by a repeated measures one-way ANOVA with Geisser-Greenhouse correction and the two-stage step-up method 
of Benjamini, Krieger  and Yekutieli .   Ψ represents a statistical significant difference between treatment and control,  Ξ represents a statistical significant 
difference between treatment and 300µM C16:0, and  φ represents a statistical significant difference between the treatment versus both control and 
300µM C16:0. All symbols represent a statistical significance q value (adjusted false discovery rate -FDR) of <1%. 
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Table 4.5: Raw CT values for a reference gene (YWHAZ) and selected genes of 
interest for determining the effect of FA on lipid metabolism in dHepG2 cells. 
total RNA was isolated from d HepG2 cells and converted to cDNA and used to 
evaluate the levels of CPT1, CPT2, SCD5, SCD1 and FASN genes by RT-qPCR using 
YWHAZ as reference gene. N represents number of independent experiments. 
Gene YWHAZ  CPT1 CPT2 SCD5 SCD1 FASN 
  Mean 
CT 
SE
M 
N Mean 
CT 
SE
M 
N Mean 
CT 
SE
M 
N Mean 
CT 
SE
M 
N Mean 
CT 
SE
M 
N Mean 
CT 
SE
M 
N 
Control (5% 
BSA) 
25.1 0.1 3 30.3 0.2 3 31.1 0.3 3 29.8 0.0 3 25.9 0.1 3 25.5 0.1 3 
100µM 
Fenofibrate  
25.4 0.1 3 27.6 0.3 3 28.6 0.4 3 27.6 0.3 3 25.8 0.3 3 25.4 0.3 3 
10µM GW6471 25.5 0.0 3 30.8 0.3 3 33.6 0.1 3 30.0 0.4 3 26.3 0.2 3 26.0 0.3 3 
50µM C15:0 25.6 0.4 3 27.5 0.3 3 28.4 0.3 3 28.2 0.2 3 25.7 0.5 3 25.9 0.2 3 
150µM 15:0 25.7 0.2 3 27.8 0.1 3 28.7 0.5 3 27.2 0.3 3 26.1 0.3 3 25.3 0.3 3 
300µM C15:0 25.6 0.1 3 27.8 0.3 3 29.3 0.1 3 28.6 0.2 3 26.1 0.4 3 25.2 0.2 3 
50µM C16:0 25.4 0.2 3 28.4 0.2 3 28.9 0.1 3 28.5 0.4 3 26.2 0.1 3 24.8 0.5 3 
150µM 16:0 25.1 0.1 3 29.1 0.2 3 29.0 0.1 3 27.9 0.2 3 25.9 0.3 3 23.9 0.2 3 
300µM C16:0 25.6 0.1 3 30.8 0.2 3 31.5 0.4 3 31.7 0.2 3 26.3 0.3 3 24.4 0.2 3 
150µM 15:0 + 
150µM 16:0 
25.5 0.2 3 28.8 0.4 3 29.4 0.7 3 28.2 0.5 3 26.3 0.5 3 25.9 0.6 3 
 
 
Table 4.6: Raw CT  values for a reference gene (YWHAZ) and selected genes of 
interest for determining the effect of FA on lipid metabolism in dHepG2 cells. 
total RNA was isolated from d HepG2 cells and converted to cDNA and used to 
evaluate the levels of ACSL1, ACADL, ACAD10, MYLCD genes by RT-qPCR using 
YWHAZ as reference gene. N represents number of independent experiments. 
Gene YWHAZ  ACSL1 ACADL ACAD10 MYLCD 
  Mean 
CT 
SE
M 
N Mean 
CT 
SE
M 
N Mean 
CT 
SE
M 
N Mean 
CT 
SE
M 
N Mean 
CT 
SE
M 
N 
Control (5% BSA) 25.4 0.2 3 30.1 0.2 3 29.2 0.6 3 27.1 0.2 3 31.2 0.4 3 
100µM Fenofibrate  25.8 0.1 3 28.8 0.5 3 28.6 0.3 3 26.1 0.7 3 31.3 0.3 3 
10µM GW6471 25.5 0.4 3 30.7 0.5 3 29.2 0.5 3 27.2 0.5 3 31.2 0.5 3 
50µM C15:0 25.6 0.2 3 28.8 0.3 3 27.7 0.2 3 25.6 0.2 3 31.2 0.6 3 
150µM 15:0 25.4 0.2 3 28.6 0.5 3 25.9 0.6 3 25.9 0.0 3 30.3 0.4 3 
300µM C15:0 25.2 0.2 3 27.8 0.3 3 26.5 0.6 3 25.9 0.4 3 30.3 0.3 3 
50µM C16:0 25.4 0.1 3 28.7 0.1 3 27.1 0.3 3 26.8 0.1 3 27.0 0.2 3 
150µM 16:0 25.5 0.4 3 29.0 0.4 3 27.5 0.0 3 26.3 0.8 3 31.1 0.7 3 
300µM C16:0 25.8 0.1 3 28.5 0.7 3 29.6 0.8 3 27.4 0.1 3 32.0 0.2 3 
150µM 15:0 + 
150µM 16:0 
25.7 0.2 3 28.9 0.2 3 26.4 0.5 3 26.8 0.1 3 31.5 0.3 3 
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Table 4.7: Raw CT  values for a reference gene (YWHAZ) and selected genes of 
interest for determining the effect of FA on lipid metabolism in dHepG2 cells. 
total RNA was isolated from d HepG2 cells and converted to cDNA and used to 
evaluate the levels of ACAA2, SLC25A20, CAT genes by RT-qPCR using YWHAZ as 
reference gene. N represents number of independent experiments. YWHAZ 
represents the reference gene CT values for ACAA2 and SLC25A20. 
Gene YWHAZ1  ACAA2 SLC25A20 YWHAZ (CAT) CAT 
  Mean 
CT 
SE
M 
N Mean 
CT 
SE
M 
N Mean 
CT 
SE
M 
N Mean 
CT 
SE
M 
N Mean 
CT 
SE
M 
N 
Control (5% BSA) 25.3 1.1 3 26.0 0.0 3 25.7 0.1 3 25.6 0.2 3 33.2 0.1 3 
100µM Fenofibrate  25.4 0.3 3 25.2 0.3 3 23.9 0.6 3 25.4 0.3 3 29.6 0.3 3 
10µM GW6471 25.6 0.3 3 26.4 0.7 3 25.8 0.5 3 25.3 0.1 3 27.9 0.2 3 
50µM C15:0 25.7 0.1 3 25.7 0.2 3 24.4 0.1 3 25.8 0.2 3 30.0 0.1 3 
150µM 15:0 25.5 0.4 3 25.7 0.4 3 24.9 0.5 3 25.6 0.1 3 30.7 0.2 3 
300µM C15:0 25.6 0.2 3 25.9 0.3 3 24.3 0.3 3 25.6 0.0 3 30.7 0.1 3 
50µM C16:0 25.5 0.1 3 26.0 0.2 3 25.2 0.2 3 25.6 0.1 3 30.9 0.2 3 
150µM 16:0 25.3 0.1 3 26.2 0.1 3 23.9 0.0 3 25.4 0.5 3 30.8 0.6 3 
300µM C16:0 25.3 0.1 3 26.2 0.0 3 24.3 0.0 3 25.5 0.2 3 33.2 0.1 3 
150µM 15:0 + 
150µM 16:0 
25.2 0.1 3 26.1 0.0 3 24.2 0.0 3 25.5 0.3 3 30.3 0.6 3 
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Figure 4.10: C15:0 reverses palmitate induced reduction in fatty acid beta-oxidation. 
dHepG2 cells were treated with fatty acids conjugated to BSA for 24hrs and analysed for gene expressionof enzymes in the mitochondria beta-oxidation 
pathway. After 24hrs incubation, cells were washed thrice with ice-cold PBS and lysed for total RNA extraction (5 million cells) and RT-qPCR estimation 
of (a) ACSL1- responsible for activating FA for beta-oxidation by converting FA to fatty acyl-COA esters, or (b) CPT1 and (c) CPT2 both  responsible for 
intra-mitochondrial transport of fatty acyl-COA esters, and (d) SLC25A20- responsible for facilitating intra-mitochondrial fatty acyl transport by 
trafficking both carnitine-FA complexes and carnitine across the inner mitochondrial membrane. Results are expressed as mean +/- SEM  (n=3 
independent experiments performed in duplicate).  
Statistical significance was determined by a repeated measures one-way ANOVA with Geisser-Greenhouse correction and the two-stage step-up 
method of Benjamini, Krieger  and Yekutieli .   Ψ represents a statistical significant difference between treatment and control,  Ξ represents a statistical 
significant difference between treatment and 300µM C16:0, and  φ represents a statistical significant difference between the treatment versus both 
control and 300µM C16:0. All symbols represent a statistical significance q value (adjusted false discovery rate -FDR) of <1%. 
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Figure 4.11: C15:0 potentiates peroxisomal oxidation of fatty acids  
dHepG2 cells were treated with fatty acids conjugated to BSA for 24hrs and analysed for gene expression markers for peroxisomal FA oxidation. After 
24hrs incubation, cells were washed thrice with ice-cold PBS and lysed for total RNA extraction (5 million cells) and RT-qPCR estimation of (a) ABCD1, 
(b) ABCD2, (c) ABCD3 - responsible for FA transport across the peroxisomal membrane, or (d) ACOX1,the first enzyme in the peroxisomal beta 
oxidation pathway, and (d) CAT, an enzyme responsible for mopping up hydrogen peroxide formed in the process of peroxisomal beta oxidation. 
Results are expressed as mean +/- SEM (n=3 independent experiments performed in duplicate).  
Statistical significance was determined by a repeated measures one-way ANOVA with Geisser-Greenhouse correction and the two-stage step-up 
method of Benjamini, Krieger and Yekutieli .   Ψ represents a statistical significant difference between treatment and control,  Ξ represents a statistical 
significant difference between treatment and 300µM C16:0, and  φ represents a statistical significant difference between the treatment versus both 
control and 300µM C16:0. All symbols represent a statistical significance q value (adjusted false discovery rate -FDR) of <1%. 
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4.4.7 C15:0 favours MUFA and ω-3 production 
De novo lipogenesis and the biosynthesis of PUFA are integral functional aspects of 
hepatocytes. Gene expression levels of key enzymes involved in de novo lipogenesis, 
FA desaturation and PUFA biosynthesis were measured to understand the 
mechanistic role of FAs in de novo pathways. 
De novo biosynthesis of FAs from acetyl-CoA is catalysed primarily by the enzyme 
fatty acid synthase (encoded by the gene FASN). Cells treated with C16:0 appear to 
upregulate FASN gene expression level compared to control in greater magnitude 
than cells treated with similar concentrations of C15:0 (Figure 4.12a). For example, 
cells treated with 300µM C16:0 increase FASN expression levels by up to two times 
more than cells treated with 300µM C15:0 (FDR < 0.001%). In fact, there was no 
statistically significant difference in FASN gene expression between cells treated with 
50µM C15:0 and controls (5.5% difference, FDR 31.2%). Conversely, cells treated 
with C15:0 upregulated MLYCD (malonyl CoA decarboxylase) gene expression levels 
more than C16:0 treated cells with similar concentrations (Figure 4.12b). Low 
concentrations of C16:0 (50µM and 150µM) did not affect MLYCD gene expression, 
while 300µM C16:0 downregulated MLYCD gene expression (FDR < 0.001%). The 
levels of stearoyl-CoA desaturase 1 and 5 (SCD1 and SCD5) gene expression levels 
were measured as a marker of MUFA production. Only 50µM and 150µM C15:0 
upregulated SCD1 gene expression levels (Figure 4.12c) compared to controls (by 
170% and 120% respectively, FDR < 0.01% for both comparisons). With SCD5 (Figure 
4.12d), 300µM C16:0 downregulated gene expression levels compared to control, 
while all other FA treatment upregulated SCD5 gene expression levels. To confirm the 
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effect of  C15:0 on MUFA production, cells were washed and extracted for FA analysis 
using gas chromatography. There was a statistically significant increase in MUFA 
content in C15:0 treated cells compared to both controls and cells treated with 300µM 
C16:0 (Table 4.12). There was a mean increase in MUFA concentration of 3.35µM, 
4.24µM, and 2.05µM compared to control for 50µM, 150µM, 300µM C15:0 treated 
cells (p < 0.05). Similarly, There was a statistically significant higher MUFA  production 
(difference of 3.24µM) in 300µM C15:0 cells compared to cells treated with a  similar 
concentration of C16:0.  
Gene expression levels of fatty acid desaturase 1 and 2 (FADS1 and FADS2), as well 
as those of ELOVL2 and ELOVL5 (elongation of very long-chain fatty acid protein 2 
and 5),  were measured to assess the effect of free FA treatments on PUFA  production 
(Figure 4.13a and  4.13b). Only C15:0 treatment significantly affected FADS1 and 
FADS2 gene expression by upregulation, and the maximum effect was seen in cells 
having 150µM C15:0. Adding C15:0 to C16:0 treated cells also resulted in upregulation 
of both FADS1 and FADS2. Cells treated with 300µM of C16:0 downregulated 
ELOVL5 gene expression by 14% (FDR < 0.01%), but had no significant impact on 
ELOVL2 gene expression levels (Figure 4.13c and 4.13d respectively). C15:0 showed 
differential expression of ELOVL5 and ELOVL2. While it upregulated ELOVL5 (Figure 
4.13c), it was found to downregulate ELOVL2 (Figure 4.13d). Similarly, cells co-
incubated with C15:0 and C16:0 slightly upregulated ELOVL5 and downregulated 
ELOVL2 gene expression levels. To confirm the effect of the FA on the production 
PUFA, FA were extracted and analysed from cells as outlined in methods. While there 
was no statistical significance difference in the level of total PUFA within treatments, 
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C15:0 treated cells showed a statistically significant higher production of total ω-3 FAs 
compared to both controls (increased by 1.4µM, 1.34µM, and 2.32µM for 50µM, 
150µM, and 300µM C15:0 respectively, p < 0.05) and cells treated with 300µM C16:0. 
Furthermore, total levels of C22:6n3 were higher in C15:0 treated cells compared to 
controls and C16:0 treated cells. On the other hand, C15:0 treated cells were shown 
to produce significantly lower levels of total ω-6 FA compared to cells treated with 
300µM C16:0 (mean reduction by 1.21µM, 1.21µM. and 0.89µM for 50µM, 150µM, 
and 300µM C15:0 respectively, p < 0.05). 
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Figure 4.12:  C15:0 favours desaturation of fatty acids to MUFA in the de novo lipogenesis pathway 
dHepG2 cells were treated with fatty acids conjugated to BSA for 24hrs and analysed for gene expression markers for enzymes in the de novo 
lipogenesis pathway. After 24hrs incubation, cells were washed thrice with ice-cold PBS and lysed for total RNA extraction (5 million cells) and RT-
qPCR estimation of (a) FASN, a multi-enzyme protein responsible for FA synthesis, (b) MLYCD, an enzyme involved in the synthesis of Acetyl-CoA, (c) 
SCD1 and (d) SCD5 are isoforms of the enzyme catalysing the rate-limiting step of MUFA production. Results are expressed as mean +/- SEM (n=3 
independent experiments performed in duplicate).  
Statistical significance was determined by a repeated measures one-way ANOVA with Geisser-Greenhouse correction and the two-stage step-up 
method of Benjamini, Krieger and Yekutieli .   Ψ represents a statistical significant difference between treatment and control,  Ξ represents a 
statistical significant difference between treatment and 300µM C16:0, and  φ represents a statistical significant difference between the treatment 
versus both control and 300µM C16:0. All symbols represent a statistical significance q value (adjusted false discovery rate -FDR) of <1%. 
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Figure 4.13: C15:0 favours further desaturation of dietary essential fatty acids to PUFA 
dHepG2 cells were treated with fatty acids conjugated to BSA for 24hrs and analysed for gene expression markers for enzymes in the de novo lipogenesis 
pathway. After 24hrs incubation, cells were washed thrice with ice-cold PBS and lysed for total RNA extraction (5 million cells) and RT-qPCR estimation 
of (a) FADS1, (b) FADS2, (c) ELOVL2 and (d) ELOVL5, enzymes responsible for desaturation and elongation of ω-3 and ω-6 fatty acids. Results are 
expressed as mean +/- SEM (n=3 independent experiments performed in duplicate).  
Statistical significance was determined by a repeated measures one-way ANOVA with Geisser-Greenhouse correction and the two-stage step-up method 
of Benjamini, Krieger and Yekutieli.   Ψ represents a statistical significant difference between treatment and control and φ represents a statistical 
significant difference between the treatment versus both control and 300µM C16:0. All symbols represent a statistical significance q value (adjusted 
false discovery rate -FDR) of <1%. 
0 .5
1
2
4
8
F a tty  a c id  tre a tm e n ts
F
A
D
S
1
 g
e
n
e
 e
x
p
r
e
s
s
io
n
 l
e
v
e
l
(f
o
ld
 c
h
a
n
g
e
 n
o
r
m
a
li
s
e
d
 t
o
 c
o
n
tr
o
l)





0 .5
1
2
4
8
F a tty  a c id  tre a tm e n ts
F
A
D
S
2
 g
e
n
e
 e
x
p
r
e
s
s
io
n
 l
e
v
e
l
(f
o
ld
 c
h
a
n
g
e
 n
o
r
m
a
li
s
e
d
 t
o
 c
o
n
tr
o
l)





0 .5
1
2
4
F a tty  a c id  tre a tm e n ts
E
L
O
V
L
5
 g
e
n
e
 e
x
p
r
e
s
s
io
n
 l
e
v
e
l
(f
o
ld
 c
h
a
n
g
e
 n
o
r
m
a
li
s
e
d
 t
o
 c
o
n
tr
o
l)
 






0 .2 5
0 .5
1
2
4
F a tty  a c id  tre a tm e n ts
E
L
O
V
L
2
 g
e
n
e
 e
x
p
r
e
s
s
io
n
 l
e
v
e
l
(
f
o
ld
 c
h
a
n
g
e
 n
o
r
m
a
li
s
e
d
 t
o
 c
o
n
tr
o
l)
 

 
a 
c d 
b 
0 .1 2 5
0 .2 5
0 .5
1
2
4
8
1 6
F a tty  a c id  tre a tm e n ts
G
L
U
T
 2
 g
e
n
e
 e
x
p
r
e
s
s
io
n
(f
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 c
o
n
tr
o
l)
 
    
C o n tro l (5 %  B S A )
1 0 0 µ M  F e n o fib ra te
1 0 µ M  G W 6 4 7 1
5 0 µ M  C 1 5 :0
1 5 0 µ M  1 5 :0
3 0 0 µ M  C 1 5 :0
5 0 µ M  C 1 6 :0
1 5 0 µ M  1 6 :0
3 0 0 µ M  C 1 6 :0
1 5 0 µ M  1 5 :0  +  1 5 0 µ M  1 6 :0
170 
 
Table 4.8: Raw CT  values for a reference gene (YWHAZ) and selected genes of 
interest for determining the effect of FA on peroxisomal oxidation of lipids in 
dHepG2 cells. 
total RNA was isolated from d HepG2 cells and converted to cDNA and used to 
evaluate the levels of ACAA2, SLC25A20, CAT genes by RT-qPCR using YWHAZ as 
reference gene. N represents number of independent experiments. YWHAZ1 
represents the reference gene CT values for ABCD1, ABCD2 and ABCD3. 
Gene YWHAZ  ACOX1 YWHAZ1 ABCD1 ABCD2 ABCD3 
  Mean 
CT 
SE
M 
N Mean 
CT 
SE
M 
N Mean 
CT 
SE
M 
N Mean 
CT 
SE
M 
N Mean 
CT 
SE
M 
N Mean 
CT 
SE
M 
N 
Control (5% 
BSA) 
25.3 0.3 3 29.7 0.3 3 25.6 0.2 3 29.2 0.4 3 29.4 0.3 3 28.2 0.2 3 
100µM 
Fenofibrate  
25.7 0.2 3 28.4 0.3 3 25.4 0.3 3 28.5 0.4 3 27.7 0.4 3 26.7 0.6 3 
10µM GW6471 25.9 0.0 3 26.0 0.3 3 25.3 0.1 3 29.8 0.3 3 29.3 0.3 3 28.2 0.4 3 
50µM C15:0 25.5 0.3 3 27.5 0.1 3 25.8 0.2 3 27.2 0.6 3 27.1 0.4 3 27.5 0.5 3 
150µM 15:0 25.6 0.2 3 27.4 0.4 3 25.6 0.1 3 27.1 0.2 3 26.6 0.1 3 26.3 0.4 3 
300µM C15:0 25.2 0.2 3 28.4 0.4 3 25.6 0.0 3 28.0 0.2 3 27.2 0.5 3 26.9 0.5 3 
50µM C16:0 25.6 0.5 3 27.1 0.2 3 25.6 0.1 3 28.6 0.2 3 28.3 0.3 3 27.4 0.2 3 
150µM 16:0 25.4 0.1 3 26.3 0.4 3 25.4 0.5 3 28.8 0.5 3 28.4 0.6 3 28.6 0.5 3 
300µM C16:0 25.6 0.0 3 28.1 0.2 3 25.5 0.2 3 28.9 0.2 3 32.0 0.3 3 27.7 0.5 3 
150µM 15:0 + 
150µM 16:0 
25.5 0.3 3 26.2 0.5 3 25.5 0.3 3 29.0 0.3 3 28.4 0.2 3 26.8 0.3 3 
 
Table 4.9: Raw CT values for a reference gene (YWHAZ) and selected genes of 
interest for determining the effect of FA on PUFA synthesis in dHepG2 cells. 
total RNA was isolated from d HepG2 cells and converted to cDNA and used to 
evaluate the levels of ELOVL2, ELOVL5, FADS1, and FADS2 genes by RT-qPCR 
using YWHAZ as reference gene. N represents number of independent experiments. 
YWHAZ1 represents the reference gene CT values for FADS1 and FADS2, while 
YWHAZ0 represents reference values for the ELOVL genes. 
Gene YWHAZ0  ELOVL2 ELOVL5 YHWAZ1 FADS1 FADS2 
  Mean 
CT 
SE
M 
N Mean 
CT 
SE
M 
N Mean 
CT 
SE
M 
N Mean 
CT 
SE
M 
N Mean 
CT 
SE
M 
N Mean 
CT 
SE
M 
N 
Control (5% 
BSA) 
25.8 0.0 3 27.8 0.0 3 26.4 0.4 3 25.2 0.2 3 24.6 0.0 3 27.3 0.0 3 
100µM 
Fenofibrate  
25.5 0.1 3 26.2 0.3 3 25.4 0.5 3 25.7 0.2 3 23.1 0.3 3 25.3 0.1 3 
10µM GW6471 25.9 0.0 3 27.7 0.5 3 26.7 0.1 3 25.2 0.1 3 24.7 0.3 3 27.3 0.4 3 
50µM C15:0 25.6 0.1 3 28.7 0.1 3 25.4 0.0 3 25.5 0.1 3 24.2 0.3 3 26.4 0.3 3 
150µM 15:0 25.4 0.4 3 28.3 0.5 3 25.1 0.6 3 25.8 0.1 3 23.6 0.1 3 25.7 0.1 3 
300µM C15:0 25.8 0.0 3 28.7 0.1 3 25.7 0.2 3 25.6 0.0 3 24.4 0.2 3 26.6 0.2 3 
50µM C16:0 25.1 0.1 3 26.8 0.5 3 25.5 0.3 3 25.3 0.1 3 24.6 0.2 3 27.4 0.5 3 
150µM 16:0 25.6 0.1 3 27.7 0.6 3 26.1 0.2 3 25.3 0.1 3 24.7 0.2 3 27.4 0.3 3 
300µM C16:0 25.1 0.1 3 27.1 0.2 3 26.0 0.1 3 25.7 0.1 3 25.0 0.2 3 27.9 0.1 3 
150µM 15:0 + 
150µM 16:0 
25.3 0.1 3 27.5 0.0 3 25.7 0.2 3 25.7 0.1 3 24.9 0.0 3 27.4 0.3 3 
 
171 
 
Table 4.10: Raw CT values for a reference gene (YWHAZ) and selected genes of 
interest for determining the effect of FA on PPARa activity in dHepG2 cells. 
total RNA was isolated from d HepG2 cells and converted to cDNA and used to 
evaluate the levels of PPARa and RxRa genes by RT-qPCR using YWHAZ as 
reference gene. N represents number of independent experiments 
Gene YWHAZ  PPARa RxRa 
  Mean CT SEM N Mean CT SEM N Mean CT SEM N 
Control (5% BSA) 25.7 0.2 3 27.5 0.3 3 28.5 0.2 3 
100µM Fenofibrate  25.8 0.1 3 24.6 0.0 3 28.6 0.2 3 
10µM GW6471 25.8 0.1 3 28.0 0.4 3 28.8 0.3 3 
50µM C15:0 25.8 0.2 3 26.6 0.3 3 28.2 0.4 3 
150µM 15:0 25.1 0.2 3 26.0 0.2 3 27.3 0.6 3 
300µM C15:0 25.9 0.1 3 27.2 0.1 3 28.5 0.2 3 
50µM C16:0 25.1 0.0 3 26.7 0.1 3 26.6 0.2 3 
150µM 16:0 25.6 0.2 3 27.9 0.1 3 28.3 0.5 3 
300µM C16:0 25.3 0.1 3 26.9 0.1 3 28.7 0.0 3 
150µM 15:0 + 150µM 16:0 25.3 0.3 3 27.1 0.2 3 27.2 0.5 3 
 
Table 4.11: Raw CT values for a reference gene (YWHAZ) and selected genes of 
interest for determining the effect of FA on PPARa activity in dHepG2 cells. 
total RNA was isolated from d HepG2 cells and converted to cDNA and used to 
evaluate the levels of KPNA2, KPNB1 and NCOA2 genes by RT-qPCR using YWHAZ 
as reference gene. N represents number of independent experiments 
Gene YWHAZ  KPNA2 KPNB1 NCOA2 
  Mean CT SE
M 
N Mean CT SE
M 
N Mean CT SE
M 
N Mean CT SE
M 
N 
Control (5% BSA) 25.3 0.3 3 24.5 0.1 3 29.8 0.1 3 30.4 0.7 3 
100µM Fenofibrate  25.5 0.2 3 23.9 0.1 3 27.7 0.3 3 29.9 0.1 3 
10µM GW6471 25.5 0.1 3 25.1 0.2 3 29.9 0.2 3 31.4 0.3 3 
50µM C15:0 25.4 0.3 3 24.2 0.7 3 26.1 0.7 3 28.7 0.1 3 
150µM 15:0 25.3 0.4 3 24.0 0.5 3 26.0 0.4 3 29.0 0.5 3 
300µM C15:0 25.4 0.1 3 24.1 0.1 3 27.0 0.3 3 29.7 0.3 3 
50µM C16:0 25.4 0.3 3 24.3 0.5 3 25.0 0.5 3 30.4 0.2 3 
150µM 16:0 25.5 0.3 3 24.6 0.8 3 27.7 0.1 3 30.0 0.5 3 
300µM C16:0 25.4 0.3 3 25.0 0.3 3 29.9 0.3 3 30.4 0.5 3 
150µM 15:0 + 150µM 16:0 25.1 0.2 3 24.2 0.5 3 26.0 0.7 3 29.6 0.1 3 
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4.4.8 The metabolic activity of C15:0 is related to PPAR alpha 
PPARs, especially PPAR alpha, have been shown to be heavily involved in lipid 
homeostasis in the liver and other organs. To determine if the general effect of C15:0 
is mediated via PPAR alpha, cells were treated with corresponding concentrations of 
FAs in comparison to a PPAR alpha agonist (100µM Fenofibrate/FB) and antagonist 
(10µM GW6471). Firstly, PPAR alpha gene expression levels were measured (Figure 
4.14a). The agonist increased PPAR alpha gene expression levels by up to eightfold 
compared to control (FDR < 0.0001%), while the antagonist reduced gene expression 
by 9.5%, albeit not meeting statistical significance levels (FDR 15.8%). Cells treated 
with C15:0 upregulated PPAR alpha gene expression levels by up to 100% compared 
to controls, with the highest stimulation from 50µM C15:0. There was no significant 
change in gene expression of PPAR alpha between lower concentrations of C16:0 
and controls. However, treating cells with 300µM C16:0 downregulated PPAR alpha 
expression by 32.3% (FDR 0.03%) compared to controls, which was even higher than 
the antagonist. The retinoid x receptor alpha (RxRa) and nuclear receptor coactivator 
2 (NCOA2) gene expression levels were measured to investigate if FA stimulation was 
exclusive to PPAR alpha,or extends to co-activators. PPAR alpha agonist and 
antagonist did not have any effect on RxRa gene expression levels (Figure 4.14b). 
Cells treated with 300µM C16:0 showed downregulation of RxRa by almost twofold 
(FDR < 0.01%), whereas cells treated with lower concentrations of C16:0 (50µM) 
showed a twofold upregulation of RxRa (FDR < 0.01%). On the other hand, both high 
and low concentrations of C15:0 elicited a statistically significant upregulation of RxRa 
of up to 80% compared to control. The function of PPAR alpha is dependent upon 
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translocation into the nucleus. Therefore, the gene expression levels of two nuclear 
shuttling proteins, karyopherin subunit alpha 2 (KPNA2) and karyopherin subunit beta 
1 (KPNB1), were measured. As expected, the PPAR alpha agonist increased both 
KPNA2 (Figure 4.14c) and KPNB1 (Figure 4.14d) gene expression levels by 80% and 
fourfold respectively (FDR < 0.001%). Similarly, C15:0 treated cells significantly 
increased both KPNA2 and KPNB1 gene expression levels irrespective of 
concentrations used, even as high as twofold more than the PPAR alpha agonist with 
KPNB1. Low concentrations of C16:0 (50µM) was associated with an upregulation of 
both KPNA2 and KPNB1 expression levels. However, C16:0 at 300µM resulted in a 
downregulation of both KPNA2 and KPNB1 similar to the PPAR alpha antagonist. 
NCOA2 is recruited by nuclear receptors to promote downstream upregulation of their 
target genes. Here, the three concentrations of C15:0 used to treat the cells 
upregulated NCOA2 gene expression by more than twofold (FDR < 0.01% for all 
comparisons), similar to 100µM fenofibrate which showed a 40% increase (FDR< 
0.001%) in NCOA2 gene expression levels compared to control (Figure 4.14e). 
Incubating cells with 300µM C16:0 did not affect NCOA2 gene expression levels 
compared to control. Co-incubating cells with C15:0 and C16:0 increased NCOA2 
gene expression levels by 18% (FDR 0.01%). A PPAR alpha transcription assay was 
performed (Figure 4.15) which confirmed a downstream response to PPAR alpha 
similar to the gene expression data. Both FB and C15:0 increased PPAR alpha activity 
by approximately 20% (p < 0.05), while GW6471 and C16:0 reduced activity by 23% 
and 43% respectively (p < 0.01 for both observations). Addition of FB or C15:0 to 
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C16:0 treated cells partially ameliorated the downregulatory effect of palmitate by 6% 
(p > 0.05) and 15% (p < 0.05) respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
175 
 
Figure 4.14: C15:0 ameliorates the downregualtory effect of C16:0 on PPARα nuclear transport and expression 
dHepG2 cells were treated with fatty acids conjugated to BSA for 24hrs and analysed for gene expression markers for PPARα expression and regulation. After 
24hrs incubation, cells were washed thrice with ice-cold PBS and lysed for total RNA extraction (5 million cells) and RT-qPCR estimation of (a) PPARα, a ligand 
activated transcription factor responsible for the catabolism of lipids, (b) RxRa, a nuclear receptor that facilitates  PPARα transcriptional activity,  (c) KPNA2 
and (d) KPNB1 are nucleorcytoplasmic proteins responsible for nuclear import of PPARα, (e) NCOA2 a PPARαtranscriptional protein coregulatory. Results are 
expressed as mean +/- SEM (n=3 independent experiments performed in duplicate).  
Statistical significance was determined by a repeated measures one-way ANOVA with Geisser-Greenhouse correction and the two-stage step-up method of 
Benjamini, Krieger and Yekutieli .   Ψ represents a statistical significant difference between treatment and control,  Ξ represents a statistical significant 
difference between treatment and 300µM C16:0, and  φ represents a statistical significant difference between the treatment versus both control and 300µM 
C16:0. All symbols represent a statistical significance q value (adjusted false discovery rate -FDR) of <1%. 
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Figure 4.15: C15:0 improves palmitate inhibition of PPARα activity but does not completely ameliorate this effect.  
dHepG2 cells were treated with fatty acids conjugated to BSA for 24hrs and analysed for PPARα transcription activity. Cells were washed three times with 
PBS after 24hrs incubation followed by nuclear extraction as detailed in methods. PPARα transcription activity was measured by a plate-based assay as 
described with analysis under absorbance spectrometry at 450nm. Results are expressed as mean +/- SEM (n=3 independent experiments performed in 
triplicate).  
Statistical significance was determined by a repeated measures one-way ANOVA with Geisser-Greenhouse correction and a Dunnett’s post-test comparison.   
Ψ represents a statistical significant difference between treatment versus control, Ξ represents a statistical significant difference between treatment versus 
300µM C16:0, and  φ represents a statistical significant difference between the treatment versus both control and 300µM C16:0. All symbols represent a 
statistical significance P value of < 0.05. 
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Table 4.12: FAME profile of dHepG2 cells treated with FAs 
FAMEs were isolated from dHepG2 cells and measured using GC. FAME data presented as percentage of total FA identified (mean 
+ SD for three independent samples). 
Fatty acid  
(% of total FA) 
Mean ± SD 
Control (5% 
BSA) 
100µM Fenofibrate 10µM 
GW6471 
50µM C15:0 150µM 15:0 300µM C15:0 50µM C16:0 150µM 16:0 300µM 
C16:0 
150µM 15:0 
 +  
150µM 16:0 
 
                                                                                                                                                                                                                                                                                                                                                                                               
C14:0 0.30 ± 0.01 0.32 ± 0.02 0.28 ± 0.03 0.31 ± 0.01 0.32 ± 0.02 0.31 ± 0.02 0.32 ± 0.02 0.32 ± 0.03 0.31 ± 0.02 0.30 ± 0.01 
C15:0 0.24 ± 0.02 0.25 ± 0.02 0.23 ± 0.01 0.38 ± 0.02 0.40 ± 0.01 0.24 ± 0.02 0.40 ± 0.01 0.26 ± 0.01 0.27 ± 0.01 0.30 ± 0.01 
C15:1 0.05 ± 0.01 0.06 ± 0.01 0.06 ± 0.01 0.19 ± 0.01 0.17 ± 0.01 0.05 ± 0.01 0.17 ± 0.01 0.06 ± 0.02 0.06 ± 0.02 0.12 ± 0.01 
C16:0 32.03 ± 0.55§ 30.00 ± 0.29†§ 32.71 ± 0.63†§ 28.51 ± 0.16†§ 28.13 ± 0.94†§ 32.00 ± 0.85†§ 28.13 ± 0.94§ 31.93 ± 0.33§ 33.83 ± 0.24† 31.06 ± 0.12†§ 
C16:1 4.62 ± 0.55§ 5.23 ± 0.49§ 4.63 ± 0.41§ 5.16 ± 0.32§ 5.36 ± 0.18†§ 5.08 ± 0.23†§ 5.36 ± 0.18 5.34 ± 0.25† 6.00 ± 0.21† 5.10 ± 0.14§ 
C17:0 0.48 ± 0.03 0.49 ± 0.02 0.53 ± 0.08 0.72 ± 0.02 0.78 ± 0.01 0.47 ± 0.02 0.78 ± 0.01 0.53 ± 0.04 0.41 ± 0.02 0.65 ± 0.02 
C17:1 0.11 ± 0.01 0.11 ± 0.01 0.08 ± 0.01 0.24 ± 0.02 0.31 ± 0.02 0.10 ± 0.01 0.31 ± 0.02 0.09 ± 0.01 0.07 ± 0.01 0.16 ± 0.01 
C18:0 12.00 ± 0.85 11.6 ± 0.45 12.72 ± 0.46†§ 10.99 ± 0.23†§ 10.56 ± 0.16†§ 10.50 ± 1.02†§ 10.56 ± 0.16†§ 10.70 ± 0.16†§ 11.86 ± 0.24 10.23 ± 0.33†§ 
C18:1n9 37.27 ± 1.26§ 39.78 ± 0.22†§ 36.16 ± 0.24†§ 39.80 ± 0.21†§ 40.4 ± 0.57†§ 38.86 ± 0.54†§ 40.40 ± 0.57†§ 38.10 ± 0.16†§ 34.73 ± 0.38† 38.10 ± 0.32†§ 
C18:2n6 2.12 ± 0.13 2.16 ± 0.13 2.05 ± 0.13 2.17 ± 0.26 2.08 ± 0.3 2.23 ± 0.09 2.08 ± 0.30 2.25 ± 0.14 2.33 ± 0.20 2.33 ± 0.20 
C18:3n6 0.34 ± 0.02 0.33 ± 0.01 0.37 ± 0.04 0.34 ± 0.01 0.35 ± 0.01 0.33 ± 0.02 0.35 ± 0.01 0.32 ± 0.01 0.35 ± 0.05 0.38 ± 0.01 
C18:3n3 0.46 ± 0.02 0.46 ± 0.01 0.46 ± 0.01 0.46 ± 0.02 0.45 ± 0.01 0.42 ± 0.01 0.45 ± 0.01 0.44 ± 0.02 0.42 ± 0.02 0.43 ± 0.01 
C20:3n6 0.68 ± 0.02 0.67 ± 0.02 0.68 ± 0.02 0.66 ± 0.03 0.68 ± 0.01 0.63 ± 0.02 0.68 ± 0.01 0.66 ± 0.01 0.64 ± 0.01 0.62 ± 0.01 
C20:3n3 0.26 ± 0.04 0.29 ± 0.01 0.22 ± 0.01 0.55 ± 0.02 0.54 ± 0.03 0.27 ± 0.02 0.54 ± 0.03 0.28 ± 0.02 0.24 ± 0.03 0.34 ± 0.02 
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Fatty acid  
(% of total FA) 
Mean ± SD 
Control (5% 
BSA) 
100µM Fenofibrate 10µM 
GW6471 
50µM C15:0 150µM 15:0 300µM C15:0 50µM C16:0 150µM 16:0 300µM 
C16:0 
150µM 15:0 
 +  
150µM 16:0 
 
                                                                                                                                                                                                                                                                                                                                                                                               
C20:4n6 4.20 ± 0.29 4.03 ± 0.24 4.33 ± 0.2 3.60± 0.16§ 3.66 ± 0.12
†
§ 3.90 ± 0.16§ 3.66 ± 0.12§ 4.33 ± 0.20 4.66 ± 0.12 4.50 ± 0.16 
C20:5n3 0.42 ± 0.04 0.44 ± 0.05 0.41 ± 0.03 0.66 ± 0.01 0.65 ± 0.01 0.40 ± 0.06 0.65 ± 0.01 0.46 ± 0.09 0.36 ± 0.06 0.48 ± 0.11 
C22:1n9 0.05 ± 0.01 0.05 ± 0.01 0.08 ± 0.02 0.06 ± 0.01 0.10 ± 0.01 0.05 ± 0.01 0.10 ± 0.01 0.05 ± 0.02 0.05 ± 0.01 0.07 ± 0.02 
C22:6n3 3.63 ± 0.24 3.36 ± 0.16 3.35 ± 0.12 4.50 ± 0.16†§ 4.46 ± 0.16†§ 3.63 ± 0.20†§ 4.46 ± 0.16 3.50 ± 0.32 3.00 ± 0.08 4.20 ± 0.21§ 
Total SFA 45.06 ± 1.38§ 42.67 ± 0.68† 46.49 ± 0.13†§ 40.93 ± 0.29†§ 40.21 ± 1.04†§ 43.53 ± 0.68†§ 40.21 ± 1.04†§ 43.75 ± 0.22†§ 46.7 ± 0.05† 42.55 ± 0.27†§ 
Total MUFA 42.11 ± 1.70§ 45.24 ± 0.73†§ 41.03 ± 0.31 45.46 ± 0.21†§ 46.35 ± 0.72†§ 44.16 ± 0.67†§ 46.35 ± 0.72†§ 43.64 ± 0.30†§ 40.92 ± 0.15† 43.56 ± 0.37†§ 
Total PUFA 12.14 ± 0.05 11.77 ± 0.2 11.90 ± 0.18 12.96 ± 0.25 12.90 ± 0.38 11.83 ± 0.38 12.90 ± 0.38 12.26 ± 0.34 12.02 ± 0.18 13.3 ± 0.14 
Total ω-3 4.78 ± 0.33 4.56 ± 0.24 4.45 ± 0.13 6.18 ± 0.15†§ 6.12 ± 0.20†§ 4.73 ± 0.30†§ 6.12 ± 0.20 4.69 ± 0.41 4.02 ± 0.16 5.45 ± 0.31§ 
Total ω-6 7.35 ± 0.34 7.21 ± 0.35 7.44 ± 0.06 6.78 ± 0.28§ 6.78 ± 0.34§ 7.10 ± 0.12§ 6.78 ± 0.34 7.57 ± 0.33 7.99 ± 0.29 7.84 ± 0.16 
OCSFA 0.72 ± 0.05 0.74 ± 0.03 0.76 ± 0.08 1.10 ± 0.01 1.19 ± 0.01 0.72 ± 0.01 1.19 ± 0.01 0.79 ± 0.05 0.68 ± 0.03 0.95 ± 0.02 
ECSFA 44.33 ± 1.41§ 41.92 ± 0.64†§ 45.72 ± 0.15† 39.82 ± 0.30†§ 39.02 ± 1.04†§ 42.81 ± 0.67†§ 39.02 ± 1.04†§ 42.95 ± 0.28†§ 46.01 ± 0.02†§ 41.6 ± 0.24†§ 
C16:1/C16:0 0.14 ± 0.01 0.17 ± 0.01 0.14 ± 0.01 0.18 ± 0.01 0.19 ± 0.01 0.15 ± 0.01 0.19 ± 0.01 0.16 ± 0.01 0.17 ± 0.01 0.16 ± 0.01 
C18:1n9/C18:0 3.12 ± 0.3 3.43 ± 0.15 2.84 ± 0.12 3.62 ± 0.07 3.82 ± 0.09 3.73 ± 0.37 3.82 ± 0.09 3.56 ± 0.03 2.92 ± 0.08 3.72 ± 0.15 
C17:0/C17:1 0.23 ± 0.04 0.22 ± 0.03 0.16 ± 0.02 0.33 ± 0.04 0.39 ± 0.02 0.21 ± 0.02 0.39 ± 0.02 0.16 ± 0.01 0.17 ± 0.03 0.25 ± 0.01 
† Represents a statistical significance of P< 0.05 for treatments vs control, while § represents a significant difference between treatment and C16:0 
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4.5 DISCUSSION 
The previous chapter described a negative correlation between C15:0 and plasma 
glucose in fasting blood samples, which is in keeping with an emerging theme in 
several large-scale longitudinal studies [200, 206, 207]. However, the cellular 
mechanisms by which C15:0 exert any metabolic effect remains unknown. This 
chapter aimed to identify a mechanistic pathway to explain the protective effect of 
OCSFA through changes to glucose and FA metabolism in the liver. The results show 
that C15:0 significantly ameliorated C16:0 induced insulin resistance in vitro, by 
increasing glycogen production and reducing gluconeogenesis; both mechanisms that 
contribute significantly to increased plasma glucose in T2DM [260-262]. Furthermore, 
C15:0 reduced TNFα and IL-8 secretion by C16:0 treated hepatocytes. Also, C15:0 
differentially modulates hepatocyte metabolic activity, favouring increased 
mitochondrial and peroxisomal oxidation of FA, which appears to be mediated via 
PPAR alpha.  
To understand the effect of FAs on hepatocyte function, HepG2 cells needed to be 
differentiated to closely resemble primary hepatocytes, which are more quiescent and 
are characterised by increased expression of markers such as albumin, urea, as well 
as phase I and phase II enzymes [41]. Here, we found that growing the cells in low 
serum media induced hepatocyte differentiation with an increase in markers of 
differentiation, including albumin, transferrin, and urea, with no effect on cellular 
viability. Traditionally, retinoic acid (RA) and its derivatives are more commonly used 
to induce cell cycle arrest and cellular differentiation [263-266], by various 
mechanisms, which include the regulation of cyclin-dependent kinases, p53, p21, 
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retinoic-X receptor (RXR) amongst others, leading to cell cycle arrest predominantly 
in the G0/G1 phase. However, low serum has been shown to be as effective resulting 
in less toxicity to cells [267, 268] as RA also induces apoptosis, especially at high 
concentrations. The other justification for using low serum to induce quiescence in this 
study is that RA interferes with lipid metabolism by transactivating the PPAR 
alpha/RxRα heterodimer [269], which would have confounded the determination of FA 
effect on PPAR alpha transcription.  
Chronic low-grade inflammation has been suggested as a link between the 
progression from NAFLD to a state of insulin resistance. Mature hepatocytes can alter 
the expression of specific proteins including cytokines, independent of resident 
macrophages, in response to inflammatory and stress stimuli [270, 271]. Here, we find 
that palmitate-treated cells induce an acute phase reaction similar to LPS without 
inducing apoptosis or affecting cellular viability. Several studies have shown palmitate-
induced inflammation in hepatocytes mediated by several mechanisms including 
upregulation of NFƘB -by inducing oxidative stress [272], or toll-like receptors [273, 
274]- upregulation of NOD-like receptor protein 4 (NLRC4) and caspase-1 activation 
mediated maturation of cytokines [275],  amongst others. Others suggest that the toxic 
effect of palmitate can be explained by the intracellular accumulation of saturated 
phospholipids and intermediates (like ceramides) resulting in cellular dysfunction, 
especially in the mitochondria, due to an insufficient capacity to dispose of SFA by 
mitochondrial beta-oxidation, [276-278]. On the other hand, C15:0 treated cells 
increased metabolic activity, at least in the first six hours of treatment, corresponding 
to an increased mitochondrial succinate dehydrogenase activity (responsible for 
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reducing MTT), which may represent an increase in mitochondrial function- as 
evidenced by improved mitochondrial β-oxidation (Figure 4.10). Co-treating cells with 
C15:0 removed the toxic effect of C16:0. These toxic effects are absent in cells treated 
with oleate, a MUFA, despite significant lipid accumulation[63]. In fact, oleate protects 
C16:0 treated cells from insulin resistance and metabolic dysfunction via several 
mechanisms in different cell lines [279, 280], suggesting a differential effect of FA on 
cellular metabolic activity and viability. It was therefore interesting that the results in 
this chapter showed an increase in oleate production and an increase in the 
MUFA/SFA ratio in C15:0 treated cells (Table 4.12). Therefore, it is plausible that the 
protective effect of C15:0 in our study could be partially due to the mobilisation of 
C16:0 produced de novo, or acquired otherwise, into the less harmful MUFA, 
especially oleate. There is conflicting evidence from clinical studies on the benefits of 
a high MUFA/SFA ratio[281-284] mainly because these studies fail to distinguish 
between FAs from diet and de novo lipogenesis[285], and also mostly look at 
C16:0/C16:1 ratio as an indication for desaturase enzyme activity. However, clear 
benefits exist when diets high on MUFA are consumed in preference to high 
carbohydrate diets [286-289].  
After establishing the presence of inflammation in C16:0 treated cells, which is 
ameliorated by C15:0, it was essential to ascertain if this had any impact on glucose 
homeostasis vis-à-vis insulin resistance. The results revealed that C15:0 significantly 
ameliorated C16:0 induced decrease in glycogen production and increase in glucose 
output;  both mechanisms that contribute significantly to increased plasma glucose in 
T2DM [260-262]. A reduction in glycogen content in cells treated with high 
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concentrations of C16:0 was associated with an upregulation of GSK3β. GSK3β is 
known to inactivate glycogen synthase by phosphorylation, therefore, preventing 
glycogen production. In animal studies where hepatic steatosis is induced by high-fat 
diet, insulin resistance develops when there is a failure to inactivate GSKβ by 
impairment of insulin-stimulated tyrosine phosphorylation of IRS-1 and IRS-2, in a 
process likely to involve PKC activation of JNK [290]. The importance of GSK3β in 
palmitate-induced insulin resistance is buttressed by studies which show an 
improvement in insulin sensitivity, glucose homeostasis and cellular viability by the 
knockdown, silencing or inhibition of GSK3β [291, 292]. Interestingly, the data also 
showed upregulation of GSK3β by cells treated with high concentrations of C15:0 
without affecting cellular glycogen content. The production of glycogen by an alternate 
pathway, possibly involving an insulin-dependent activation of glycogen synthase via 
glucose-6-phosphate, in C15:0 treated cells cannot be ruled out [293]. The data also 
showed upregulation of GLUT2 mRNA and gene expression by all FA treatments. 
However, only 300µM C16:0 treated cells showed a significant increase in glucose 
output in the supernatant. The upregulation of GLUT2 is an unreliable indicator for 
increased gluconeogenesis because the glucose transporter is bi-directional and non-
specific for glucose[294] and very likely to reflect any movement of glucose across the 
cell membrane irrespective of FA treatments or concentration. It is also plausible that 
the upregulation of GLUT2 seen here reflects the acute insulin-mediated uptake of 
glucose by FAs [295]. However, as shown in some studies, GLUT2 is indispensable 
for glucose uptake [296] and alternative mechanisms exist for glucose output [297, 
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298]. Therefore, it is difficult to interpret the results of the GLUT2 data with respect to 
insulin resistance. 
So far, we have seen that C15:0 reduced IL-8 and TNFα secretion by C16:0 treated 
hepatocytes. Previous studies have shown that lipid accumulation following C16:0 
treatment induces an immune-mediated metabolic dysregulation [252] with reduced 
insulin-stimulated glucose uptake mediated via PI3-kinase signalling [196]. Moreover, 
Lee, Jin-young and colleagues observed insulin resistance in C16:0 treated HepG2 
cells without significant lipid accumulation [299]. However, lipid accumulation features 
prominently in the pathway connecting inflammation and insulin resistance. Here, 
C16:0-induced increase in glucose output and reduced glycogen storage was 
associated with both raised inflammatory markers and lipid accumulation. It was 
important to understand the mechanisms that led to lipid accumulation in hepatocytes 
following FA treatment.  
Hepatic lipid accumulation is thought to arise as a result of an interplay between 
excess uptake, defective FA oxidation, de novo lipogenesis, and VLDL export [300]. 
In this chapter, the first three factors have been studied using gene expression data. 
To examine the differential effect of FA on lipid uptake, gene expression of CD36 and 
liver-specific fatty acid binding protein (FABP) were examined. There was a high basal 
expression of CD36 in dHepG2 cells (similar mRNA content as relatively abundant 
reference gene), which is in keeping with hepatocyte maturity and differentiation. 
Unsurprisingly, all FA treatments upregulated CD36 gene expression, but to different 
degrees, with cells treated with 300µM C16:0 appearing to exert to most effect. 
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Several factors are known to increase the expression of CD36 including age, a high-
fat diet, and insulin [301-303]. More specifically, SFA [304], MUFA [305], and PUFA 
[306] are all known to stimulate CD36 expression, to aid their cellular intake; however, 
there has been no report of differential sensing of FA by CD36 in the liver, despite 
limited evidence supporting this occurrence in other cells [307]. Similarly, all FA 
treatments in this study upregulated L-FABP. L-FABP plays an important role in 
trafficking cytoplasmic FAs into organelles, including the mitochondria and 
peroxisomes for β-oxidation, and the nuclei, where these FA could act as ligands for 
transcription factors [308]. In addition to FA, hypolipidaemic drugs like statins regulate 
L-FABP by interacting with PPAR alpha [309]. Therefore, it is possible that the 
differential upregulation of L-FABP by FA may be related to their individual ability to 
stimulate PPAR. It is difficult to predict the phenotypic expression and function of these 
FA transporters by their gene expression data. However, going by the data presented 
so far, high concentrations of C16:0 is associated with massive influx of FAs mediated 
by CD36 upregulation, which is not matched by a similar rise in L-FABP, leaving the 
possibility of cytoplasmic lipid accumulation leading to the formation of neutral lipid 
droplets and/or lipid intermediates such as ceramides, diacylglycerol, and 
lysophosphatidylcholine (LPC). Considerable but distinct upregulation of both CD36 
and L-FABP may partly explain the increased lipid accumulation noted in cells treated 
with high concentrations of C16:0, but does not explain why other FA treated cells, 
which similarly upregulated both CD36 and L-FABP, show comparable amounts of 
neutral lipid accumulation with control cells. Therefore, FA oxidation was explored to 
explain any differences in mitochondrial or peroxisomal metabolism in FA stimulated 
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cells. Here, cells treated with high concentrations of C16:0 show similar gene 
expression levels CPT1 and CPT2 as controls, which is disproportionate to the level 
of CD36 and L-FABP as seen earlier. CPT1 is usually considered the rate-limiting step 
for mitochondrial FA oxidation, and along with CPT2, is responsible for the transport 
of fatty acid acyl esters across the mitochondrial membrane, in a process involving the 
incorporation of carnitine to fatty acyl esters [310-312]. The importance of CPT1 to FA 
oxidation is reinforced by mice knockout studies where the deficiency of CPT1 results 
in lipid accumulation secondary to reduced mitochondrial FA oxidation [313], and in 
studies where in vitro inhibition of CPT1 by etomoxir produces the same outcome 
[314]. Palmitate usually stimulates CPT1 & CPT2, especially in lower concentrations. 
In fact, there is only limited direct evidence in support of a  downregulatory effect at 
concentrations as high as 750µM resulting in dysfunctional FA oxidation [315]. Here, 
the effect of palmitate is disproportionally equivocal to control suggesting a reduction 
in FA oxidation in these cells. However, in in vitro and mice models of palmitate-
induced insulin resistance, lipid accumulation is usually associated with generalised 
mitochondrial dysfunction and consequently reduced FA oxidation, ameliorated by 
MUFA and PPAR alpha [310, 316-319]. The results from this chapter also show that 
co-incubating cells with C15:0 and C16:0 ameliorates palmitate-induced dysfunction 
in genes involved in mitochondrial and peroxisomal β-oxidation, in a process that might 
be similar to how MUFA protect cells from palmitate-induced dysfunction. Additionally, 
the results suggest that C16:0 treated cells probably favour de novo lipogenesis by 
upregulating FASN gene expression. Put together, cells treated with high 
concentrations of C16:0 potentiate intracellular lipid traffic but show disproportionate 
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β-oxidation functionality, which in addition to increase de novo lipogenesis could 
explain increased intracellular lipid accumulation as observed. Conversely, C15:0 
treated cells appear to maintain normal levels of neutral lipids by increasing FA 
oxidation to account for the influx of FA and likely slight increase in de novo 
lipogenesis. 
The protective effect of C15:0 on palmitate-induced hepatocyte dysfunction has so far 
mirrored that of MUFA in literature. In this chapter, the result shows that C15:0 
increased the expression of both SCD1 and SCD5, suggesting that some of the 
protective effect of C15:0 may be the consequence of MUFA production. This is 
confirmed by a higher MUFA/SFA ratio in these cells compared to palmitate-treated 
cells. Interestingly, only C15:0 treated cells upregulated SCD1, which is more highly 
expressed in dHpG2 cells. Furthermore, an examination of ELOVL1, FADS1 and 
FADS2 show that C15:0 treated cells show a preference for the biosynthesis of ω-3 
PUFA as opposed to ω-6 PUFA, which are preferentially produced by C16:0 treated 
cells. Again, PUFA shows a comparable protective effect as MUFA in literature in the 
context of palmitate-induced hepatocyte dysfunction. Therefore, the ability of C15:0 to 
promote the production of MUFA and PUFA may underpin its overall effect on 
hepatocytes metabolically.  
The apparent hypolipidaemic effect of C15:0, especially in the context of increased FA 
oxidation (especially in the peroxisomes) raises the suspicion of PPAR involvement. 
Pararasa et al. (2013) have previously shown that the effect of FA on macrophage 
differentiation and phenotype was related to PPARγ [252]. It was therefore pertinent 
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to identify any associations between C15:0 and PPAR alpha, which is more 
predominantly involved with FA oxidation than other PPARs in the liver. As seen in the 
results, C15:0 treated cells appear to upregulate PPAR alpha upstream similar to the 
fenofibrate, a known PPAR alpha agonist, associated with a rise in RxRα expression, 
which is required to form the PPAR alpha/RxRα heterodimer prerequisite for 
transcriptional activity. Moreover, C15:0 at all concentrations upregulate KPNA2 and 
KPNB1, necessary for nuclear translocation of ligands and proteins. Importantly, 
C15:0 and fenofibrate exclusively increase gene expression levels of NCOA2, which 
amplifies the downstream transcriptional activity of target genes by histone acetylation 
[320, 321]. To verify the gene expression data, a transcription activity assay was 
performed which shows that C15:0 significantly increased PPAR alpha activity 
compared to control, similar to fenofibrate.The fact that PPAR alpha transcriptional 
activity was similar between C15:0 treated and fenofibrate treated cells suggested that 
the protective effect of C15:0 vis-a-vis the increase in MUFA content could be 
mediated via a PPAR alpha pathway. Moreover, C15:0 increased PPAR alpha activity 
in C16:0 treated cells more than fenofibrate and the addition of a PPAR alpha 
antagonist eliminated this effect. PPAR alpha activation has been shown to increase 
FA catabolism, β-oxidation, improve insulin resistance and reduce liver steatosis and 
inflammation in mouse models[322-324]. However, these effects were seldom 
observed in humans until recently when the use of a dual PPAR alpha/δ agonist 
(GFT505) showed a liver-specific reduction in insulin resistance[325]. Once activated, 
PPAR alpha regulates several genes to promote lipid metabolism. This study found 
many of these genes (CPT1, CPT2, SCD1, NCOA2, FADS1, FADS2) to be highly 
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upregulated with C15:0 treatment alone, or with C15:0 and C16:0. An upregulation of 
SCD1 is in keeping with our finding of an increased level of MUFA in C15:0 treated 
cells. Some PUFA acts as natural ligands for PPAR alpha [251] and would make sense 
if the PPAR alpha activation noted with C15:0 is partly due to the increased PUFA 
production elicited by C15:0. There is a suggestion from our results that C15:0 may 
be acting as a ligand for PPAR alpha. We cannot exclude effects on other PPARs due 
to their overlapping regulatory effects and redundancy.  
Gene expression for de novo lipogenesis pathway was marginally upregulated with 
C15:0 treatment in our study. This is in line with a recent study that identified de novo 
lipogenesis as an essential player in the generation of an endogenous ligand for PPAR 
alpha, 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Taking 
this evidence together, it is plausible that in addition to PUFA production, C15:0 either 
acts directly as a ligand for PPAR alpha or induces the process of producing an 
endogenous PPAR alpha ligand, subsequently leading to PPAR alpha transcription 
and downstream target gene expression. 
This study is limited by relying on gene expression data to demonstrate metabolic 
mechanisms underpinning lipid metabolism. Gene expression by RT-qPCR provides 
information on the relative abundance of mRNA and is no way indicative of 
gene/protein function. Moreover, there are several other complex processes involved 
in gene regulation and function such as post-transcriptional and post-translational 
changes, that determine the physiologic and functional end-product of genes. These 
processes were not accounted for in this study. Consequently, fold change gene 
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expression data does not account for downstream production of target proteins or their 
activation and inhibition. Therefore, the degree of regulation at gene expression level 
does not necessarily reflect target protein expression or function. 
This study did not qualify or quantify the enzymes involved in lipid metabolism in 
hepatocytes or attempt to identify their phosphorylated product as a measure of 
regulation. Therefore, the results from this study are physiologically redundant and at 
best, provides a useful suggestion for future studies. 
In conclusion, this study attempted to demonstrate a cellular metabolic mechanism to 
explain the effect of OCSFA on palmitate-induced cellular dysfunction in a model of 
insulin-resistant hepatocytes. C15:0 treated cells showed a different metabolic 
outcome compared to its even chain counterpart (C16:0) in terms of glucose 
production, glycogen storage, and intracellular accumulation of neutral lipids. 
Furthermore, results from RT-qPCR suggest a differential gene expression profile 
between C15:0 and C16:0 in lipid metabolism. However, further studies are required 
to shed more light on the physiologic importance of these differences and to validate 
the mechanisms underpinning the effect of OCSFA on hepatocyte function. 
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5 CHAPTER 5: EFFECT OF FATTY ACIDS ON MONOCYTE 
FUNCTION 
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5.1 INTRODUCTION 
The mechanisms linking inflammation and insulin resistance are complex and mostly 
still held as hypotheses. Many factors have been identified as either inducers or 
modifiers of the inflammatory process leading to metabolic disorders, and monocytes 
and macrophages have been acknowledged as key players in this inflammatory 
process [326, 327]. 
The circulation of excess FFA is usually causally linked to the development of the 
chronic low-grade inflammation associated with T2DM and other metabolic syndromes 
[328-331]. A few clinical studies have shown a positive correlation between obesity 
indices, such as elevated FFA, and raised inflammatory markers like CRP [332-334]. 
Although the exact mechanism by which FAs induce and maintain inflammation is still 
mostly unknown, much work has been done in recent times to explore the mechanistic 
effect of FA on innate immunity. SFA have been shown to activate Toll-like receptors 
(TLRs), especially TLR2 and TLR4, both of which are implicated with LPS-induced 
pro-inflammatory changes [335, 336]. TLRs mediate the expression of IL-6 and TNFα 
[337-339], which have become useful biomarkers of inflammation in lipid research. 
Interestingly, UFA inhibit TLR mediated expression and signalling of pro-inflammatory 
activity [340-342] and it is still unknown if OCSFA will behave differently compared to 
the more abundant even chain SFAs like palmitate. TLRs and their associated 
cytokines are highly expressed in monocytes, making this peripheral immune cells an 
essential target for lipid research. 
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Monocyte diversity and macrophage polarisation are becoming increasingly important 
in the discussion around the immune induction of metabolic diseases [143, 343-348]. 
Monocyte and macrophage phenotypes are functionally distinct in innate-immune 
driven processes; therefore, a careful understanding of the different classes of 
monocytes and macrophages, their phenotypic differences, and the different factors 
that modulate these phenotypes can shed light on the occurrence of a low-grade 
inflammatory state prevalent in metabolic diseases. Monocytes are classified as 
classical, intermediate, or non-classical; depending on the expression of CD14 and 
CD16 on the cell surface [349, 350]. The classical monocyte subset represents 80% 
of circulating monocytes and expresses high levels of CD14 and very low levels of 
CD16 (otherwise denoted CD14++/CD16- population) [351, 352]. This subpopulation 
of monocytes express less TNFα and more IL-10 cytokines after LPS stimulation and 
are thought to be anti-inflammatory, with high phagocytic function, but quick resolution 
post-inflammation. Intermediate monocyte subsets are characterised by high levels of 
CD14, and higher levels of CD16 compared to classical monocytes (denoted as 
CD14+/CD16+ monocytes) and have been denoted to be pro-inflammatory in more 
recent studies. Along with intermediate monocytes, the non-classical monocytes (or 
CD14-/CD16++ sub-population) are associated with increased production of pro-
inflammatory cytokines and are increased in infectious diseases as well as chronic 
metabolic disorders [349, 353]. Similarly, monocytes differentiate into distinct classes 
of macrophages depending on the stimuli. M1 macrophages, like intermediate and 
non-classical monocytes, are associated with elevated levels of pro-inflammatory 
cytokines like IL-6 and TNFα [354, 355]. Whereas, M2 macrophages, induced in vivo 
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by T helper 2  cells, express an anti-inflammatory or pro-resolution phenotype, 
associated with increased secretion of IL-10 [354, 355].. There is a complex 
relationship between FAs and monocyte/macrophage differentiation, and there is a 
dearth of studies exploring the mechanisms by which FAs influence the diversity of 
monocytes and macrophages. Pararasa (2013) showed that palmitate cause 
differential alteration of macrophages by inducing a pro-inflammatory environment, 
resulting in the production of M1 macrophage, compared to oleate, an UFA, which 
tends towards M2 induction; highlighting the importance of FA class/type in immune 
modulation [356]. However, there has been no study looking at the possible difference 
in monocyte/macrophage induction or differentiation among OCSFAs in comparison 
with even chain SFAs.  
 
5.2 AIMS AND HYPOTHESIS 
There is a growing recognition of the contribution of monocyte phenotypes in normal 
healthy physiology and disease states. Recent studies have shown that FA classes 
may have different effect on monocytes and macrophages. Many of these studies 
have concentrated on the more abundant even chain FAs. However, with growing 
evidence in support of a protective effect of OCSFA on diseases like T2DM known to 
be associated with chronic inflammatory states, it has become imperative to elucidate 
the effect of OCSFA on monocyte function. The harmful effect of FAs on immune cells 
as shown in literature is usually mediated via disturbances in metabolic activity and an 
expression of a pro-inflammatory phenotype. However, work from several studies 
have shown that PPAR alpha antagonists induce an anti-inflammatory response in 
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immune cells. Subsequently, results from section 4.4.8 show that C15:0 increases 
transcriptional activity of PPAR alpha in hepatocytes. Therefore, this chapter aims to 
show the differential effect of OCSFA compared to palmitate on monocyte phenotype 
and function by exploring their influence on LPS stimulated monocytes.  
5.2.1 Hypothesis 
The Hypotheses for this study are as follows: 
1. C15:0 will increase metabolic activity in THP-1 cells 
2. C15:0 and C16:0 will show differential alteration in cell surface markers 
corresponding to different monocyte subsets 
3. C15:0 will ameliorate pro-inflammatory response to LPS in THP-1 cells 
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5.3 METHOD 
5.3.1 Determination of metabolic activity 
Following treatment, the metabolic activity of THP-1 monocytes was determined by 
the MTT assay as described in section 2.7. 
5.3.2 Quantification of cellular growth and viability 
Cell growth and viability were measured using the trypan blue exclusion method with 
the counting of cells using a haemocytometer as described in section 2.6. 
5.3.3 DNA cell cycle analysis by Flow Cytometry 
Following treatment, cell cycle analysis was performed following the method described 
by Phillips et al. (2003) as detailed in section 2.4 [357] 
5.3.4 Flow cytometry analysis of surface antigen expression 
Flow cytometry was used to quantify surface expression of CD14, CD16, and CD36 
as described in section 2.5. 
5.3.5 Differentiation of monocyte 
Following priming with FAs, THP-1 monocytes were differentiated to macrophages by 
stimulating with PMA as detailed in section 2.3. 
5.3.6 Quantification of cytokines 
Following treatment, IL-6, IL-10, and TNFα were quantified from supernatants by 
ELISA as described in section 2.12. 
5.3.7 Statistical analysis 
Data expressed as mean +/-  SEM for three independent experiments. FACS data 
expressed as median fluorescence intensity to account for the non-normally 
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distributed flow intensity data. Statistical significance was estimated using repeated 
measures one way ANOVA with a Geisser-Greenhouse correction to correct for the 
unequal variability of differences, and a Dunnett’s post-test for multiple comparisons. 
FACS data were analysed by a Friedman’s test with Dunn’s post-test for multiple 
comparisons. Data obtained was analysed using GraphPad Prism (v7.0) 
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5.4 RESULTS 
5.4.1 C15:0 increases metabolic activity 
THP-1 monocytes were cultured at 500,000 cells/ml with indicative concentrations of 
FA or control for 6hrs and 24hrs, to determine cellular metabolic activity. The result 
shows that C15:0 is associated with an increase in metabolic activity (Figure 5.1a) by 
13% (p < 0.001), 12% (p < 0.001), and 10% (p < 0.001) compared to control for 50µM, 
150µM, and 300µM C15:0 respectively after 6hrs of incubation. In comparison to cells 
treated with 300µM C16:0, this represents an increase in metabolic activity by 30% (p 
< 0.001), 27% (p < 0.001), and 24% (p < 0.001) for 50µM, 150µM, and 300µM C15:0 
respectively. Treating cells with C16:0 showed the opposite effect compared to C15:0 
treated cells. C16:0 decreased metabolic activity in THP-1 cells corresponding to a 
1.6% (p < 0.05), 2.7% (p < 0.01), and 11% (p < 0.001) decrease in metabolic activity 
after 6hrs compared to control for 50µM, 150µM, and 300µM C16:0 concentrations 
respectively. Interestingly, the decrease in metabolic activity with C16:0 is abolished 
when co-treated with C15:0. Over 24hrs, there was no statistically significant 
difference in metabolic activity between all C15:0 treated cells and controls (Figure 
5.1b). However, cells treated with C16:0 still showed a significant reduction in 
metabolic activity compared to control by 1.8% ( p < 0.05), 1.9% (p < 0.01), 11.6% (p 
< 0.001) for 50µM, 150µM, and 300µM C16:0 concentrations respectively. Again, this 
effect is abolished by co-treating with C15:0. Furthermore, as seen in figure 5.2, high 
concentrations of C16:0 reduces total cell count in monocytes as early as 6hrs after 
treatment.  
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5.4.2 C16:0 is associated with markers of cell death 
THP-1 cells were assessed for cell viability to exclude any toxic effect of FAs. As seen 
in previous results, C15:0 increases metabolic activity, while C16:0 decreases activity. 
To determine if this effect is confounded by the toxicity of FA to cells, propidium iodide 
was used to assess cellular viability. Viable cells with intact membranes usually 
exclude dyes such as trypan blue and propidium iodide; therefore, providing a means 
of checking viability. The ability of the fluorescent dye, propidium iodide, to intercalate 
with DNA, provides a useful means to measure the proportion of dead cells in any 
given sample. Apoptotic cells have reduced DNA content. It is evident from the results 
that cells treated with C16:0 show significantly increased levels of apoptotic nuclei in 
a dose-dependent manner (Figure 5.3a). There was a 9.3% (p < 0.05), 15.2% (p < 
0.001), and 22.4% (p < 0.01) increase in apoptotic nuclei found in cells treated with 
50µM, 150µM, and 300µM C16:0 respectively compared to control cells. There was 
an excellent linear correlation between treatment concentration of C16:0 and 
percentage increase in apoptotic nuclei (R2 0.99). In contrast, cells treated with varying 
concentrations of C15:0 had less apoptotic cells compared to controls. There was a 
44.2%, 52%, and 41% decrease in the number of apoptotic cells compared to controls 
in cells treated with 50µM, 150µM, and 300µM C15:0 respectively (all p values < 
0.001). 
5.4.3 FAs alter cell cycle dynamics of monocytes 
It is clear from the results shown so far that C16:0 inhibits metabolic activity and 
impacts negatively upon cell growth, probably by inducing apoptosis, whereas, C15:0  
appears to improve these indices. Therefore, it was important to investigate the effect 
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of these FAs on cell cycle dynamics (Figure 5.3). Generally, for C15:0 treated cells, 
there were more cells found in the G0/G1 phase with a reciprocal decrease in cells 
found in the S-phase. C15:0 treatment increased the proportion of cells found in the 
G0/G1 phase by 13% (p < 0.01), 16% (p < 0.001), and 13% (p < 0.001) for 50µM, 
150µM, and 300µM C15:0 respectively compared to control cells. In contrast, there 
were less cells found in the S-phase compared to control by 10% (p > 0.05), 13% (p 
< 0.05), 13% (p < 0.05) for 50µM, 150µM, and 300µM C16:0 respectively. Only 150µM 
C15:0 treated cells accounted for statistically significant fewer cells in the G2/M phase 
compared to controls among C15:0 treated cells (13% reduction, p < 0.05). There was 
no statistically significant difference in the proportion of cells in the G1/G0 or S-phase 
in C16:0 treated cells compared to controls. However, there was a dose-dependent 
decrease in the proportion of cells in the G2/M phase for C16:0 treated cells compared 
to control; 3.4% (p < 0.05), 11.4% (p < 0.01), 16% (p < 0.01) decrease for 50µM, 
150µM, and 300µM C16:0 respectively. 
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Figure 5.15.1: C15:0 is associated with a short-lived increase in metabolic activity in monocytes.  
THP1 monocytes at a density of 5 x 105 cells were treated with fatty acids conjugated to BSA and analysed for metabolic activity using MTT 
reduction after 6 and 24hrs of exposure. Cells were exposed to varying concentrations of fatty acids, or control (5% BSA) as outlined. MTT 
reagent was added to the media 4 hours prior to the end of the experiment. Cells were then lysed with lysis reagent overnight before analysis 
under absorbance spectrometry at 570nm. (a) Effect of fatty acid treatments after 6hrs and (b) 24hrs. Results are expressed as mean +/- 
SEM (n=3 independent experiments). Statistical significance was determined by a repeated measures one-way ANOVA with Geisser-
Greenhouse correction and a Dunnett’s post-test comparison.   Ψ represents a statistical significant difference between treatment versus 
control, Ξ represents a statistical significant difference between treatment versus 300µM C16:0, and  φ represents a statistical significant 
difference between the treatment versus both control and 300µM C16:0. All symbols represent a statistical significance P value of < 0.05. 
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Figure 5.2: High concentrations of C16:0 causes Monocyte growth arrest 
THP1 monocytes at a density of 5 x 105 cells were treated with fatty acids conjugated to BSA and analysed for cell growth after 6 and 24hrs of 
exposure. Cells were exposed to varying concentrations of fatty acids, or control (5% BSA) as outlined.  To assess cell growth, THP1 cells were counted 
with a haemocytometer after (a) 6hrs or (b) 24hrs of fatty acid treatment.  Results are expressed as mean +/- SEM (n=3 independent experiments).  
Statistical significance was determined by a repeated measures one-way ANOVA with Geisser-Greenhouse correction and a Dunnett’s post-test 
comparison.  Ψ represents a statistical significant difference between treatment versus control, Ξ represents a statistical significant difference 
between treatment versus 300µM C16:0, and  φ represents a statistical significant difference between the treatment versus both control and 300µM 
C16:0. All symbols represent a statistical significance P value of < 0.05. 
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5.4.4 C15:0 and C16:0 show differential alteration of cell surface antigen expression 
in THP-1 monocytes 
FA have been shown to induce phenotypic changes on monocytes, including antigen 
cell surface expression. It has already been shown from results above that OCSFA 
differs in its interaction with monocytes regarding cellular viability and metabolic 
activity. To determine if there was a distinction between C15:0 and C16:0 on monocyte 
cell surface expression, the levels of CD14, CD16, and CD36 were measured (Figure 
5.4) by FACS. High concentrations (300µM) of both FA significantly reduced CD14 
cell surface expression, but C16:0 (p < 0.001) by up to twofold more than C15:0 (p < 
0.01). There was no significant difference in the cell surface expression of CD14 
between control and the lower concentrations of C15:0 treated cells, or with cells 
treated with 50µM C16:0. However, there was a significant decrease in CD14 
expression in cells treated with 150µM C16:0 (p < 0.05). Furthermore, there was a 
negative linear correlation between the concentration of C16:0 and CD14 cell surface 
expression (R2 0.99). FA treatment did not affect CD16 cell surface expression (Figure 
5.4b) irrespective of chain length or concentration. High concentrations of C16:0 
(300µM) significantly increased the cell surface expression of CD36 (Rank sum 
difference 21, p < 0.05) compared to control (Figure 5.4c), and there was a positive 
linear correlation between the concentration of C16:0 and CD36 surface expression 
(R2 0.98). In contrast, there was no statistically significant change in CD36 expression 
for THP-1 cells treated with varying concentrations of C15:0.  
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5.4.5 Palmitate but not C15:0 increases pro-inflammatory cytokine production 
We have already seen from previous results that FA may modify monocyte phenotype 
by altering cell surface expression of CD14. Here, we determine if FA induce a pro-
inflammatory or anti-inflammatory environment by measuring the levels of cytokine 
production via ELISA as outlined in methods. THP-1 monocytes were incubated with 
varying concentrations of FA for 24hrs, after which the supernatant was extracted and 
measured for production of IL-6, IL-10, and TNFα (Figure 5.5). There was a definite 
linear correlation between FA concentration and TNFα production (R2 0.98 for C15:0 
and R2 0.94 for C16:0). 50µM C15:0 was associated with a 17% reduction in TNFα 
production compared to control (p < 0.05). There was no statistically significant 
difference in TNFα production between control and cells treated with 150µM and 
300µM C15:0, or any concentration of C16:0. LPS, used as a positive control, was 
associated with a fourfold increase in TNFα production (p < 0.001). IL-6 production 
followed a similar trend to TNFα (Figure 5.5b). Among all FA treatments, only 300µM 
C16:0 showed a significant difference in IL-6 production compared to controls (27% 
increase, p < 0.05). Furthermore, no FA treatment, irrespective of concentration, 
altered the production of the anti-inflammatory cytokine IL-10.  
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Figure 5.3: C15:0 causes cell cycle arrest at G0 phase and protects THP1 monocytes from palmitate induced apoptosis. 
THP1 monocytes at a density of 5 x 105 cells were treated with fatty acids conjugated to BSA and analysed using flow cytometry for cell cycle 
arrest as outlined in methods. Cells were exposed to varying concentrations of fatty acids, or control (5% BSA) as outlined. (a) Apoptosis (b) 
G0/G1 phase (c) S-phase (d) G2/M phase. Results are expressed as mean +/- SEM (n=3 independent experiments).  
Statistical significance was determined by a repeated measures one-way ANOVA with Geisser-Greenhouse correction and a Dunnett’s post-
test comparison.   Ψ represents a statistical significant difference between treatment versus control, Ξ represents a statistical significant 
difference between treatment versus 300µM C16:0, and  φ represents a statistical significant difference between the treatment versus both 
control and 300µM C16:0. All symbols represent a statistical significance P value of < 0.05. 
205 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
0 .0
0 .5
1 .0
1 .5
2 .0
F a tty  a c id  tre a tm e n ts
M
e
t
a
b
o
l
i
c
 
a
c
t
i
v
i
t
y
 
a
f
t
e
r
 
6
 
h
r
s
(
a
b
s
o
r
b
a
n
c
e
 
a
t
 
5
7
0
n
M
)   
  

C o n tro l (5 %  B S A )
5 0 µ M  C 1 5 :0
1 5 0 µ M  1 5 :0
3 0 0 µ M  C 1 5 :0
5 0 µ M  C 1 6 :0
1 5 0 µ M  1 6 :0
3 0 0 µ M  C 1 6 :0
1 5 0 µ M  1 5 :0  +  1 5 0 µ M  1 6 :0
0
2 0
4 0
6 0
8 0
1 0 0
F a tty  a c id  tre a tm e n ts
C
D
3
6
 e
x
p
re
s
s
io
n
(M
e
d
ia
n
 F
lo
u
re
s
c
e
n
t 
In
te
n
s
it
y
)


 

0
1 0 0
2 0 0
3 0 0
F a tty  a c id  tre a tm e n ts
C
D
1
4
 e
x
p
re
s
s
io
n
(M
e
d
ia
n
 F
lo
u
re
s
c
e
n
t 
In
te
n
s
it
y
)
 

  
0
5 0
1 0 0
1 5 0
2 0 0
F a tty  a c id  tre a tm e n ts
C
D
1
6
 e
x
p
re
s
s
io
n
(M
e
d
ia
n
 F
lo
u
re
s
c
e
n
t 
In
te
n
s
it
y
)a b 
c 
Figure 5.4: Effect of fatty acids on the cell surface expression of CD14, CD16 and CD36. 
THP1 monocytes at a density of 5 x 105 cells were treated with fatty acids conjugated to BSA and analysed using flow cytometry for cell surface 
expression of CD14, CD16 and CD36 as outlined in methods. Briefly, cells were exposed to varying concentrations of fatty acids, or control (5% 
BSA) and then incubated with anti-CD14, andti-CD16, and anti-CD36 antibodies. (a)MFI for CD14 (b) MFI for CD16  (c) MFI for CD36. Results 
presented for 3 independent experiments).  
Statistical significance was determined by a Friedman’s test and a Dunn’s post-test comparison.   Ψ represents a statistical significant 
difference between treatment versus control,  Ξ represents a statistical significant difference between treatment versus 300µM C16:0. All 
symbols represent a statistical significance P value of < 0.05. 
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Figure 5.5: C16:0 at high concentrations is associated with an increase in pro-inflammatory cytokines in THP1 monocytes. 
THP1 monocytes at a density of 5 x 105 cells were treated with fatty acids conjugated to BSA or 200ng/ml of LPS. Supernatants were extracted 
after 24hrs of incubation and analysed for cytokines by ELISA. (a) TNFα secretion (b) IL-6 secretion (c)IL-10 secretion. Results are expressed as 
mean +/- SEM (n=3 independent experiments).  
Statistical significance was determined by a repeated measures one-way ANOVA with Geisser-Greenhouse correction and a Dunnett’s post-
test comparison.  Ψ represents a statistical significant difference between treatment versus control, Ξ represents a statistical significant 
difference between treatment versus 300µM C16:0, and  φ represents a statistical significant difference between the treatment versus both 
control and 300µM C16:0. All symbols represent a statistical significance P value of < 0.05. 
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5.4.6 Pre-treatment with C15:0 ameliorates pro-inflammatory response to LPS 
Previous reports have shown that C16:0 is associated with a pro-inflammatory 
response in monocytes and prior results in this chapter have shown that the C15:0 
treated cells show a different monocyte phenotype compared to C16:0 treated THP-1 
cells. To further understand how FA affect monocytes in a pro-inflammatory 
environment, THP-1 cells were pre-treated with FA for 6hrs then with LPS for 18hrs 
(total treatment time of 24hrs), followed by analysis of the supernatant for pro-
inflammatory cytokines TNFα and IL-6 (Figure 5.6). There was a sixfold increase in 
TNFα production with monocytes treated with LPS vs baseline control cells (p < 
0.001). Although cells treated with C15:0 + LPS showed higher levels of TNFα 
compared to controls (5% BSA no LPS), the levels of TNFα were significantly reduced 
compared to positive controls [5% BSA + LPS] (72%, 70%, and 65% reduction for 
50µM, 150µM and 300µM C15:0 respectively; p < 0.01). Whereas, C16:0 treated cells 
did not alter TNFα secretion compared to positive control. In fact, there was a slightly 
higher but statistically insignificant increase in TNFα secretion in cells treated with 
300µM C16:0 compared to positive control (6.5% increase, p > 0.05). The same trend 
was noted with IL-6 secretion (Figure 5.6b); C15:0 treated cells significantly reduced 
IL-6 secretion compared to positive control cells (p < 0.001), while there was no 
significant difference in IL-6 output between C16:0 treated cells and positive control.  
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5.4.7 C15:0 prime macrophages display an anti-inflammatory phenotype.  
THP-1 monocytes can differentiate into classical (M1), or alternative (M2) 
macrophages, broadly corresponding to a pro-inflammatory or anti-inflammatory 
phenotype respectively. THP-1 cells primed with FA for 6hrs were differentiated to 
macrophages with PMA for 48hrs. Cytokine analysis was performed on the 
macrophages to determine the phenotype. Cells primed with LPS was used as positive 
control for pro-inflammatory macrophage differentiation. TNFα secretion was 
increased by more than three folds in LPS primed macrophages (Figure 5.7a) 
compared to controls (5% BSA). Priming with C16:0 was associated with an increase 
in TNFα secretion compared to control cells primed with 5% BSA, corresponding to a 
pro-inflammatory phenotype- 21.6% (p > 0.05), 36.2% (p < 0.05), 68% (p < 0.001) 
increase for 50µM, 150µM and 300µM C16:0 respectively. There was no statistically 
significant difference in TNFα secretion between control and C15:0 primed 
macrophages. On the other hand, C15:0 primed macrophages appear to display an 
anti-inflammatory phenotype by increasing IL-10 secretion by 70% (p < 0.01), 54% (p 
< 0.05), and 65% (p < 0.001) for 50µM, 150µM and 300µM C15:0 respectively. There 
were no significant differences between control and C16:0 primed macrophages  
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Figure 5.7: C15:0 is associated with an anti-inflammatory macrophage phenotype. 
THP1 cells were pre-incubated with fatty acids or control conditions (5% BSA) for 6hrs then treated with PMA for 72hrs to induce 
macrophage differentiation as outlined in methods. LPS pre-treated cells were used as positive control. Supernatants were 
extracted after 24hrs of incubation and analysed for cytokines by ELISA. (a) TNFα secretion (b) IL-10 secretion. Results are expressed 
as mean +/- SEM (n=3 independent experiments).  
Statistical significance was determined by a repeated measures one-way ANOVA with Geisser-Greenhouse correction and a 
Dunnett’s post-test comparison.   Ψ represents a statistical significant difference between treatment versus control, Ξ represents a 
statistical significant difference between treatment versus 300µM C16:0,  φ represents a statistical significant difference between 
the treatment versus both control and 300µM C16:0. All symbols represent a statistical significance P value of < 0.05.  
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Figure 5.6: C15:0 ameliorates LPS induced increase in pro-inflammatory cytokines 
THP1 monocytes at a density of 5 x 105 cells were treated with fatty acids conjugated to BSA or control (5% BSA) for 6hrs then with 
200ng/ml LPS to make up a total of24hrs. Supernatants were extracted after 24hrs of incubation and analysed for cytokines by 
ELISA. (a) TNFα secretion (b) IL-6 secretion. Results are expressed as mean +/- SEM (n=3 independent experiments).  
Statistical significance was determined by a repeated measures one-way ANOVA with Geisser-Greenhouse correction and a 
Dunnett’s post-test comparison.   Ψ represents a statistical significant difference between treatment versus control,  Ξ represents 
a statistical significant difference between treatment versus 300µM C16:0,  φ represents a statistical significant difference between 
the treatment versus both control and 300µM C16:0, and Ʃ represents a statistical significant difference between the treatment 
versus  control, 300µM C16:0 and 200ng/ml LPS. All symbols represent a statistical significance P value of < 0.05. 
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5.5 Discussion 
Monocytes and macrophages play a critical role in innate immunity and are influential 
in the development and sustenance of several diseases [358, 359]. The onset of T2DM 
is likely to be multifactorial, involving complex mechanisms; however, the presence of 
chronic low-grade inflammation, induced by elevated levels of FA, has been 
continually observed and implicated as a possible bridge between those with 
borderline hyperglycaemia and full-blown diabetes [331, 360, 361]. There has been a 
surge in the study of monocytes and macrophages (clinical and in vitro studies) as 
chief players in innate immunity and the differential response to inflammatory stimuli 
in healthy individuals compared to people with metabolic disorders. In vitro 
experiments of monocytes have been performed using immortalised cell lines, the 
most popular being THP-1 cells. Several studies have reported glaring differences 
between primary monocytes and THP-1 cells while others have shown it to very 
closely replicate primary monocytes by phenotype and function [362-365]. The THP-
1 cells used in these studies will vary according to age, batch, passage numbers, 
among other factors, which may explain the disparity within results. However, THP-1 
cells are accepted as good monocyte models within lipid research. In this chapter, 
THP-1 cells have been used as a model to determine the effect of two classes of FAs 
on monocyte phenotype and function in the context of cell surface expression, 
macrophage differentiation and cytokine production.  
In general, the results show that cells treated with OCSFA maintain the same level of 
expression of CD14, CD16 and CD36 as controls, whereas palmitate-treated cells 
appear to have depleted CD14 expression, concurrently increasing CD16 and CD36 
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expression. There also appeared to be an effect of nutrient overload on CD14 
expression, evident by a reduction in CD14 surface expression with high 
concentrations of both FA, even though this effect was more pronounced in palmitate-
treated cells compared to its odd chain counterpart. As previously discussed, the cell 
surface expression of CD14 and CD16 determine monocyte phenotype regarding its 
overall ability to be pro/anti-inflammatory, which is in contrast to the previously 
misleading method of classifying monocytes by morphology alone. There has been an 
increased interest in monocyte classification over the last decade. Continuous 
attempts to better qualify monocyte populations has been warranted by their role in 
disease states. For example, the intermediate sub-population of monocytes and non-
classical monocytes are increased in bacterial and viral infections, stress, as well as 
in metabolic and inflammatory conditions such as rheumatoid arthritis, cardiovascular 
diseases, and chronic kidney disease [349, 353].  
The CD14 expression in this study did not change with low concentrations of FA 
(50µM); however, a differential effect is noticed as the concentration of FA begin to 
increase. At 150µM, palmitate-treated cells begin to show a reduction in CD14 
expression, trending even further downwards as concentrations reached 300µM. This 
is in contrast to C15:0 treated cells that only show a reduction in CD14 expression at 
300µM. CD14 expression reduces as monocytes move between the spectrum from 
classical to non-classical monocytes. CD14 is an important co-receptor for the 
detection of pathogens, with LPS being its principal ligand [366, 367].  Saresella et al. 
(2017) showed that “Western diet” characterised by high SFA content, is associated 
with a reduction in CD14 expression in monocytes [368], indicating that high energy 
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load is negatively correlated with CD14 expression. Conversely, Sun-Mi Kim et al. 
(2015) showed that consumption of a high cholesterol diet increases expression of 
CD14 [369]. There are many reasons why these and many other studies looking at the 
effect of diet on cell surface expression are not directly comparable, explaining the 
disparity in results, including differences in sample population and intervention used. 
More importantly, these studies differ in the methods used to quantify CD14 
expression; the anti-CD14 antibodies used, the gating strategy, and most importantly, 
the use of isotype controls (the former applies isotype controls, and the latter does 
not). The use of isotype control for FACS analysis divides opinions [370-373]. In this 
study, an isotype control, gate compensation and the use of blocking agent were 
employed for each analysis to minimise background signal and reduce the chance of 
false positives. Frey and De Maio (2007) provide further evidence in support of the 
fact that high energy load could lead to lower CD14 expression. They showed that 
treating macrophages with lovastatin to lower cholesterol increases membrane-bound 
CD14 expression [374]. Energy overload may partly explain why the CD14 expression 
is lower in palmitate-treated cells compared to C15:0 with higher concentrations of 
treatment. It is plausible that higher concentrations of C15:0 is required to overwhelm 
monocytes compared to palmitate as seen with hepatocytes in the previous chapter. 
The CD36 expression lends credence to this. Palmitate treated at high concentrations 
have a significantly higher CD36 expression compared to control and C15:0 treated 
cells at a similar concentration. CD36 interacts with oxidised low-density lipoproteins 
to increase the influx of lipids. Therefore, palmitate-treated cells are more likely to 
accumulate lipids leading to energy overload.  
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Neither C16:0 nor C15:0 affected CD16 expression in this study. The finding is similar 
to studies performed by Pararasa et al. (2013) in vitro, and Alshahrani et al. (2017) in 
vivo that showed no effect of SFA on CD16 surface expression [356, 375]. There is 
insufficient evidence from literature showing a direct link between diet or FA on CD16 
expression. However, many studies have shown that CD16+ cells express high levels 
of TLRs which is the primary driver of its pro-inflammatory phenotype [376, 377]. This 
is important to note because several studies have shown a direct association between 
saturated FAs and increased TLRs expression [378-381].  
Put together; one  may suggest that OCSFA induce a phenotype at least close to the 
classical monocyte sub-population, while palmitate at high concentrations influences 
a more intermediate or non-classical phenotype. However, there are several 
limitations to this interpretation.  
Firstly, this study was not designed to measure both CD14 and CD16 surface 
expression simultaneously. Traditionally, both surface antigens are measured at once 
using fluorescent dyes at distinct wavelengths (for example, FITC and APC). Three 
gates can then be set to quantify classical, intermediate, and non-classical 
populations. However, this is not without considerable challenge, and it is often difficult 
to optimise. Gating is very subjective and is likely subject to much variabilities, making 
standardisations difficult [382, 383]. More so, dye spillover may occur, especially when 
one dye is much brighter than the other (e.g. FITC and APC). In this study, appropriate 
compensation techniques were applied to mitigate dye spill over; however, 
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compensation is not standerdised across studies, making pooled analysis and 
interpretation across studies difficult.  
Secondly, the effect of the distinction in cellular viability on CD16 or CD14 cell surface 
expression cannot be ignored. Heidenreich (1999) showed that a reduction in CD14 
surface expression precedes apoptosis induced by IL-4 in monocytes [384]. 
Additionally, work by Fingerle-Rowson et al. (1998) and Ziegler-Heitbrock (2015) 
allude to the fact that glucocorticoid-induced stress prompts selective apoptosis in 
non-classical monocytes [385, 386]. Here, palmitate induces apoptosis and reduces 
CD14 expression at concentrations more than 150µM. Moreover, cells treated with 
high concentrations of palmitate begin to show reduced cell proliferation and growth 
(measured by cell count relative to control) even as early as 6hrs with no associated 
cell cycle arrest. Many studies confirm the cytotoxic effect of palmitate on THP-1 cells 
and even show that MUFA can protect THP-1’s from palmitate-induced toxicity. No 
previous study has demonstrated the effect of OCSFA on THP-1 viability or metabolic 
activity. Palmitate induces cell death by several mechanisms including activation of 
various caspases (3/4/5), increased MMP-9 expression, inhibition of Sirt1, an increase 
in mitochondrial ROS, and p53 pathway; all of which can be mediated by TLR4 
signalling [387-392].  
Put together; it is difficult to interpret these results as representative of monocyte sub-
population differentiation by cell surface markers. However, an examination of the 
functional ability to produce cytokines remains a viable indication for monocyte 
phenotype. Cytokine production was measured in monocytes and macrophages to 
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determine their functional phenotype after FA stimulation. The role of cytokines in the 
development of T2DM and its complications is well defined in the literature. There is a 
vicious cycle comprised of elevated metabolites, like glucose and FA, and increased 
adipokines that activate monocytes, leading to a rise in pro-inflammatory cytokines, 
which potentially instigates and enhances insulin resistance by various mechanisms. 
Kim and coworkers (2012) were able to show that hyperglycaemia triggers the 
acetylation of p65 and inhibition of histone deacetylase (HDAC) by activating histone 
acetylases (HAT) resulting in NF-ƙB activation, consequently leading to IL-6 and TNFα 
expression [393]. Subsequently, Kang et al. (2016) showed a strong correlation 
between TNFα in adipose tissue and HOMA-IR in obese people with prediabetes, with 
no macrophage infiltration or change in macrophage phenotype, suggesting that 
alterations in cytokine production precede any monocyte/macrophage phenotypic 
modifications [394]. The results from this chapter demonstrate an alteration in the 
baseline pro-inflammatory cytokine profile in cells treated with high concentrations of 
palmitate for 24hrs, which is consistent with the hypothesis of a low-grade 
inflammatory state stimulated by elevated FA. However, cells treated with similar 
concentrations of C15:0 did not show an elevation of pro-inflammatory cytokines, 
indicating that the inflammatory process triggered by palmitate is not entirely explained 
by a high energy state. There is evidence to suggest that cells have different 
cytotoxicity thresholds for different classes of FA, but the differences are usually more 
divergent, for example, there is a considerable difference between palmitate, MUFA 
and PUFA because of the double bonds linking the carbon atoms. On the other hand, 
the only distinguishing feature between palmitate and C15:0 is a single carbon atom. 
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This subtle difference has already been discussed in the previous chapter, and the 
observable difference in the inflammatory profile may be related to signalling ability or 
the distinction in the metabolic pathway as discussed. In addition to having a higher 
baseline level of pro-inflammatory cytokines, THP-1 cells primed with palmitate display 
a pro-inflammatory cytokine profile resembling an M1 phenotype [395], while PUFA 
priming show M2 anti-inflammatory phenotype. This is in keeping with what is seen in 
this chapter with palmitate showing an M1 phenotype; with an increase in TNFα 
secretion and no change in IL-10 secretion. Like PUFAs, C15:0 primed macrophages 
displayed an anti-inflammatory M2 phenotype, with raised IL-10 secretion. This 
discrepancy has not been elucidated previously. This interaction is likely to be more 
complicated in vivo as it is still unknown to what extent in vitro experiments in 
immortalised cells represent in vivo environments; however, this research presents a 
novel perspective regarding saturated FAs as a whole, as indeed, C15:0 is a SFA. 
After establishing that palmitate and C15:0 show differential effect on baseline 
cytokine levels and plausibly macrophage differentiation, it was pertinent to elucidate 
the effect of FA on monocytes in the event of ongoing inflammation. THP-1 cells were 
primed with FA 
 for 6hrs then treated with LPS to simulate an ongoing inflammatory response. 
Interestingly, but in keeping with previous results in the chapter, C15:0 primed cells 
exhibited an anti-inflammatory response contrasting with C16:0 treated cells. LPS is 
the main ligand for CD14 and stimulates an inflammatory response by triggering TLRs. 
Palmitate is known to stimulate TLRs with or without LPS (also known as sterile 
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inflammation); therefore the results were not surprising [396, 397]. The study failed to 
expound the exact mechanism that C15:0 mediates an anti-inflammatory response in 
LPS induced monocytes. There is a good reason to think that it is plausible it does so 
in similar fashion to ω3-PUFAs, which acts as regulators of inflammation. One of the 
ways ω3-PUFA regulates inflammation is by acting as a competitive substrate for ω6-
PUFA metabolism. ω6-PUFAs act as substrates for prostaglandins and leukotrienes 
and are therefore naturally pro-inflammatory. It is plausible that OCSFA acts 
competitively against its even chain counterpart to regulate inflammation. We saw from 
the hepatocyte chapter that palmitate-treated cells favour ω6-PUFA production, while 
C15:0 cells showed preferential production of ω3-PUFA. Perhaps the regulatory 
properties of C15:0 is mediated via ω3-PUFA production associated with all its 
downstream effects, including, but not limited to increased resolving lipids, competitive 
activation of GPR120, or downregulation of NF-ƙB via TLR4.  
Taken together, the results in this chapter indicates an exciting prospect for OCSFA 
as anti-inflammatory agents. Further research is required to elucidate the mechanisms 
that underpin this process and explore the role of gut microbiota in the metabolism 
and function of OCSFA in the context of the immune system.  
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219 
 
6.1 General discussion 
The major aim of this study was to identify a relationship between FA and fasting 
plasma glucose, with particular focus on OCSFAs, and to explain the mechanistic link 
between energy excess, inflammation and insulin resistance.  
The contribution of FA to the development and maintenance of T2DM has been heavily 
studied in the past and continues to divide opinions. Recent improvement in GC and 
mass spectrometry technologies has amplified the search for FA biomarkers for 
diseases. In this study, a GC detection technique was optimised to allow for optimal 
detection of OCSFAs in small quantities of plasma. Furthermore, a multiple linear 
regression analysis was carried out to identify FA predictive of insulin resistance.  
In this study, elevated levels of ECSFA, like palmitate and stearate, were more likely 
to predict a unit rise in fasting plasma glucose in a multiple linear regression model 
despite no significant difference in absolute levels between control and T2DM cohorts.  
Hyperglycaemia is one of the consequences of insulin resistance, which is a state 
characterised by an inability to drive glucose into tissues. ECFA are known to correlate 
positively with insulin resistance in the literature. In fact, the most commonly held 
opinions on SFA and insulin resistance is influenced by palmitate, which is the most 
abundant SFA.  Animal knockdown studies along with in vitro cellular models of insulin 
resistance have highlighted the association between elevated palmitate levels and the 
development of ER stress, mitochondrial dysfunction, direct inhibition of insulin 
signalling, as part of many ways in which elevated palmitate levels results in the 
development of insulin resistance in tissues. Therefore, the relationship between 
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palmitate and insulin resistance is well established from a mechanistic point of view. 
However, in human studies, this distinct relationship is usually much more difficult to 
ascertain for various reasons, and the presence of metabolic disease, or even obesity, 
does not always translate to higher circulating levels (absolute) of palmitate, as seen 
in this study. There are a few reasons for this. Firstly, the circulating levels of FAs are 
amendable to diet and physical exercise and this is (at least the former) difficult to 
accurately quantify in large scale studies. Also, daily variations in plasma FA levels 
exist and the effect of age, stress, gender on FA levels cannot be ignored. Some 
authors have tried to mitigate these confounders by presenting and analysing results 
as percentage of total FA (%wt). However, this method is likely error prone because 
currently available lipid extraction and analysis methods are not robust enough to 
detect every FA in a given sample. Here, a multiple linear regression method was 
instead used to adjust for known confounders.  
The GC optimisation was targeted specifically to increase recovery of OCSFA to good 
effect. This meant that the OCSFA, C15:0, was more accurately assessed in our study. 
The concentration of C15:0 detected in this study is slightly higher than plasma levels 
found in previous other larger scale cross-sectional studies [80, 206], reinforcing the 
importance of the lipid extraction and FAME detection optimisation. Here, the 
concentration of C15:0 as a proportion of FAs measured was higher in controls 
compared to individuals with T2DM, which is consistent with other studies which show 
higher levels of C15:0 in healthy individuals compared to different disease states. For 
example, a nested case control design within the EPIC study looking at more than two 
thousand incident cases of coronary heart disease (CHD), found an inverse 
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relationship between plasma C15:0 levels and the development of CHD [398]. 
Subsequently, a multi-ethnic US cohort of just under three thousand participants found 
a 19% reduction in atherosclerotic risk with every unit increase in C15:0, which was 
found in higher concentration among controls [78]. In terms of epidemiologic evidence 
for the relationship between C15:0 and diabetes, three Australian studies found a 
negative correlation between C15:0 and indices of insulin resistance similar to the 
results in this study [79, 81, 399]. Furthermore, studies have reported gender and age-
specific differences in C15:0 plasma concentrations [400]. Interestingly, people who 
report healthy lifestyles, including non-smoking, moderate alcohol intake, and 
increased physical activity, usually have significantly higher levels of plasma C15:0 
[398]. The direct interpolation of C15:0 plasma concentration between health and 
disease is therefore likely to be confounded by lifestyle choices and modifications. 
Consequently, it was important to employ a multiple linear regression model to test the 
relationship between C15:0 and fasting plasma glucose, adjusting for age, gender, 
and BMI. Plasma glucose correlated negatively with C15:0 in this study, in line with 
many other longitudinal studies. Despite a clear correlation, it is difficult to pinpoint if 
this finding is a cause or consequence of plasma glucose levels.   
This study was a nested case control design within an already existing cohort that was 
not designed for FA analysis. Therefore, there was no dietary assessment in this 
study. It is impossible to comment on the likely impact of dietary habits on the FA 
profile of individuals within this study. Indeed, C15:0 levels have been correlated with 
dietary habits in previous studies [85]. However, diet alone is unlikely to fully explain 
the beneficial effect of C15:0 regarding T2DM prevention. An interesting observation 
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from literature regarding diet and OCSFA is the similarity in the dietary sources of ALA 
(an ω-3 PUFA) and OCSFA [401], both being abundant in dairy products and fish oil. 
To summarise, the clinical data from this study although limited by low sample size 
and a lack of dietary assessment, provides data in support of a correlation between 
C15:0 and fasting blood glucose, similar to other large cross-sectional and longitudinal 
studies. The close relationship between diet and C15:0 and the similarity between the 
dietary source of PUFA and C15:0 provides an explanation for the possible 
mechanism by which C15:0 is prevents T2DM in the absence of in vitro or animal 
studies to explain the mechanistic link between C15:0 and glucose homeostasis. 
There is substantial evidence suggesting a disparity in cellular metabolic response to 
SFA in comparison to their unsaturated counterparts. The metabolic switch in 
response to different classes of FA has been put forward as a possible reason for the 
differential effect of saturates in terms of insulin resistance. A distinction in metabolic 
activity was observed between OCSFA and palmitate in this study, including 
differences in the biosynthesis and catabolism of FA, as well as differences in PPAR 
alpha signalling.  
In this study, C15:0 induced an acute increase in metabolic activity, which is observed 
to normalise within 24hrs, in both hepatocyte and monocyte cell lines. The reduction 
of MTT to purple formazan is influenced by several factors including cell proliferation, 
availability of reduced products (like reduced glutathione), and increased 
mitochondrial number and function. In rapidly proliferating cells, like immortalised 
cancer cells, MTT reduction has long been correlated with cellular proliferation and 
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multiplication. However, there are a few reasons why the increase in MTT reduction 
found in this study is less likely to reflect proliferation. Firstly, MTT reduction in C15:0 
treated cells did not correspond to an increase in number of cells compared to control 
in both monocyte and hepatocyte cell lines. Furthermore, in hepatocytes, C16:0 
elicited a decrease in MTT reduction compared to control and C15:0 treated cells 
despite no significant changes in cell count after 6hrs or 24hrs. In addition, in THP-1, 
the observable reduction in cell count as a reflection of cellular proliferation, did not 
correlate with the magnitude of MTT reduction in C16:0 treated cells. The other 
possible explanation for the difference in MTT reduction is the presence of reducing 
enzymes. This study did not measure glutathione levels; therefore, it is impossible to 
comment on the likely effect of C15:0 on glutathione synthesis. However, previous 
studies have showed that oleate and palmitate are able to affect the levels of 
glutathione differently in THP-1  monocytes (Pararasa, 2013), while some authors 
have observed a direct association between glutathione synthesis/depletion with MTT 
reduction [402]. The use of MTT as a measure of cellular proliferation and viability 
relies on the assumption that mitochondrial activity is constant for all viable cells [403]. 
However, researchers have shown that mitochondrial activity is modulated by FA. 
Dietary PUFA has been shown to alter mitochondrial bioenergetics by several 
mechanisms, including modification of mitochondrial membrane composition and 
function, changes to mitochondrial redox state, as well as altering mitochondrial 
enzymes [404-408]. MUFA are also known to favourably alter mitochondrial function 
[409, 410], while palmitate induce mitochondrial dysfunction [411-413]. It is plausible 
that improved mitochondrial β-oxidation in C15:0 treated cells, as seen in this study, 
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is partially responsible for increases in metabolic activity. It is also plausible that C15:0 
increased metabolic activity by increasing the production of propionyl Co-A, an 
anaplerotic intermediate for the citric acid cycle [414, 415]. 
Normally, the liver reacts to excess FA by increasing lipid catabolism and reducing de 
novo lipogenesis. However, more energy demands lead to formation and 
accumulation of triglycerides, in a vicious cycle that ultimately results in inflammation 
and insulin resistance. In NAFLD, a condition that is common in people with T2DM, 
cellular lipid and glucose homeostasis is impaired, worsening on disease progression. 
Many studies have been able to directly correlate an impairment of FA oxidation with 
the development of fatty liver in animal and in vitro models of high fat diet and FA 
induced NAFLD. In chapter 4, the result show a difference in the gene expression of 
FA oxidation between C15:0 and C16:0 in hepatocytes; and considering the limitations 
of the methodology, it provides a limited understanding of the differences between 
OCSFA and its even chain counterpart, partly explaining why OCSFA may be 
protective with T2DM disease development or progression. Cells treated with high 
concentrations of palmitate showed marked lipid accumulation which can be partially 
explained by key differences between C16:0 and C15:0 treated cells in gene 
expression of β-oxidation enzymes. Here, cells treated with high concentrations of 
C16:0 show disproportionate expression of CPT1 and CPT2 genes. These two genes 
are typically overexpressed during fasting and other conditions that prompt increased 
FA oxidation. Bazhan and colleagues showed an age-related deficiency of CTP1 in 
adult C57B1 mice, which was not improved by fasting [416]; this deficiency resulted in 
age-related obesity and subsequently impaired glucose homeostasis. Similarly, 
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Fujiwara and colleagues showed that a downregulation of CPT2 is associated with 
steatohepatitis in mice fed a high fat diet [417]. CPT1 and CPT2 are integral 
components of the carnitine palmitoyltransferase system, which mediates the transfer 
of activated FA across the mitochondrial membrane for β-oxidation. Therefore, their 
upregulation, as seen with cells treated with C15:0 would be the expected response 
in high fat environments, to shift intracellular FAs towards mitochondrial β-oxidation. 
The same pattern of expression was observed for C15:0 and C16:0 treated cells with 
respect to gene expression of the enzymes that catalyse the final steps of 
mitochondrial FA β-oxidation. Again, C16:0 at high concentrations show equivocal 
expression of ACADL and ACAD10, and a downregulation of ACAA2. This correlates 
with the data showing reduced CPT1 and CPT2 expression and suggests a deficient 
β-oxidation, which would explain increased lipid accumulation. The ability of C15:0 to 
drive β-oxidation would explain why the clinical data in chapter 3 shows a statistically 
significant negative correlation between the concentrations of C15:0 and C16:0 and 
provides a reasonable explanation to why increase in dairy intake is associated with 
C16:0 levels in cross-sectional studies. Further robust in vivo studies would be 
required to fully explain a causal relationship between C15:0 and C16:0 levels. The 
alternate explanation for a negative correlation between C15:0 and C16:0 levels in 
studies would be the possibility of α-oxidation. Alpha oxidation involves a series of 
steps where FA are hydroxylated at the α-carbon after activation, requiring Iron and α-
keto-glutarate as co-factors, then followed by the removal of the terminal carboxyl 
group in a process involving thymine pyrophosphate and magnesium ions. The 
product of these steps is able to undergo normal β-oxidation. Alpha oxidation has been 
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proven to occur in humans but was previously thought to be confined to peroxisomes 
and the oxidation of phytanic acid. However, recent evidence suggests that SFA can 
undergo α-oxidation and the mitochondria is also heavily involved in this process; 
C16:0 and C18:0 can be converted to C15:0 and C17:0 as an endogenous source of 
OCSFA. However, the trigger for this event is unknown, but the gut microbiome has 
been implicated. An increase in α-oxidation as a consequence of C15:0 treatment may 
explain why mitochondrial activity (evidenced by increased FA oxidation and high MTT 
reduction) and peroxisome transport (ABCD genes) is upregulated in this study. 
Although, this is difficult to prove, it is plausible that the induction of an extra oxidative 
pathway amplifies FA oxidation, consequently leading to less lipid accumulation. 
Taken together, C15:0 may be acting as an activator of the α-oxidation pathway which 
amplifies β-oxidation, ultimately promoting the endogenous conversion of C16:0 to 
C15:0. This hypothesis is limited by the ratio of C16:0 to C15:0 (approximately 150:1) 
in plasma, even in healthy individuals. This shows that the intracellular relationship 
between C15:0 and C16:0 is likely to be complex and tightly regulated. The difference 
between C15:0 and C16:0 observed in this study only seem to appear at palmitate 
concentrations of 300µM. One limitation of this study is that it was not designed to 
explain the metabolic switch that occurred across different concentrations of C16:0. In 
fact, there is a dearth of published evidence in support of a metabolic switch induced 
by FA, but this is usually thought to be secondary to energy overload. Therefore, it 
was interesting that this switch only occurred with C16:0. C15:0 is only found in small 
quantities in plasma; however, this study employed concentrations as high as 300µM 
to eliminate the possibility that energy overload is responsible for the differential effects 
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of C16:0. This finding highly suggests that the differential effect found between C15:0 
and C16:0 is likely to be related to a difference in signalling pathway. PPAR alpha is 
heavily implicated in diet induced metabolic switch from glucose to FA energy 
dependence. PPAR alpha transcription mediates FA oxidation by enhancing genes 
involved with β-oxidation and mitochondrial function. It was therefore logical that 
PPAR alpha activity is explored as a possible mechanism by which C15:0 exerts its 
differential effect. Here, all concentrations of C15:0 induced PPAR alpha activity at 
gene expression and transcription level, which translated to PPAR alpha target gene 
expression. Conversely, C16:0 inhibited PPAR alpha transcription activity similar to 
the antagonist GW6471. Natural PPAR alpha ligands have been reported to include 
PUFA (like DHA and EPA), as well as palmitoylethanolamide (PEA). It is possible that 
C15:0 acts as a natural ligand, or as seen in this study, may induce PPAR alpha by 
increasing production of PUFA. Taken together, the differential effect of C15:0 and 
C16:0 can be explained by their stimulation of PPAR alpha. The “excess energy” 
environment created by C15:0 leads to effective sensing of PPAR alpha resulting in 
energy burning mediated via increased FA oxidation, while an improper PPAR alpha 
sensing by C16:0 results in defective FA oxidation, lipotoxicity, lipid accumulation, and 
eventually insulin resistance. Therefore, the potential impact of OCSFA on PPAR 
alpha as a mechanism that underpins anti-inflammatory process cannot be ruled out. 
In this study, palmitate-induced pro-inflammatory responses were abrogated by C15:0 
in hepatocytes, while LPS-induced inflammation was ameliorated by C15:0 in 
monocytes. Furthermore, C15:0 played a role in the differentiation of M2 macrophage 
phenotype. All these effects have been replicated in studies using PPAR alpha 
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agonists, suggesting a possible role of PPAR alpha in the anti-inflammatory phenotype 
observed with C15:0. PPAR alpha mediated inhibition of pro-inflammatory cytokines 
has been shown to be PPRE independent. Upon activation by a ligand, PPAR alpha 
binds to either p65 or the N-terminus JNK-responsive part of cJun, preventing them 
from binding to NF-ƙB response element, consequently leading to inhibition of TNFα 
and IL-6 expression [418]. Alternatively, a suppression of TNFα-induced IL-6 
transcriptional activity can be achieved by ligand-activated PPAR alpha-GR 
(glucocorticoid receptor) interaction coupled to p65 and p50 [419]. In addition, the anti-
inflammatory properties of C15:0 could be driven via increased PUFA, specifically ω-
3 PUFA, which also acts as natural ligands for PPAR alpha. 
The effect of propionate, a likely end-product of alpha-oxidation of OCSFA, merits 
discussion. Propionate has been shown to induce satiety and anti-inflammation in 
adipocytes by stimulating leptin [420] and GPR41/GPR43 receptors [421, 422]. It has 
also been shown to reduce fatty liver in a six month dietary intervention study of people 
with NAFLD [423]. In monocytes, it has been shown to reduce TNFα secretion induced 
via TLR1/2 as well as IL-6 induced via TLR4, but not LPS stimulated TNFα via TLR4 
[424]; showing that propionate production does not wholly explain the anti-
inflammatory properties of C15:0 (at least in monocytes). It is important to mention 
briefly the role of the gut microbiota, which produces propionate and other SCFA 
derivatives as a possible source or consequence of C15:0 mediated anti-inflammatory 
properties. Propionate is produced by the gut microbiome by several mechanisms 
including fermentation of fibres and it is directly correlated with C15:0 production. In 
an animal dietary intervention study where C3H/HeOuJ mice diets were supplemented 
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with propionate, C15:0 production increased after 22 weeks supplementation, 
associated with an attenuation of insulin resistance and fatty liver [425]. Consequently, 
neonates with propionic acidaemia have high circulating levels of C15:0, re-enforcing 
the link between C15:0 and propionate [77]. Moreover, emerging evidence shows that 
propionate upregulates PPAR alpha by ERK phosphorylation.  
6.2 Conclusion 
Taken together, the results obtained here suggest that the anti-inflammatory 
properties of C15:0 and its protection of hepatocytes from palmitate-induced 
consequence of insulin resistance is likely mediated via PPAR alpha and although 
there were observable differences in the abundance of MUFA and ω-3 PUFA between 
samples, the study was not designed to measure their metabolic impact. This study 
has also shown that C15:0 predicts fasting blood glucose in a healthy and T2DM 
cohort. Individuals with T2DM have significantly highly markers of inflammation, which 
can also be predicted by FAs.  
6.3 Future work  
Several studies will be required to supplement the work in this thesis. The link between 
OCSFA and T2DM is becoming well-established in literature. However, many of these 
studies have been conducted in small groups or as part of a nested cohort. 
Considering the relatively low abundance of OCSFA in plasma, and their variability, 
large samples are required to adequately power studies to detect significant 
associations with markers of inflammation and indices of glucose homeostasis. 
Moreover, sub-set analyses are challenging and limited by sample sizes. Therefore, a 
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meta-analysis of current data will be informative in providing a broader view of the 
associations especially within sub-sets, like people with prediabetes, or with poorly-
controlled T2DM with or without complications. In chapter 3, FAME profiles were 
measured with an optimised GC protocol. GC has been a useful tool in measuring 
FAME profiles for decades; however, mass spectrometry (MS) is a more sensitive 
approach for measuring FAME profiles especially with OCSFA and other FAs 
displaying low abundance. Future work will involve the optimisation of a GC-MS 
protocol for optimal identification and quantification of OCSFAs. Furthermore, a GC-
MS technique will allow quantification of isomers of C15:0 with specific focus on 
anteiso-C15:0, to differentiate between different sources of C15:0 (diet, de novo 
lipogenesis, and gut microbiome). 
In chapter 4, an attempt was made to identify cellular mechanisms underpinning the 
differential effects of C15:0 and C16:0 in hepatocytes. Future work will rely on a model 
of primary hepatocytes owing to the limitations of HepG2 cells as discussed. 
Furthermore, more robust methodology will be used to measure glucose and lipid 
homeostasis. The primary aim of the future work on hepatocytes will be to identify the 
metabolic fate of glucose and FAs after treatment with C15:0. A radioisotope study will 
be used to determine the metabolic fate of glucose and FAs in primary hepatocyte 
treated with C15:0. Subsequently, Western blot and MS techniques will be optimised 
to measure protein concentrations of enzymes identified in gene expression data to 
confirm downstream regulation and physiologic function. This thesis did not explore 
the potential modulation of cell surface receptors in hepatocytes by C15:0. Future work 
will aim to develop western blot and immunoprecipitation techniques to identify key 
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differences in insulin signalling in cells treated with C15:0, with particular focus on IRS-
1/AKT kinase-mediated insulin signalling. 
In chapter 5, this study showed that C15:0 displayed some anti-inflammatory 
properties in LPS stimulated THP-1 cells. Future work should focus on optimising 
techniques for isolating monocytes from plasma of healthy controls and T2DM to 
determine the effect of C15:0 on inflammation in both sub-sets. Specifically, the FACs 
protocol will be optimised to measure CD14 and CD16 expression simultaneously, to 
determine M1 and M2 monocyte sub-sets. The major focus of future work on 
monocytes will cover the downstream effect of the competitive activation of GPR120, 
or downregulation of NF-ƙB via TLRs by C15:0. 
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Table 8.8.1: Correlation matrix 
    Age BMI Visc Fat score FASTING 
BLOOD 
Glucose 
sol 
thrombomodu
lin ng/ml 
E-selectin 
ng/ml 
CRP ug/ml Protein 
Carbonyl 
Leptin 
Age Pearson 
Correlation 
1 0.216 .755** .298* 0.065 -0.126 .287* .348** .348** 
  Sig. (2-tailed)   0.100 0.000 0.021 0.620 0.336 0.026 0.006 0.007 
    96 95 94 96 96 96 96 96 95 
BMI Pearson 
Correlation 
0.216 1 .722** 0.246 0.051 0.231 .291* .290* .276* 
  Sig. (2-tailed) 0.100   0.000 0.060 0.703 0.079 0.026 0.026 0.036 
    95 95 94 95 95 95 95 94 94 
Visc Fat score Pearson 
Correlation 
.755** .722** 1 .407** 0.179 -0.004 .332* .348** .434** 
  Sig. (2-tailed) 0.000 0.000   0.002 0.178 0.977 0.011 0.007 0.001 
    96 95 94 96 96 96 96 96 95 
FASTING 
BLOOD 
Glucose 
Pearson 
Correlation 
.298* 0.246 .407** 1 .417** .318* 0.229 0.220 .630** 
  Sig. (2-tailed) 0.021 0.060 0.002   0.001 0.013 0.078 0.091 0.000 
    96 95 94 96 96 96 96 96 95 
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    Age BMI Visc Fat score FASTING 
BLOOD 
Glucose 
sol 
thrombomodu
lin ng/ml 
E-selectin 
ng/ml 
CRP ug/ml Protein 
Carbonyl 
Leptin 
sol 
thrombomodu
lin ng/ml 
Pearson 
Correlation 
0.065 0.051 0.179 .417** 1 0.240 -0.230 -0.112 .560** 
  Sig. (2-tailed) 0.620 0.703 0.178 0.001   0.065 0.077 0.392 0.000 
    96 95 94 96 96 96 96 96 95 
E-selectin 
ng/ml 
Pearson 
Correlation 
-0.126 0.231 -0.004 .318* 0.240 1 0.070 0.063 0.205 
  Sig. (2-tailed) 0.336 0.079 0.977 0.013 0.065   0.595 0.632 0.119 
    96 95 94 96 96 96 96 96 95 
CRP ug/ml Pearson 
Correlation 
.287* .291* .332* 0.229 -0.230 0.070 1 .489** 0.143 
  Sig. (2-tailed) 0.026 0.026 0.011 0.078 0.077 0.595   0.000 0.280 
    96 95 94 96 96 96 96 96 95 
Protein 
Carbonyl 
Pearson 
Correlation 
.348** .290* .348** 0.220 -0.112 0.063 .489** 1 .274* 
  Sig. (2-tailed) 0.006 0.026 0.007 0.091 0.392 0.632 0.000   0.035 
    96 95 94 96 96 96 96 96 95 
Leptin Pearson 
Correlation 
.348** .276* .434** .630** .560** 0.205 0.143 .274* 1 
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    Age BMI Visc Fat score FASTING 
BLOOD 
Glucose 
sol 
thrombomodu
lin ng/ml 
E-selectin 
ng/ml 
CRP ug/ml Protein 
Carbonyl 
Leptin 
  Sig. (2-tailed) 0.007 0.036 0.001 0.000 0.000 0.119 0.280 0.035   
    95 94 93 95 95 95 95 95 95 
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Table 8.8.2: Parameter estimates for CRP 
      
Paramete
r 
Estimates 
    
 
Parameter B 
Std. 
Error 
95% Wald 
Confidence 
Interval   
Hypothesi
s Test     Exp(B) 
95% Wald 
Confidenc
e Interval 
for Exp(B)    
      Lower Upper 
Wald Chi-
Square df Sig.   Lower Upper  
(Intercept) -7.381 3.0434 -13.346 -1.416 5.881 1 0.015 0.001 1.600E-06 0.243 
 
C182n6ct_1 
0.003 0.0025 -0.002 0.008 1.474 1 0.225 1.003 0.998 1.008 
 
Age 0.020 0.0278 -0.035 0.074 0.492 1 0.483 1.020 0.966 1.077  
FASTINGBLOODGlucose_
1 -0.027 0.1319 -0.286 0.231 0.043 1 0.836 0.973 0.751 1.260 
 
BMI_1 0.068 0.0610 -0.052 0.188 1.246 1 0.264 1.071 0.950 1.207  
ProteinCarbonyl_1 
1.544 0.5774 0.412 2.676 7.149 1 0.007 4.683 1.510 14.520 
 
LEPTINNgml 
-0.128 0.0820 -0.288 0.033 2.418 1 0.120 0.880 0.750 1.034 
 
Eselectinngml 
0.016 0.0219 -0.027 0.059 0.519 1 0.471 1.016 0.973 1.060 
 
C222_1 0.066 0.0233 0.020 0.112 7.949 1 0.005 1.068 1.020 1.118 
 
C181n9ct_1 
0.002 0.0028 -0.004 0.007 0.386 1 0.535 1.002 0.996 1.007 
 
(Scale) 8.550a 1.5742 5.960 12.266             
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Table 8.3: Parameter estimates for soluble thrombomodulin 
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Table 8.4: Parameter estimates for leptin 
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Table 8.5: Parameter estimates for BMI 
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Table 8.6: Parameter estimates for fasting plasma glucose 
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Table 8.7: Parameter estimates for soluble E-Selectin 
 
